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Application of Hot-melt Extrusion in the Manufacturing of Amorphous 
Solid Dispersions Containing Thermally Labile Drugs 
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Supervisor: Robert O. Williams III 
 
Hot-melt extrusion has gained favor over traditional pharmaceutical formulation 
techniques in bioavailability/solubility enhancement because it is a solvent-free and 
continuous operation process that does not require major downstream processing. 
However, the thermal and mechanical energy applied during the extrusion process can 
cause chemical degradation of drugs and polymeric carriers 
In Chapter 1, different methods of preparing amorphous solid dispersions were 
reviewed. The amorphous solid dispersions generated by different methodologies were 
compared in terms of physical stability, chemical stability, and the in vivo/in vitro 
performance. 
In Chapter 2, the solubility advantage of amorphous solid dispersions was 
investigated through the heterogeneous phase equilibria analysis. A thermodynamic model 
for the quantitative assessment of solubility advantage of amorphous solid dispersions was 
then presented. The thermodynamic model accounted for the chemical potential change as 
a result of (a) amorphization, (b) ASD formation, and (c) water partition. Experimental 
solubility advantages of amorphous solid dispersions containing indomethacin was studied 
by means of intrinsic dissolution measurement. The thermodynamic model allowed 
predicting the solubility advantage of amorphous solid dispersions. 
ix 
 
 
In Chapters 3 and 4, the strategies used in hot-melt extrusion to facilitate 
manufacture of amorphous solid dispersions containing thermally labile drugs were 
investigated. Formulation screening based on Flory-Huggins theory, and the utilization of 
polymer designed for the extrusion process was evaluated in Chapter 3. With the selection 
of proper formulations, amorphous solid dispersions containing 30% (w/w) carbamazepine 
were manufactured without any degradation. Improved dissolution properties were also 
revealed with the final formulations. In Chapter 4, gliclazide was identified as a thermally 
labile drug with severe degradation by hydrolysis at elevated temperatures, especially when 
it existed in amorphous or solution form. After optimization of the hot-melt extrusion 
process, including improved screw design, machine setup, and processing conditions, 
gliclazide amorphous solid dispersion with ~95% drug recovery was achieved. This study 
demonstrated the importance of the following factors on drug degradation: (a) changing 
screw design to facilitate shorter amorphous (melt) residence time, (b) lowering processing 
temperature to avoid excess thermal exposure, and (c) minimizing processing parameters 
to reduce unnecessary mechanical energy input. 
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Chapter 1: Effect of Preparation Process on Properties of Amorphous 
Solid Dispersions 
1.1 ABSTRACT 
The use of amorphous solid dispersions to improve bioavailability of active 
ingredients belonging to BCS II and IV classifications continues to gain interest in the 
pharmaceutical industry. Over the last decade, methods of generating amorphous solid 
dispersions have been well established in commercially available products and literature. 
However, the amorphous solid dispersions manufactured by different technologies differ 
in many aspects, such as chemical stability, physical stability, and in vitro/in vivo 
performance. This review will analyze the impact of manufacturing methods on those 
properties of amorphous solid dispersions. For example, the chemical stability of drugs and 
polymers can be influenced by the different level of thermal exposure during fusion- and 
solvent-based processes; the physical stability of amorphous content will vary based on the 
thermal history, particle morphology, and nucleation process of amorphous solid 
dispersions made by different methods; the in vitro/in vivo performance of the amorphous 
formulations will also be affected by the different particle morphology and molecular 
interactions caused by manufacturing methods. Additionally, the mechanism of 
manufacturing methods along with the thermodynamic theories related to amorphous 
formulations will be described in this review.  
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1.2 INTRODUCTION 
High throughput screening techniques and combinational chemistry have been 
widely used in the pharmaceutical industry for drug candidate selection during the drug 
discovery phase, resulting in an increasing number of active pharmaceutical ingredients 
being discovered with relatively high molecular weight and lipophilicity (1, 2). These 
properties enable drugs to bind to their target receptors more effectively, but at the same 
time often reduce their solubility in water (3). It has been reported that about 70% of the 
newly developed active pharmaceutical ingredients exhibit poor water solubility (4). 
The oral route of administration is the most common and preferred method of 
delivery due to the ease of administration and compliance by patients (5). For an orally 
administered drug to be absorbed from the gastrointestinal (GI) tract and exhibit a 
therapeutic effect, a sufficient amount of drug must be first dissolved in gastric and/or 
intestinal fluids and then permeate the membranes of the GI tract to reach systemic 
circulation. Therefore, a drug with poor aqueous solubility will typically exhibit solubility 
or dissolution rate limited absorption, causing poor bioavailability, and high absorption 
variability among patients (6). 
Various techniques have been reported to enable the successful delivery of poorly 
water-soluble drugs (7, 8). These can be categorized into four strategies, namely drug 
solubilization, molecular modification, morphology modification, and intermolecular 
modification. In the case of drug solubilization, co-solvents, lipid vehicles, micelles 
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(surfactants) and complex formation are often employed. This formulation strategy has 
been widely reported in the production of liquid formulations (9). Molecular modification 
normally comprises the change of chemical structure. By adjusting the molecule’s polarity, 
the solubility and permeability of the entire molecule will be altered, typically presenting 
a different pharmacokinetic behavior. Examples of molecular modification include pro-
drug (10), twin-drug (11), salts (12), and co-crystals (13). For the morphology modification 
strategy, the goal is to increase the surface area of the particle by reducing the particle size, 
which according to the Noyes–Whitney equation (14), will enhance the drug dissolution 
rate and therefore bioavailability for drugs with dissolution rate limited absorption (15). 
Size reduction can be accomplished by either top-down or bottom-up methods, resulting in 
particles in the nano- to micron-size range (16). The intermolecular modification strategy, 
such as forming polymorphs or amorphous formulations, can be applied, when strong 
intermolecular interactions exist in between the drug molecules impacting the dissolution 
process (17). Among these four formulation strategies, intermolecular modification 
involving amorphous solid dispersion is a typically tried strategy to address solubility 
challenges, as evident by considering both approved commercial products and the literature 
(18, 19). Amorphous formulations not only provide improved drug dissolution rate and 
solubility, but also maintain the possibility of producing solid dosage form without 
changing the chemical structure of drug molecule (20). 
Amorphous formulations are mainly manufactured by solvent- and fusion-based 
methods. For solvent-based method, drug and polymer are dissolved in a solvent (or solvent 
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combination), forming a homogeneous solution system. Different strategies can be used to 
rapidly remove (by evaporation or isolation) the solvent in the solution to form amorphous 
solid dispersion. Typically, the secondary drying process in a batch step is required to 
further remove the residual solvent. As for fusion-based methods, heat and shear are 
applied to soften or melt the polymer and drug. With the following mixing and cooling, the 
drug can be solubilized in the polymer and solidified into the amorphous solid dispersion. 
Therefore, amorphous solid dispersions made by different methods will be exposed to 
different conditions, resulting in various chemical stability, physical stability, and in 
vitro/in vivo performance. 
This review will outline the advantages and challenges for amorphous 
formulations, together with a discussion of methods for generating amorphous solid 
dispersions. In addition, comparisons of chemical stability, physical stability, and in 
vitro/in vivo performance of ASDs manufactured by these methodologies will be reviewed 
with observations of current market trends.  
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1.3 AMORPHOUS SOLIDS AND AMORPHOUS SOLID DISPERSIONS 
Amorphous solids differ from their crystalline polymorphic counterparts by the 
lack of long-range crystalline order. That is, molecules are completely randomly distributed 
and exist in various conformational states. Crystalline materials, on the other hand, have 
three-dimensional long-range symmetry operators over a domain of more than a thousand 
individual molecules. Due to the different packing arrangement compared to crystalline 
materials, amorphous solids lack sharp crystalline diffraction peaks, distinct melting point, 
and birefringence when analyzed by X-ray diffraction, differential scanning calorimetry, 
and polarized light microscope, respectively. Such diverse molecule arrangements also 
explain the different physicochemical properties between amorphous and crystalline solids, 
such as the density, hardness, and thermal properties. 
1.3.1 Pure Amorphous Drug 
Pure amorphous drugs represent the highest energy form of drugs in solid state. 
Thus, as mentioned before, benefits in solubility and dissolution rate are expected for pure 
amorphous drugs. Despite the mentioned advantages mentioned of amorphous solids, only 
few commercial products on the market containing pure amorphous drugs. Zaﬁrlukast 
(Accolate®) was approved as a pure amorphous drug in 1999 by FDA (21). Crystalline 
zafirlukast is a poorly water-soluble drug [about 0.6 microgram/mL in FaSSIF (22)] with 
low oral bioavailability. When converted to the amorphous form in the commercial 
product, greater bioavailability is achieved (23). However, the pure amorphous zafirlukast 
recrystallizes into its monohydrate crystalline form in the presence of water, resulting in 
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decreased solubility and bioavailability (24). Some recent studies have shown that the 
incorporation of polymers (hydroxypropylmethyl cellulose acetate succinate, 
hypromellose, and polyvinylpyrrolidone) in the amorphous formulation can inhibit drug 
precipitation during the dissolution process, and increase drug concentration in the 
supersaturated state (22, 25). There are several other examples of marketed pure 
amorphous drugs, such as quinapril hydrochloride (Accupril®), cefuroxime axetil 
(Ceftin®), and nelﬁnavir mesylate (Viracept®). Due to the inherent high energy state of 
pure amorphous drug, these products have been reported to have thermodynamic instability 
issues leading to relaxation, nucleation, crystallization (26) and even chemical degradation 
(27) during storage or within the GI tract. Therefore, the application of pure amorphous 
drugs has been mainly limited to those reported mainly in lab-scale pre-formulation studies. 
1.3.2 Amorphous Solid Dispersion 
Amorphous solid dispersion (ASD) refers to a one-phase solid system containing 
amorphous drug molecularly dispersed in a polymeric carrier(s). Compared to pure 
amorphous drug, the addition of polymeric carriers improves the drug long-term storage 
and dissolution properties in different ways. These include interactions of the polymer with 
the drug to lower the energy state (chemical potential) of the amorphous drug and the 
polymer providing stereo-hindrance (local viscosity) to reduce the collision between 
amorphous drug molecules. Polymers are also known to help maintain desirable 
supersaturation conditions by delaying solvent-induced recrystallization to improve drug 
absorption. Moreover, hydrophilic polymers such as Kollidone®, Kollidone® VA64, 
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AFFINISOL™ HPMC HME (28), and METHOCEL™ are widely used in ASD 
formulation strategies, and the incorporation of highly water-soluble polymers also 
facilitates the water uptake during dissolution process and therefore increases the drug 
dissolution rate.  
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1.4 METHOD OF GENERATING AMORPHOUS SOLID DISPERSIONS 
Generally speaking, based on the drug dissolution process in a polymer carrier, the 
methods of manufacturing amorphous solid dispersions can be categorized into two 
classes: (a) fusion-based methods; (b) solvent-based methods. Commercially available 
ASDs made by different methods are listed in Table 1.1. 
1.4.1 Fusion-based Methods 
Typical fusion-based methods of manufacturing ASDs consist of two major steps: 
(a) melting the drug within the carrier at elevated temperature; (b) rapid cooling of the 
molten material to solidify into a one-phase system (29). During the melting process, high 
temperature will be applied to the material, resulting in a high molecular mobility of the 
drug to fulfill the amorphous conversion (30). A common adaptation to the melting phase 
consists of suspending the active drug in a molten polymeric carrier to allow the dissolution 
of the drug instead of melting the drug and polymer together, which can help break the 
drug crystalline lattice at a reduced processing temperature (31). Different cooling methods 
can be used to provide various cooling rates, which can be used to control the crystalline 
growth inside the molten material (32, 33). However, a limitation of manufacturing ASDs 
using fusion-based methods is the high temperatures and shear conditions involved in the 
process, which may induce material chemical degradation. 
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1.4.1.1 Hot-melt Extrusion (HME) 
HME technology is an industry-scale manufacturing method adapted from the 
plastics industry. A typical extruder consists of a feeder, an extrusion barrel, a screw shaft 
equipped with screw elements, a die, and potential downstream processing equipment (34), 
as shown in Figure 1.1. During the process, drug and polymer physical blend is fed into 
the extruder consistently, and the machine will perform the operations of conveying, 
melting, mixing, and condensing. The molten material is then shaped through a die and 
collected for downstream processing. During the melting and mixing, a homogenous 
system is formed, and after extrusion, the rapid cooling will result in a raise in system 
viscosity, which contributes to the kinetically stabilized ASD (35).  
1.4.1.2 KinetiSol® Dispersing Technology (KSD) 
KSD technology, also adapted from the thermo-kinetic mixer used in the plastics 
industry, is a new processing technology to manufacture ASD from a pharmaceutical 
perspective (36). As shown in Figure 1.2, the equipment consists of a processing chamber 
with rotating blades mounted at the center which rotate at high RPMs (typical thousands 
of RPMs) during the process. This high energy mixing technique utilizes the shear and 
thermal energy inputs generated by the fast rotating blades to process the drug and polymer 
blend for the production of homogeneous amorphous solids. Typical processing time is 
less than twenty seconds, and the materials being processed are exposed to elevated 
temperature conditions for less than five seconds before being ejected from the KSD unit 
and cooled down (36). In addition, the mechanical design of KSD machine enables the 
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processing of polymers with high melt-viscosity, which allows a wider selection of 
pharmaceutical excipients to be used (37). 
1.4.2 Solvent-based Methods 
Typical solvent-based ASD manufacturing methods consists of three major steps: 
(a) dissolving (or suspending) of the drug and carrier in a volatile solvent; (b) isolating 
majority solvent to get solids; (c) secondary drying to further remove residual solvent (38). 
Differences in solvent removal processes are related to the solvent isolation procedure, 
which usually includes vacuum drying (39), rotary evaporation (40), spray-drying (41), 
freeze-drying (42), co-precipitation (43), and the use of supercritical fluids (44). For 
solvent-based methods, the relatively lower processing temperature and/or cooling effect 
during solvent evaporation can help mitigate the thermal decomposition issue during the 
process (45). However, the use of organic solvents, the high preparation cost, and the 
difficulties in completely removing the solvent are some of the disadvantages associated 
with solvent-based manufacturing methods (38). 
1.4.2.1 Spray Drying 
Spray-drying is one of the most commonly-used solvent-based procedures in the 
production of ASDs. Three major components are involved in a spray dryer, namely 
feeding system (pump and spray nozzle), drying chamber, and collecting system (cyclone 
and collector) (46), as shown in Figure 1.3. A condensation system is required if organic 
solvents are used. For spray drying process, a molecular dispersed feed solution is first 
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achieved after dissolving the drug and polymer in the volatile solvent (such as ethanol, 
chloroform, acetone, or a solvent mixture). The feed solution is then pumped into the 
drying chamber through a spray nozzle, forming atomized droplets. Upon contacting the 
hot gas (air or nitrogen), solvent is then removed. Finally, the dried material is separated 
by a cyclone and collected in the collector for further process. Based on the solvent and 
processing conditions used, secondary drying may be required to further remove the 
residual solvent in the ASD. 
1.4.2.2 Co-precipitation (Micro-precipitated Bulk Powder) 
Another process is the co-precipitation method, which is based on solvent-
antisolvent precipitation (47). As shown in Figure 1.4, the co-precipitation process starts 
from dissolving the drug an ionic polymer in nonvolatile solvent (such as 
dimethylacetamide, dimethylformamide, and dimethylsulfoxide). The solution is then 
transferred gradually into a pH-controlled and chilled aqueous media acting as an 
antisolvent to cause rapid co-precipitation (48). After the controlled co-precipitation 
process, the solids still contain relatively high amount of organic solvent which needs to 
be removed. Organic solvent removal is achieved by washing the solids with aqueous 
medium until residual organic solvent content is less than 0.1% (47). After washing with 
water, secondary drying process (forced air oven or fluid bed dryer) is required to remove 
the aqueous medium in the precipitates.  
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1.5 COMPARISON BETWEEN AMORPHOUS SOLID DISPERSIONS MANUFACTURED BY 
DIFFERENT METHODS 
In the following sections, comparisons are made between solution-based and 
fusion-based manufacturing methods. To be more specifically, spray drying, co-
precipitation, HME, and KSD. 
1.5.1 Chemical Stability 
Materials are subjected to various types of conditions during the conversion to 
amorphous form using different processing technologies. The elevated temperature and 
shear employed in the fusion process (e.g., HME and KSD), solution state in solvent drying 
process, and acidic or basic solution state in co-precipitation process can expose materials 
to chemical degradation. Moreover, the fact that amorphous drugs exist in a higher energy 
state makes them more vulnerable to chemical degradation compared to their crystalline 
counter-parts (49). 
Spray drying has been known to be a mild processing technology for the generation 
of ASDs. Even though heat is induced during the process for the removing of solvent, the 
real temperature of the processed materials is normally low due to the solvent-evaporation 
cooling effect (50). However, the incompatibility of feed components in solution state can 
raise chemical stability issue for the spray drying technique. The application of novel-
designed nozzle consisting of multiple liquid/gas pathways has been reported to allow 
spray drying of incompatible materials by separating the feed solution (51). A three-fluid 
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concentric nozzle was used in spray drying the acid labile drug omeprazole with the enteric-
coating polymer Eudragit® L 100-55 (52). Component compatibility should also be 
addressed in co-precipitation technology since: (a) solution state is also involved during 
the co-precipitation process, (b) the amorphous MBP is formed by co-precipitation of drug 
and polymer in acidic (mostly) or basic media, (c) an estimation of several hours to several 
days of exposure in those conditions is expected for the whole process based on the scale 
of the manufacture (53). Therefore, it is critical to perform forced-degradation experiments 
in order to evaluate the component compatibility profile of the drug and polymer used in 
solution-based ASD manufacturing process. 
Compared to solution-based methods, higher temperature and shear will be applied 
to material processed by fusion-based methods. According to the Arrhenius equation, 
elevated temperatures can significantly increase the degradation rate (54). Moreover, the 
shear energy input has also been shown to trigger chemical degradation for shear-sensitive 
materials (55). In a recent study (56), HME and spray drying were used to prepare 
albendazole ASD. Severe degradation (from 71.1% to 97.4%) was observed in the melt-
extruded samples, while full recovery was achieved in ASD prepared by spray drying, and 
less than 1% degradation was observed in spray-dried ASD after 6-month storage at room 
temperature. The long residence time and high shear environment of the HME process 
exacerbated the thermal degradation of albendazole, resulted in low drug recovery. It 
should be noted though, the residence time and shear condition provided by HME have 
been shown to be adjustable through the application of different screw designs, machine 
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setup, and processing conditions (57). The thermally labile drug gliclazide was 
manufactured without severe degradation using HME after adapting the proper machine 
setup to reduce the processing pressure, applying the optimal screw design to minimize 
melt residence time, and selecting the optimized specific mechanical energy input to fulfill 
the amorphous conversion without providing excess shear force. 
In the last decade, KSD, an emerging fusion-based manufacturing technology for 
production of ASDs, is recognized for being able to process materials at relatively lower 
temperatures with shorter periods of time compared to conventional fusion-based 
technology like HME (36). The chemical stability of a thermally labile drug and polymer 
during KSD process was recently reported (37). Ritonavir which was used as the thermally 
labile drug, undergoes hydrolytic degradation at elevated temperatures (58). A polymeric 
carrier (PVA 4-88) with high melt viscosity was chosen in the study bringing more 
challenges to thermal processing of ritonavir. HME process of PVA 4-88 requires either 
plasticizers or high processing temperatures (180 ℃) due to its semi-crystalline nature (59, 
60), which will hamper the physical stability of the extruded ASD and the chemical 
stability of the drug being processed, respectively. In this case, HME process of ritonavir 
with PVA 4-88 without chemical degradation was not realistic since the lowest processing 
temperature of PVA 4-88 was 30 ℃ higher than the degradation onset temperature of 
ritonavir. With the help of KSD process, it has been shown that ASD containing ritonavir 
and PVA 4-88 can be successfully manufactured using. After proper KSD process 
optimization, ritonavir ASD was produced without any drug or polymer degradation. 
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Direct comparisons between the ability of processing thermally labile drug using HME and 
KSD has also been done in several publications (61-63), showing the unique ability of KSD 
for the processing of highly viscous polymers and thermally labile drugs. 
The lower processing temperatures used in solution-based methods to manufacture 
ASDs relative to fusion-based methods benefit the chemical stability challenges of the 
processed materials by keeping the chemical degradation constant low. The chemical 
stability of ASDs made by fusion-based methods, however, can usually be addressed by 
optimizing the processing conditions of the solvent-free processes. In addition, KSD has 
been shown to result in ASDs with improved chemical stability, thus is used as an 
alternative strategy to manufacture ASDs. 
1.5.2 Physical Stability 
Physical stability of amorphous solid dispersions is a major concern in the industry 
(64). In order to maximize the benefits of ASDs, it is crucial to maintain the drugs in 
amorphous form during storage and following delivery. Formulation factors have been 
studied and reviewed, such as the selection of polymers as crystallization inhibitors (64) 
and the application of plasticizers as a processing aid (65). Besides the formulation factors, 
ASD preparation methods can also affect the physical stability of amorphous drugs through 
influences on thermal history, particle morphology, and nucleation process of ASDs. 
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1.5.2.1 Thermal History 
It is widely accepted that the properties (e.g., solubility, physical and chemical 
stability) of formulations are closely related to the thermal history of the materials (65). 
For amorphous formulations, depending on the manufacturing processes used, materials 
will be exposed to different level of heat exposure, resulting in ASDs with different thermal 
histories. Amorphous molecules with different thermal histories have been reported to 
exhibit different molecular mobility which will further impact the crystallization 
propensity of the materials (66, 67).  
As mentioned before, secondary drying process is required for solvent-based 
methods (e.g., freeze drying and spray drying), which can cause enthalpic relaxation 
leading to potential nucleation problems (68). For fusion-based methods (e.g., HME, KSD, 
and melt-quenching), however, temperature is dropped immediately upon melting the 
material to freeze the drug in amorphous state. To evaluate the effect of processing 
conditions on the physical stability of amorphous trehalose, four different methods, namely 
freeze drying, spray drying, dehydration, and melt quenching were used to manufacture 
amorphous trehalose (69). The thermal characterization revealed that processing 
technologies did not change the Tg and fragility of the amorphous materials. However, 
enthalpic relaxation, crystallization tendency, and water vapor sorption were influenced. 
In this case, secondary drying process was applied to freeze-drying process at 50 ℃ and 60 
℃ for a total of 48 hours. And, a relatively high outlet temperature (about 90 ℃) was used 
in the spray drying process. Also, the total exposure of material at about 100 ℃ for 24 
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hours was applied to dehydrate the drug. The different level of thermal exposures resulted 
in the different relaxations, as shown in Figure 1.5. The dehydrated sample exhibited the 
highest enthalpy relaxation, followed by spray-dried and freeze-dried samples, and melt-
quenched sample underwent the least relaxation during preparation. The resistance to 
crystallization showed the same rank order as trehalose prepared by dehydration < freeze 
drying ≈ spray-drying < melt quenching. The impact of thermal history of ASDs on 
physical stability was also evaluated in another study (70). It was shown that the 
crystallization kinetics of amorphous trehalose was strongly correlated to the α-relaxation 
time, which was affected by the amorphous processing methods. As shown in Figure 1.6, 
in the sub-Tg region, spray-dried amorphous trehalose exhibited the longest α-relaxation 
time, followed by those made by freeze drying and dehydration, which was in agreement 
with rank order of the resistance to crystallization. Similar trend has also been reported in 
other literature (71-73). These results indicated that the preparation methods influenced 
physical stability by imparting different mobility states of the amorphous materials. Due to 
the exposure to elevated temperatures during the secondary drying process, amorphous 
materials produced by solvent-based methods exhibited more relaxation than fusion-based 
methods, causing higher crystallization tendency. 
1.5.2.2 Particle Morphology 
The effect of particle morphology on crystallization tendency has been evaluated 
from multiple aspects, including particle size (74), particle shape (75), and surface 
heterogeneities (76). In general, solvent-based manufacturing methods generate ASDs with 
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smaller particle size and relatively large surface area. For example, spray-dried particles 
exhibit inflated or collapsed sphere shape with porous structure, and based on processing 
conditions particle can be observed as a mixture of fractured spheres, broken and non-
broken shells (77); MBP particles normally have a relatively smooth and round surface 
with a spongy network structure below the surface (78). Conversely, a low porosity 
material is generally achieved after fusion-based process (normally with intensive mixing, 
pressure, and or heat), due to the reduction of free space present in the polymer drug blends. 
Therefore, particle shape and size of the final products made by fusion technologies are 
typically irrelevant to the manufacturing process, but dependent on the milling process 
(79). 
The presence of residual solvent and the relatively smaller particle size of the ASDs 
manufactured by solution-based methods have been proposed to negatively affect the 
physical stability in a study comparing physical stability of ASDs manufactured by HME 
and spray drying (80). The spray-dried ASD was achieved with the particle size of less 
than 10 microns, which was significantly smaller than the particle size HME ASD (> 250 
microns), and the surface area of the spray-dried ASD was more than 22-fold higher than 
that of HME ASD, as shown in the Figure 1.7. The small particle size and high surface area 
significantly increased the surface energy of the spray-dried ASD, thus resulted in the 
higher crystallization rate. After being stored under accelerated conditions (40 ℃, 75% 
RH) for 8 weeks, spray-dried ASD started to show recrystallize peaks in X-ray diffraction. 
Similar result has been reported in another comparison study (81). 
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ASD made by another solvent-based method (co-precipitation) has also been 
reported to have reduced physical stability when compared to an HME ASD (43). Both 
HME and co-precipitated ASDs exhibited acceptable physical stability after storage at 40 
℃/75% RH for 3 months. However, the HME ASD was more stable than the co-
precipitated ASD at accelerated conditions (aqueous suspension) due to the relatively 
smaller surface area. 
These studies revealed that smaller particle size, larger surface area, and the 
potential residucal solvent of the ASDs made by solvent-based methods contributed to the 
higher surface energy, which can negatively affect physical stability. 
1.5.2.3 Nucleation Process (converting power) 
ASDs processing methods can affect product physical stability through impacting 
nucleation process. That is, different processing methods present different amorphous 
converting power, thus ASDs can be made containing not fully-converted crystalline drug. 
Due to the limitation of the typically-used characterization technologies (82), those small 
amount of trapped nuclei in the ASDs are difficult to detect, which can affect the 
crystallization tendency significantly (83). For example, at storage temperatures (below 
Tg), nuclei can act like seeds for crystal growth as glass can undergo α- or β-relaxation and 
molecules diffuse to the nuclei (84); or elevated temperature (above Tg), the nuclei will be 
exposed to the significantly enhanced crystalline growth rate causing crystallization (85). 
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The effect of spray drying and HME process of manufacturing ASDs on the kinetic 
miscibility of a poorly water-soluble drug miconazole and the graft copolymer 
polyethyleneglycol-co-vinylalcohol was investigated (86). The solid dispersions were 
prepared at different drug-polymer ratios (range from 4–43% w/w) using a lab-scale Büchi 
mini spray-dryer B-191 and a co-rotating mini twin screw extruder. The thermal analysis 
result showed that spray dried material with more than 12% w/w drug load exhibited an 
endothermic peak on top of the broad endothermic signal, pointing to the presence of a 
crystalline drug phase. HME products, on the other hand, the endothermic peak did not 
show up until 27% w/w drug load. Is has been shown that hot-melt extrusion results in a 
higher degree of mixing relative to the spray drying process. It was also confirmed in 
another publication comparing amorphous converting power between HME and spray 
drying, that HME provided sufﬁcient energy for more intimate mixing to be achieved 
between drug and polymer, which could further improve physical stability of HME ASDs 
relative to spray-dried ASDs (87). In addition, it was proposed that spray drying allowed 
generation of ASDs with higher drug concentration than HME, but the FTIR results 
showed the existence of amorphous drug-rich domains within those high drug-loaded 
spray-dried samples, indicating phase separation. Interestingly, a recent publication 
addressed the difference in converting power between HME and spray drying through the 
relationship between the amorphous molecule mobility and viscosity (88). Crystallization 
occurs in two steps: nucleation and crystal growth (89), and the rates of both steps are 
related to transport frequency, which is inversely related to the solution viscosity. In 
addition, crystal growth rate is related to diffusion coefficient, which is also inversely 
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related to viscosity as described by the Stokes-Einstein Equation (90). Naproxen and PVP 
K25 were used in this study because naproxen is a fast crystallizer with strong 
interaction/miscibility with PVP K25 (91, 92). During HME process, naproxen was 
gradually dissolved in the melt PVP K25 at the processing temperature relying on the 
strong interaction of drug and polymer, since HME was conducted below the melting point 
of naproxen. And after the process, the product relied on the high viscosity of the 
formulation matrix to kinetically inhibit the crystallization of naproxen. Therefore, 
compared to the low viscosity environment naproxen experienced throughout the spray 
drying process, the viscosity during extrusion remains orders of magnitude higher, even 
with plasticization of PVP K25 from NPX during extrusion, ensuring that NPX has limited 
mobility. In summary, the physical stability difference caused by converting power 
between HME and spray drying is mainly caused by the fast recrystallization happened 
during the drying process due to the high molecular mobility. 
Co-precipitation has similar recrystallization issue to spray drying during the 
process. Moreover, the relatively longer solvent exposure in co-precipitation process brings 
more physical stability challenges to the co-precipitation process (93). Therefore, the 
selection of drug and polymeric carriers are crucial to the success of stable co-precipitated 
ASD. 
When comparing the amorphous converting power between fusion-based methods, 
the high shear rate inherent to KSD has been known to accelerate the dissolution kinetics 
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of drugs in molten polymeric carriers (36). Consequently, a high converting power is 
expected for this technique. ASDs were achieved at lower processing temperature with 
KSD where the processing of HME were not possible (37) or the extrudates came out with 
phase separation (94) with HME HAAKE Minilab II Micro compounder. However, it 
should be noted that the amorphous converting power of HME is highly dependent on the 
screw design, processing conditions, and the model of the extruder used (95). It has been 
demonstrated that ASDs made by the same extruder and screw design with two different 
screw speeds could result in completely different physical stability performances due to 
the homogeneity of the drug in the ASD system (96). 
1.5.3 In vitro/In Vivo Performance 
The ultimate goal of preparing ASD is to enhance the bioavailability of drug. 
Therefore, it is crucial to compare the in vitro/in vivo performances of ASDs made by 
different methods. It has been reported that several factors can affect the in vitro/in vivo 
performance of ASDs, such as particle size, system homogeneity, and intermolecular 
interactions (97). The effect of methods of manufacturing ASDs on the in vitro/in vivo 
performance will be discussed based on that.  
As expected, ASDs made by different methods exhibited various particle sizes, 
which have been shown to cause different in vitro performances as shown in a study with 
a poorly water-soluble compound A (~0.2 microgram/mL in 50 mM pH 6.8 phosphate 
buffer) (43). ASDs with acceptable physical stability were prepared successfully with 40% 
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(w/w) compound A in HPMCAS-LF using both HME and co-precipitation methods. The 
ASDs manufactured by both methods exhibited similar true density (~ 1.30 g/cm3). But a 
much higher speciﬁc surface area of 6.19 m2/g was achieved for co-precipitated ASD 
compared with 0.13 m2/g for the HME product. The high surface area of co-precipitated 
ASD resulted in a faster dissolution rate, which was also observed in a comparison study 
between spray-dried ASD and HME ASD (98), confirming that the smaller particle size 
and the higher surface area generated by the solvent-based methods contributed to the faster 
dissolution rates of some poorly water-soluble drugs. 
A challenge for ASDs is the ability to resist crystallization upon contacting the 
dissolution media. Rapid release of API in the supersaturation state certainly can be an 
advantage in improving absorption (97). However, it may be equally important for the 
polymer to provide stabilization against solvent-mediated crystallization by remaining in 
close contact with the drug. For example, in a comparison study of ASDs made by spray 
drying, HME, and ball milling technique with PVP and three poorly water-soluble 
compounds, namely carbamazepine, dipyridamole, and indomethacin (99), it was found 
that the dissolution rates of the spray-dried ASDs were the lowest for ASDs of all three 
drugs, even though smallest particle sizes were observed with the spray-dried ASDs. The 
slow dissolution rate was attributed to the rapid dissolution of the highly water soluble 
PVP, leaving behind amorphous drug without the intimate presence of the polymer, which 
likely caused in rapid recrystallization of the drug and would have certainly reduced the 
overall dissolution rate and wetting of the drug. Similar observations have also been 
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reported (100). Moreover, it was believed that the intermolecular interactions between drug 
and polymer would determine the dissolution rate. Namely, the stronger hydrogen bonding 
between indomethacin and PVP limited the rapid loss of PVP from the indomethacin spray-
dried ASD due to the increase in hydrophobicity of PVP. Therefore, spray-dried 
indomethacin ASD showed comparable dissolution rate to ASDs prepared by the other two 
methods, while spray-dried carbamazepine ASD exhibited significantly slower dissolution 
rate due to the lack of intermolecular interaction with PVP. 
The manufacturing method can influence the stabilization effect of polymers by 
generating ASD systems with different levels of homogeneity. As mentioned earlier, 
fusion-based technologies such as HME can provide more mixing of drug and polymer 
during ASD manufacturing, resulting in systems with better homogeneity relative to 
solution-based methods. The better homogeneity has also been shown to benefit the in vivo 
performance of ASDs (35). For example, ASDs of a poorly water-soluble Compound I 
(aqueous solubility of 0.03 mg/mL at pH 1, and < 0.003 mg/mL in the pH range of 3 to 9, 
pKa values of 2.9 and 10.0) were made by HME, spray drying, spray granulation, and 
rotary evaporation for solubility/bioavailability enhancement (101). The ASDs were 
prepared with 20% (w/w) Compound I, 70% PVP K30, and 10% Sorbitol, and then 
compared in a beagle dog study with a control formulation made of crystalline drug 
triturated with Poloxamer 188. The melt-extruded ASD provided a 7-fold greater 
bioavailability than the control crystalline formulation, followed by the ASD made by 
rotary evaporation. The spray-dried and spray-granulated solid dispersions produced 
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relatively lower bioavailability enhancement of 2- to 3-fold. The authors speculated that 
the degree of dispersion of the spray-dried and spray-granulated formulations as compared 
to that manufactured by HME, which had been exposed to high shear mixing. Another 
study comparing fusion-based method (KSD) and solvent-based method (rotary 
evaporation) also revealed that a more homogeneous ASD was generated by KSD as 
compared to the rotary evaporation method (102). Although faster dissolution rate was 
observed in a pH change non-sink dissolution test for the rotary-evaporated ASD with 
higher surface area as mentioned before, the ASD made by KSD exhibited better ability to 
prevent recrystallization in the dissolution. The difference was attributed to the higher 
degrees of thermodynamic stability in the ASD manufactured by rotary evaporation 
method than KSD. For further in vivo test, KSD samples were used due to the inferior 
physical stability performance compared to rotary-evaporated ASD, resulting in a 10-fold 
higher absorption than the crystalline drug in the Sprague–Dawley rat model.  
Comparison between two fusion-based methods (KSD and HME) has also 
confirmed the importance of ensuring a homogeneous ASD system (94, 103). In one study 
(94), it was shown that both KSD and HME were capable of providing ASDs with 
improved dissolution behavior. However, as shown in Figure 1.8, KSD ASD provided a 
faster in vitro dissolution rate in comparison to the HME ASD processed by a HAAKE 
Minilab II extruder with no kneading element (low mixing ability). This observation 
supported the solid state characterization in this paper showing the increased amorphous 
homogeneity of KSD ASD. The oral bioavailability study using a Sprague–Dawley rat 
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model indicated ASDs from both processes exhibited enhanced AUC compared to 
crystalline drug, but a higher AUC value was observed with KSD ASD compared to that 
of HME ASD, which was also attributed to the improved homogeneity. Generally, if the 
active ingredient is not homogeneously distributed in the carrier, there will be drug-rich 
and polymer-rich zones, which may impact the drug release process. And for the ASD 
system containing poorly water-soluble drug (hydrophobic), a greater concentration of 
drug can negatively impact wetting and dissolution rate, therefore, a decrease in drug 
release would be anticipated from the system relative to a homogenous (evenly 
hydrophilic) system. 
A reformulation of Zelboraf®, a marketed co-precipiated ASD product containing 
vemurafenib has been done recently with KSD (104). Vemurafenib is a poorly water-
soluble drug, and due to its high melting point, poor solubility in low and moderate boiling 
temp organic solvents, common technologies of manufacturing ASD with vemurafenib are 
limited (105). It has been shown that similar supersaturation state was achieved with the 
KSD ASD and the commercial product in the in vitro dissolution study, demonstrating the 
versatility of KSD technology for the production of ASDs. 
Due to the complexity of the in vitro/in vivo performance of ASDs, the ASD 
manufacturing methods can affect performance. Based on this review, solvent-based 
methods tend to generate ASDs with smaller particle sizes resulting in faster drug release 
rate; fusion-based methods, on the other hand, tend to generate more homogeneous ASDs 
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with better resistance to recrystallization in the dissolution media resulting in better in vivo 
absorption. 
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1.6 CONCLUSIONS 
The application of ASDs for improving the bioavailability of poorly water-soluble 
drugs has gained interest in pharmaceutical industry. Fusion-based and solvent-based 
methods have been widely investigated and used to prepare ASDs. It has been shown that 
stability challenges involved in ASD formulations such as chemical stability, physical 
stability, and in vitro/in vivo performance vary based on the manufacturing method. Based 
on this review of the literature, solvent-based methods exhibit better chemical stability than 
fusion-based methods, however, residual solvent, high surface area, potential nuclei, and 
molecular relaxation during the secondary drying process may negatively impact the 
physical stability of ASDs manufactured by solvent-based methods. In vitro/in vivo 
performance depends on a number of factors including, the homogeneity of ASD systems, 
the intermolecular interactions between drug and polymer, and the morphology of the 
materials, which can be influenced by the manufacturing method. It should be noted 
though, besides the manufacturing methods, the overall performance of ASD also largely 
depends on the physicochemical properties of the drug and polymer. Therefore, selecting 
the right manufacturing method based on the properties of the materials is crucial to the 
success of the ASD. 
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1.8 LIST OF FIGURES 
 
Figure 1.1 Schematic representation of a typical pharmaceutical twin-screw extruder. 
Reproduced with permission from (34). 
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Figure 1.2 (a) Batch-mode GMP KSD compounder model TC-254B; (b) Cross-
sectional view of the KSD processing chamber. Reproduced with 
permission from (36, 106). 
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Figure 1.3 Overview of the spray drying process key operations. Reproduced with 
permission from (46). 
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Figure 1.4 Schematic of co-precipitation process. Co-precipitation is comprised of 
several unit operations including stock solution preparation, controlled co-
precipitation, filtration, washing cycles, isolation of co-precipitation, drying, 
and downstream processing. Reproduced with permission from (47). 
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Figure 1.5 DSC heating scans of amorphous trehalose prepared by different methods. 
Following drying at 60 ℃ the samples were cooled to room temperature and 
heated to 230 ℃ at 10 ℃/min. The glass transition, enthalpic recovery, 
crystallization and melting events are shown. Reproduced with permission 
from (69). 
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Figure 1.6 Temperature dependence of (a) relaxation in amorphous trehalose prepared 
by freeze-drying (black), spray-drying (red) and dehydration of trehalose 
dihydrate (green). Circles, diamonds, triangles and inverted triangles 
represent, respectively, α-relaxation time above Tg, α-relaxation time below 
Tg, β2-relaxation time and β1-relaxation time. Dashed line represents VTF 
fit while dotted lines represent Arrhenius fit (every data point is the mean of 
3 determinations; in many cases, the error bar was smaller than the symbol 
size). In the supercooled liquid region, since the relaxation times were 
independent of the preparation method, only one symbol is readily visible; 
(b) crystallization time (squares; plotted on the right y-axis) and α-relaxation 
time (circles at temperatures above Tg and diamonds below Tg; plotted on 
the left y-axis) for trehalose prepared by different methods. Reproduced 
with permission from (70). 
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Figure 1.7 True density, surface area and powder ﬂow for slugged and milled spray 
dried and milled hot melt extruded dispersion (above). Scanning electron 
microscopy images for spray dried dispersion and hot melt extruded 
dispersion (below). Reproduced with permission from (81). 
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Figure 1.8 Supersaturated dissolution proﬁle of HME (solid triangle) and KSD (solid 
square) processed solid dispersions. Each vessel (n = 3) contained 50.0 
mg/mL ITZ equivalent corresponding to 10 times the equilibrium solubility 
of ITZ in the acid phase. Testing was conducted for 2 h in 900 mL of 0.1 N 
HCl. Reproduced with permission from (94). 
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1.9 LIST OF TABLES 
 
Table 1.1 Commercially available amorphous solid dispersions manufactured by 
different methods. 
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Chapter 2: Solubility Advantage (and Disadvantage) of Pharmaceutical 
Amorphous Solid Dispersions1 
2.1 ABSTRACT 
The solubility of a drug is ultimately governed by its chemical potential as it is 
present in the undissolved solute. For a pharmaceutical amorphous solid dispersion (ASD), 
its solubility depends on the state and composition of the undissolved solute when the ASD 
is equilibrated with water. Concerning the undissolved solute phase which can contain up 
to three components (drug, polymer, and water), we develop a complete thermodynamic 
model to calculate the chemical potential of a drug in the multi-component, amorphous 
system. This approach enables the estimation of the true solubility advantage of ASD from 
calorimetric measurements and moisture sorption isotherms. Both theoretical estimation 
and experimental studies, using indomethacin/Eudragit E ASD systems, show that the 
solubility advantage of the amorphous indomethacin is significantly reduced through ASD 
formation and water partitioning. For the ASD with 70% drug loading, the solubility of 
indomethacin is lower than its crystalline counterpart. Our results show that stabilization 
through the ASD formation and water sorption can be manifested by the lowering of drug 
solubility, and demonstrate that the core property in ASD development is the drug chemical 
                                               
 
1 Huang, S., Mao, C., Williams, R. O., Yang, C. Y. Solubility Advantage (and Disadvantage) of 
Pharmaceutical Amorphous Solid Dispersions. Journal of Pharmaceutical Sciences 105, 3549-3561. 
I am the primary author of this work. 
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potential, which is essentially the thermodynamic driving force and can be quantitated 
using the model presented in this work.  
2.2 INTRODUCTION 
In today’s pharmaceutical development, delivering molecules through the 
preparation of an amorphous solid dispersion (ASD) has become a routine practice for 
small molecule drugs exhibiting poor aqueous solubility. Since the idea of the ASD was 
accepted into to the mainstream of pharmaceutical industry at the turn of the century (1, 2), 
substantial advances have been made regarding the preparation, characterization, 
stabilization, and biopharmaceutical performance of the ASD systems, which have been 
well elaborated in a diverse array of review articles (3-6). 
One of the main purposes of an ASD formulation is to improve the drug exposure 
in humans through the elevation of the apparent drug solubility. Nevertheless, the answer 
to a highly germane question to this end: “What is the true solubility advantage of the ASD 
system over that of crystalline drug?”, still remains elusive. Numerous experiments have 
been carried out to evaluate the maximum solubility or supersaturation an ASD system can 
sustain (7-10), but attempts to estimate the true solubility advantage of ASD have been 
scarce.  
Unlike ASDs, the estimation of the solubility advantage of neat amorphous drugs 
was extensively studied separately by Hancock et al and Murdande et al. (11-14). In both 
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studies, the true solubility advantage of the amorphous drug compared to its crystalline 
counterpart was assessed by evaluating the free energy difference between the two forms 
through the measurement of their thermal properties. Both studies treated the amorphous 
drug as a supercooled liquid form. Additionally, through the work of the Murdande et al., 
corrections were made to account for the solubility change due to water sorption and the 
difference in solution ionization status, and this exercise led to close proximity between 
the estimated and experimental solubility values, particularly for drugs that remained in 
their amorphous state for a prolonged period of time in water (12-14). 
Similar to the neat amorphous drug, the solubility advantage of a drug in the form 
of an ASD is also determined by the free energy. In a more precise term, provided that an 
ASD is a miscible 1-phase, multi-component system, the solubility advantage is governed 
by the partial molar free energy, or chemical potential of the drug. Because of the presence 
of extra components in the system, the free energy of the drug is not equivalent to its neat 
amorphous counterpart, and we believe this will lead to a considerable difference in their 
corresponding solubility advantage. 
Another effect one must consider is the fate of the ASD upon exposure to water. A 
common perception in the current literature is that once an ASD is in contact with water, 
the highly hydrophilic, soluble polymer will dissolve away, leaving the amorphous drug 
present as the undissolved solute in the super-saturated condition, and the dissolved 
polymer could potentially act to retard the drug crystallization. From the phase equilibria 
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standpoint, this conception may be an over-simplification. An ASD in equilibrium with 
water is a ternary system, containing three components (drug, polymer and water). At 
constant temperature and pressure, the phase rule permits the coexistence of up to three 
phases, and the phase behavior depends largely on the mutual solubilities of the three 
components. Take co-crystals as an example (like ASD, it is also a 1-phase, 2-component 
system), the coexistence of three phases is extremely common for co-crystals in 
equilibrium with water (a solution phase, a co-crystal phase, and either the drug or 
coformer phase) (15, 16). In fact, the phase behavior for the ASD-water system can be 
more sophisticated because, unlike in co-crystals, significant water partitioning can take 
place in the ASDs, potentially enabling the coexistence of multiple 3-component phases 
(this phenomenon is not possible for co-crystals because crystal does not absorb significant 
amount of water into its lattice).(17) There have been many reports on “amorphous-
amorphous” phase separation when an ASD is exposed to elevated humidity.(18-20) In 
essence, the case of “ASD in high humidity” is not fundamentally different from the 
situation where an ASD is equilibrated with bulk water. It simply represents different 
positions in the same drug-polymer-water ternary phase diagram, which ultimately dictates 
the number of phases present and their respective compositions. 
In principle, the solubility of a drug is essentially governed by the chemical 
potential of the drug in the undissolved solute. The complication concerning ASD 
solubility therefore stems from the fact that the undissolved solute is no longer the neat 
drug, but rather a multi-component phase containing up to three components including the 
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drug. Application of this concept to ASDs implicates that in order to contemplate the issue 
of ASD solubility, two sequential topics must be addressed: 1) the state of the undissolved 
solute and its quantitative composition, and 2) quantitative determination of the chemical 
potential of the drug in such undissolved solute. In this study, we aim to address these two 
fundamental questions, so that the mechanism of solubility enhancement of ASD (or the 
lack thereof) can be elucidated, both qualitatively and quantitatively. To achieve this 
objective, we present a full thermodynamic model to enable the estimation of the chemical 
potential of a drug, by considering all processes involved in ASD formation and 
dissolution, i.e. drug amorphization, mixing with polymer, and water partitioning. As 
verification, experimental solubility advantages of model ASD systems were also obtained 
through intrinsic dissolution studies. Through this work, we hope to emphasize that a 
highly critical thermodynamic property of an ASD system is the drug’s chemical potential, 
of which the solubility is a manifestation. Because our model allows for the mapping of 
the drug chemical potential in the ASD, this approach can also be used to estimate the 
thermodynamic driving force for various ASD systems under different storage conditions, 
a vital attribute for the physical stability evaluation.  
2.3 THEORY: CALCULATION OF SOLUBILITY ADVANTAGE AND DISADVANTAGE OF 
DRUGS IN AMORPHOUS SOLID DISPERSIONS 
The solubility enhancement of a drug in an amorphous state is solely the 
consequence of increasing chemical potential (𝜇), or thermodynamic activity (a), of the 
drug. Consider, under constant temperature and pressure, the saturated solutions each 
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equilibrated with the crystalline or with the amorphous drug. Because the activity of the 
undissolved solute is equal to the activity of the dissolved solute, the evaluation of 
solubility ratio between the amorphous and crystalline drug is made possible by assessing 
their chemical potential difference: 
∆𝜇𝐴−𝑋 = 𝑅𝑇ln
𝑎𝐴,𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑
𝑎𝑋,𝑢𝑛𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑
= 𝑅𝑇ln
𝑎𝐴,𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑
𝑎𝑋,𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑
= 𝑅𝑇ln
𝑋𝐴𝛾𝐴
𝑋𝑋𝛾𝑋
 (1) 
The symbol 𝑋𝐴 and 𝑋𝑋 represent the molar fraction of amorphous and crystalline 
drug in a saturated solution (a.k.a, solubility), respectively; R is the gas constant and T is 
the temperature in Kelvin. Under infinite dilution assumption (which holds true for poorly 
water soluble drugs), the activity coefficient of the amorphous and crystalline drugs are 
considered equal: 𝛾𝐴 = 𝛾𝑋 . Thus the solubility ratio between the amorphous and 
crystalline drug can be determined by rearranging equation 1 as: 
𝑋𝐴
𝑋𝑋
= exp⁡(
∆𝜇𝐴−𝑋
𝑅𝑇
)  (2) 
As shown in equation 2, the theoretical solubility ratio between the amorphous and 
crystalline drug can be calculated by measuring the chemical potential differences between 
these two states. The ensuing sections delineate the approaches to estimate the chemical 
potential changes resulting from the processes which transform a neat crystalline drug to 
the drug mixed within an ASD system, and from the water sorption into the ASD system. 
Specifically, the following three processes are considered: 
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1. Chemical potential change of the drug due to amorphization, i.e., chemical 
potential difference of the neat drug between the amorphous state and crystalline state; 
2. Chemical potential change of the drug as a result of mixing with a polymeric 
component, or ASD formation; 
3. Chemical potential change of the drug resulting from water partitioning into the 
ASD when it is in equilibrium with water. 
Assuming identical solution properties (e.g., the same ionization and complexation 
status in solution state) and free of water-mediated crystallization, the consideration of the 
above effects, combined, is adequate to provide a quantitative measure of the drug 
solubility in an ASD, as compared with the neat amorphous or crystalline state. 
2.3.1 Chemical Potential Difference between the Neat Amorphous and Crystalline 
Drug States 
The calculation of the chemical potential difference between the amorphous and 
crystalline states of drugs has been described in the articles by Hancock and Parks (11), 
and by Murdande et al. (12). Notably, in both papers, the calculation was presented by 
taking the supercooled liquid, rather than glass, as the reference amorphous state. While it 
was believed that the thermodynamic properties of the supercooled liquid and glass states, 
relevant to the solubility evaluation, are very similar,(12) we nevertheless present the 
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equations by referring the amorphous state as both a glass and supercooled liquid, so as to 
provide a quantitative comparison over these two assumptions.  
Regardless of the choice of amorphous state, the derivation follows the same 
principle: the chemical potential is calculated by designing hypothetical process paths, 
which allow for the determination of enthalpy and entropy differences between crystalline 
and amorphous states at the temperature of interest using measureable thermal properties 
(such as heat or heat capacity).  
When the supercooled liquid is assumed as the reference amorphous state, the 
enthalpy and entropy difference between the amorphous and crystalline state can be 
determined via a hypothetical path including: 1) heating the crystalline phase from 
temperature of interest to melting temperature, 2) fusion, and 3) cooling the liquid phase 
back to the temperature of interest (illustrated in Figure 2.1A). The equations representing 
this hypothetical path are therefore as follows: 
∆𝐻𝐴−𝑋(𝑇) = ∆𝐻𝑚 − ∫ (𝐶𝑝,𝐿 −
𝑇𝑚
𝑇
𝐶𝑝,𝑋)𝑑𝑇  (3) 
∆𝑆𝐴−𝑋(𝑇) =
∆𝐻𝑚
𝑇𝑚
− ∫
𝐶𝑝,𝐿−𝐶𝑝,𝑋
𝑇
𝑇𝑚
𝑇
𝑑𝑇  (4) 
where ∆𝐻𝑚  and 𝑇𝑚  are the heat of fusion and melting temperature; 𝐶𝑝,𝐿  and 
𝐶𝑝,𝑋 are the heat capacity of the liquid and crystal, respectively. The chemical potential 
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difference (which is interchangeable with free energy, G, for one component system) is 
therefore: 
∆𝐺𝐴−𝑋(𝑇) = ∆𝐻𝐴−𝑋(𝑇) − 𝑇∆𝑆𝐴−𝑋(𝑇)  
= ∆𝐻𝑚 (
𝑇𝑚−𝑇
𝑇𝑚
) − ∫ (𝐶𝑝,𝐿 −
𝑇𝑚
𝑇
𝐶𝑝,𝑋)𝑑𝑇 + 𝑇 ∫
𝐶𝑝,𝐿−𝐶𝑝,𝑋
𝑇
𝑇𝑚
𝑇
𝑑𝑇 (5) 
Since all properties at the right hand side of equation 5 are available through direct 
measurement or extrapolation from measurable thermal quantities, the chemical potential 
difference can readily be evaluated through calorimetric analysis. Note that because the 
glass is not the reference amorphous state, this approach does not take into account the 
glass transition process.  
Alternatively, when the glass is assumed as the reference amorphous state, the glass 
transition needs to be included in the hypothetical process path designed for the calculation 
of chemical potential difference. The path therefore includes the following steps: 1) heating 
the crystalline phase from temperature of interest to melting temperature, 2) fusion, and 3) 
cooling the liquid phase back to the glass transition temperature, 4) glass transition (from 
liquid to glassy state), and 5) cooling the glass from the glass transition temperature to the 
temperature of interest (illustrated in Figure 2.1B). Following this path, the enthalpy, 
entropy, and free energy difference are given as follows: 
∆𝐻𝐴−𝑋(𝑇) = ∆𝐻𝑚 − ∫ (𝐶𝑝,𝐺 −
𝑇𝑔
𝑇
𝐶𝑝,𝑋)𝑑𝑇 − ∫ (𝐶𝑝,𝐿 −
𝑇𝑚
𝑇𝑔
𝐶𝑝,𝑋)𝑑𝑇 (6) 
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∆𝑆𝐴−𝑋(𝑇) =
∆𝐻𝑚
𝑇𝑚
− ∫
𝐶𝑝,𝐺−𝐶𝑝,𝑋
𝑇
𝑇𝑔
𝑇
𝑑𝑇 − ∫
𝐶𝑝,𝐿−𝐶𝑝,𝑋
𝑇
𝑇𝑚
𝑇𝑔
𝑑𝑇 (7) 
∆𝐺𝐴−𝑋(𝑇) = ∆𝐻𝑚 (
𝑇𝑚−𝑇
𝑇𝑚
) − [∫ (𝐶𝑝,𝐺 −
𝑇𝑔
𝑇
𝐶𝑝,𝑋)𝑑𝑇 + ∫ (𝐶𝑝,𝐿 −
𝑇𝑚
𝑇𝑔
𝐶𝑝,𝑋)𝑑𝑇] +
𝑇 [∫
𝐶𝑝,𝐺−𝐶𝑝,𝑋
𝑇
𝑇𝑔
𝑇
𝑑𝑇 + ∫
𝐶𝑝,𝐿−𝐶𝑝,𝑋
𝑇
𝑇𝑚
𝑇𝑔
𝑑𝑇] (8) 
where 𝐶𝑝,𝐺  is the heat capacity of glass and 𝑇𝑔 is the glass transition temperature. 
The solubility ratio between the amorphous and crystalline state of a neat drug can 
therefore be assessed by combining equation 2 with equation 5 (using supercooled liquid 
as reference amorphous state), or with equation 8 (using glass as reference amorphous 
state). 
2.3.2 Chemical Potential Change of Drug Resulting from ASD Formation  
The formation of a fully miscible ASD is in essence a mixing process giving rise to 
a one-phase, two-component system. Because pharmaceutical ASDs typically involve a 
small molecule drug and a polymeric component, the system is pertinently described by 
the Flory-Huggins equation originally used to study polymer-solvent miscibility.(21) 
Based on the Flory-Huggins formalism, the free energy of mixing ∆𝐺𝑚𝑖𝑥 for the ASD 
system is: 
∆𝐺𝑚𝑖𝑥 = 𝑅𝑇 (∅𝑑𝑟𝑢𝑔ln∅𝑑𝑟𝑢𝑔 +
∅𝑝𝑜𝑙𝑦
𝑟
ln∅𝑝𝑜𝑙𝑦 + 𝜒∅𝑑𝑟𝑢𝑔∅𝑝𝑜𝑙𝑦) (9) 
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where ∅𝑑𝑟𝑢𝑔  and ∅𝑝𝑜𝑙𝑦  are the volume fraction of the drug and polymer, 
respectively. The symbol 𝑟 is the volume ratio of polymer and drug (𝑟 = 𝑉𝑝𝑜𝑙𝑦/𝑉𝑑𝑟𝑢𝑔), 
and 𝜒 is the interaction parameter. 
It’s important to note that the Flory-Huggins equation (equation 9) assesses the free 
energy of the ASD system only, whereas the component of interest is in fact the drug. To 
consider the change of chemical potential, or partial molar free energy, of the drug in the 
ASD system, one is to take the partial derivative of ∆𝐺𝑚𝑖𝑥  with respect to the molar 
quantity of the drug (∆𝜇𝑑𝑟𝑢𝑔 =
𝜕∆𝐺𝑚𝑖𝑥
𝜕𝑛𝑑𝑟𝑢𝑔
|
𝑃,𝑇,𝑛𝑝𝑜𝑙𝑦
). The derivation leads to (22): 
∆𝜇𝑑𝑟𝑢𝑔
𝑅𝑇
= ln∅𝑑𝑟𝑢𝑔 + (1 −
1
𝑟
) ∅𝑝𝑜𝑙𝑦 + 𝜒∅𝑝𝑜𝑙𝑦
2
 (10) 
Equation 10 describes the chemical potential change of an amorphous drug when it 
is mixed with a polymeric component to form the miscible ASD. Because the volume 
fraction and size difference of two components are readily available from the drug loading 
and the molecular properties of individual components, the effect of ASD formation on the 
chemical potential of the drug can be quantitatively evaluated as long as the interaction 
parameter 𝜒, representing the enthalpic contribution of the drug-polymer interaction, is 
known. 
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2.3.3 Chemical Potential Change of Drug in ASD Resulting from Water Partition  
Unlike the crystalline drug, which does not take up a significant amount of water 
in its lattice, amorphous systems are characterized by stronger moisture absorption in an 
environment with high water activity. For a saturated aqueous solution equilibrated with 
ASD, water partition into the undissolved solute during water equilibration will take place 
and will effectively lower the activity of the drug.(23) Namely, the chemical potential of 
the drug in an ASD will be further reduced as the result of water partitioning, when the 
ASD is exposed to water. 
The impact of water sorption on chemical potential of the neat drug was previously 
investigated in a number of articles (12, 13, 24, 25) following the Gibbs-Duhem equation. 
Unlike the neat drug, a total of 3 components must be accounted for regarding the ASD-
water system. At constant temperature and pressure, the Gibbs-Duhem equation therefore 
takes the following form: 
𝑥𝑑𝑟𝑢𝑔𝑑𝜇𝑑𝑟𝑢𝑔 + 𝑥𝑝𝑜𝑙𝑦𝑑𝜇𝑝𝑜𝑙𝑦 + 𝑥𝑤𝑎𝑡𝑒𝑟𝑑𝜇𝑤𝑎𝑡𝑒𝑟 = 0 (11) 
Rearranging equation 11 and integrating from zero to complete water saturation 
gives: 
∆𝜇𝑑𝑟𝑢𝑔 +
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
∆𝜇𝑝𝑜𝑙𝑦 = −∫
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
𝑑𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟
0
0
  (12) 
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Because 𝜇𝑤𝑎𝑡𝑒𝑟 = 𝜇𝑤𝑎𝑡𝑒𝑟
0 + 𝑅𝑇ln𝑎𝑤𝑎𝑡𝑒𝑟, where 𝜇𝑤𝑎𝑡𝑒𝑟
0  is the chemical potential 
of water at standard state, and 𝑎𝑤𝑎𝑡𝑒𝑟  is the water activity, and assuming 
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
 remains 
unchanged regardless of the extent of water sorption in ASD, equation 12 can be re-written 
as: 
∆𝜇𝑑𝑟𝑢𝑔 +
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
∆𝜇𝑝𝑜𝑙𝑦 = −𝑅𝑇 ∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
 (13) 
If we make an assumption that the ASD is a homogenous 1-phase system, and that 
the interaction of water with drug and with polymer are identical, such that ∆𝜇𝑑𝑟𝑢𝑔 =
∆𝜇𝑝𝑜𝑙𝑦 , then the chemical potential of the drug in ASD becomes: 
∆𝜇𝑑𝑟𝑢𝑔
𝑅𝑇
= −(∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
) / (1 +
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
) (14) 
The evaluation of ∆𝜇𝑑𝑟𝑢𝑔  from standard dynamic vapor sorption experiment is 
thus enabled by equation 14. The vapor sorption isotherm of the ASD, covering the relative 
humidity of 0% to 100%, can be integrated following equation 14 to obtain the quantitative 
estimation of the chemical potential change of the drug resulting from water partition into 
the ASD. 
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2.3.4 Drug Solubility Ratio: ASD vs. Neat Crystalline or Amorphous Drug 
By accounting for the process of amorphization, ASD formation, and water 
partition, one can estimate the solubility ratio between the drug in ASD and the drug in 
neat crystalline state, 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
. Specifically, the solubility ratio is obtained by combining 
equations 2, 5 (or 8), 10, and 14 as: 
ln
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
= {
∆𝐻𝑚
𝑅
(
1
𝑇
−
1
𝑇𝑚
) −
1
𝑅𝑇
∫ (𝐶𝑝,𝐿 −
𝑇𝑚
𝑇
𝐶𝑝,𝑋)𝑑𝑇 +
1
𝑅
∫
𝐶𝑝,𝐿−𝐶𝑝,𝑋
𝑇
𝑇𝑚
𝑇
𝑑𝑇} + {ln∅𝑑𝑟𝑢𝑔 +
(1 −
1
𝑟
) ∅𝑝𝑜𝑙𝑦 + 𝜒∅𝑝𝑜𝑙𝑦
2} − {(∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
) / (1 +
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
)} (15) 
Equation 15 assumes that the supercooled liquid is reference amorphous state, or: 
ln
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
= {
∆𝐻𝑚
𝑅
(
1
𝑇
−
1
𝑇𝑚
) −
1
𝑅𝑇
[∫ (𝐶𝑝,𝐺 −
𝑇𝑔
𝑇
𝐶𝑝,𝑋)𝑑𝑇 + ∫ (𝐶𝑝,𝐿 −
𝑇𝑚
𝑇𝑔
𝐶𝑝,𝑋)𝑑𝑇] +
1
𝑅
[∫
𝐶𝑝,𝐺−𝐶𝑝,𝑋
𝑇
𝑇𝑔
𝑇
𝑑𝑇 + ∫
𝐶𝑝,𝐿−𝐶𝑝,𝑋
𝑇
𝑇𝑚
𝑇𝑔
𝑑𝑇]} + {ln∅𝑑𝑟𝑢𝑔 + (1 −
1
𝑟
) ∅𝑝𝑜𝑙𝑦 + 𝜒∅𝑝𝑜𝑙𝑦
2} −
{(∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
) / (1 +
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
)} (16) 
Equation 16 assumes that the glass is the amorphous reference state.  
The three curly brackets on the right hand side of equations 15 and 16 represent the 
contributions from the process of amorphization, ASD formation, and water partitioning, 
respectively. 
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The derivation also allows for the estimation of solubility ratio between the drug in 
ASD and the drug in neat amorphous state, 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡. Although the drug remains amorphous 
in both conditions, their chemical potentials (and thereby solubilities) are different due to 
the mixing process from the ASD formation, as well as the difference in their ability to 
absorb water upon water exposure. 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡 is expressed by combining equations 2, 10, and 
14: 
ln
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡 = [ln∅𝑑𝑟𝑢𝑔 + (1 −
1
𝑟
) ∅𝑝𝑜𝑙𝑦 + 𝜒∅𝑝𝑜𝑙𝑦
2] − [(∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
) / (1 +
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
)]
𝐴𝑆𝐷
+ [∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
]
𝑛𝑒𝑎𝑡
 (17) 
The subscripts “ASD” and “neat” on the right hand side of equation 17 indicate the 
water absorption with the ASD and with the neat amorphous drug, respectively.  
Collectively, equations 15, 16, and 17 establish the full thermodynamic treatment 
of the solubility advantage (and disadvantage) of the drug in the form of an ASD, as 
compared to its crystalline and amorphous counterparts.  
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2.4 MATERIALS AND METHODS 
2.4.1 Materials 
Crystalline indomethacin (IMC) was purchased from Acros Organics (Fisher 
Scientific, Waltham, WA). EUDRAGIT® E PO (EPO) was obtained from Evonik (Evonik 
Industries, Piscataway, NJ). Phosphoric acid and HPLC grade acetonitrile were purchased 
from Fisher Scientific (Fisher Scientific, Houston, TX). All other chemicals used in this 
study were of American Chemical Society (ACS) grade. 
2.4.2 Methods 
2.4.2.1 Preparation of Amorphous Drug and Amorphous Solid Dispersions 
Amorphous IMC and IMC/EPO ASDs with IMC loadings of 30%, 50%, and 70% 
w/w were prepared by quench cooling the molten raw crystalline IMC (γ-form) or the 
IMC/EPO physical blends. Specifically, the crystalline IMC or IMC/EPO physical blends 
were kept in a scintillation vial in an oven set at 175 ℃ until they were visually 100% 
molten. The vial was then stored in the oven for an additional 5 minutes. The molten 
materials were then quench-cooled by immersion into liquid nitrogen and further milled 
using pre-chilled mortar and pestle in a dry glove box to avoid moisture condensation.  
The resulting melt-quenched samples were confirmed to be fully amorphous by the 
absence of birefringence under cross polarized microscopy, the absence of a crystalline 
diffraction pattern by powder x-ray diffraction, and by the presence of a glass transition 
  
76 
and absence of melting endotherm by differential scanning calorimetry. All amorphous 
samples were analyzed by reverse phase HPLC (high-performance liquid chromatography) 
to assess their chemical purity after melting and quench cooling. All amorphous 
compounds were determined to have > 99% purity relative to the original crystalline 
sample. Amorphous samples were stored in a desiccator over phosphorus pentoxide and 
were presented for analysis as powders of between 74 (200 US mesh) and 125 μm (120 US 
mesh). The water content of each of these samples was found to be less than 0.2% w/w by 
Karl-Fisher titration. 
2.4.2.2 Intrinsic Dissolution 
To evaluate the true solubility advantage of ASDs, intrinsic dissolution tests were 
carried out as an alternative to the equilibrium solubility measurements to minimize the 
likelihood of potential water-mediated crystallization (26, 27). For a diffusion-controlled 
dissolution process, the intrinsic dissolution rate (dm/dt) is governed by the Noyes-
Whitney equation: 
𝑑𝑚
𝑑𝑡
= 𝐴
𝐷
ℎ
(𝐶𝑠 − 𝐶0) (18) 
where A is the surface area, D is the diffusion coefficient, h is the thickness of the 
diffusion layer, and C_s and C_0 are the concentration at the inner boundary of the 
diffusion layer (or saturated solubility) and in the bulk, respectively. As far as IMC is 
concerned, when the intrinsic dissolution tests of the IMC/EPO ASDs (including the 
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IMC/EPO physical mixtures) are conducted with identical surface area, under sink 
conditions, and with identical hydrodynamics, the solubility of the IMC (C_s) is linearly 
proportional to its intrinsic dissolution rate (dm/dt). The solubility advantage of ASDs can 
therefore be obtained by comparing the intrinsic dissolution rate of an ASD with the 
corresponding IMC/EPO physical mixture of the same drug loading.  
A custom-made system, modified from the traditional Wood’s design (28), was 
used for the intrinsic dissolution testing. For each run, 75 mg of ASD powder between 74 
to 125 μm in size were compressed into compact in an 8-mm round die using a Carver 
press. For the intrinsic dissolution testing of IMC/EPO physical mixtures, the two 
components were co-ground using mortar and pestle to achieve intimate mixing before 
compressing into compact. The compact was produced at the compression force of 1.5 
metric ton and the dwell time of 3 second to ensure that a highly smooth compact surface 
was produced. The compact was then ejected against a smooth metal surface so that the 
bottom face of the compact was fully exposed. No phase transformation or chemical 
degradation was observed due to compression.  
The compact-die assembly was placed at the center of a 500-mL beaker containing 
200 mL 50 mM, pH 6.0 citrate buffer pre-warmed at 25 °C. A paddle was placed 1 inch 
above the exposed compact surface and stirred at a rate of 50 RPM. Dissolution medium 
samples were collected at predetermined time points and analyzed using HPLC. Only the 
data from the samples collected at early time points (below 10 min), which fit well into a 
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straight line in the concentration-time profile, were used for dissolution rate analysis. The 
pH of the dissolution medium was found to remain unchanged during the course of the 
dissolution run. For tests where ASDs or the neat amorphous drug were used as specimen, 
the remaining compacts were collected at the end of the run and subjected to powder X-
ray diffraction analysis to confirm the lack of crystallization. At least three separate 
measurements were carried out for each material. To ensure identical surface area and 
hydrodynamic conditions, the exact same experimental setup and accessory parts, 
including the beaker, were used for all measurements. 
2.4.2.3 Heat Capacity Measurement 
The calorimetric analysis of IMC, EPO and ASDs were measured by a TA Q2000 
differential scanning calorimeter (DSC) equipped with a refrigerated cooling system (TA 
Instruments, New Castle, DE). Dry nitrogen gas at a flow rate of 40 mL/min throughout 
the testing was used to purge the cell. For heat capacity measurement, the standard ASTM 
method was adopted (29). Firstly, empty hermetic pans with lids (without crimping) was 
heated from 25 °C to 105 °C at the heating rate of 20 °C/min and then cooled to -20 °C, 
followed by a 5 minutes isothermal hold. The pans were then heated back to 180 °C at the 
heating rate of 20 °C/min. Secondly, the accurately weighed (±0.001 mg) disc-shape 
sapphire standard were loaded into the same sample pan and subjected to the identical 
“heat-cool-heat” cycle. Thirdly, the sapphire standard disc was removed from the same 
sample pan and replaced by the specimen. The same thermal cycle was performed again. 
The heat capacity of the specimen was calculated from the heat flow data and by 
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referencing the heat capacity data of the sapphire standard, following the ASTM method 
(30). 
2.4.2.4 Melting Point Depression Analysis 
The interaction parameter of the IMC/EPO system was determined by the melting 
point depression analysis. Physical IMC/EPO mixtures containing 0, 5, 10, 15, 20, and 
25% wt of EPO (w/w) were prepared by geometric mixing. These mixtures were stored in 
desiccator over phosphorous pentoxide until use. The melting temperature of the IMC in 
the presence of EPO was measured with the TA Q2000 DSC equipped with a refrigerated 
cooling system at a scan rate of 1 ℃/min. The extrapolated onset melting temperature was 
used for the data analysis. The details of the method is described elsewhere.(31) 
2.4.2.5 Dynamic Vapor Sorption Analysis 
The water sorption isotherm of amorphous IMC and ASDs were determined at 25 
℃ using a DVS2000 dynamic vapor sorption apparatus (Scientific Measurement Systems, 
Manchester, UK). The sample (about 10 mg) was transferred to the quartz holder where 
they were dried at 25 ℃, 0.4% relative humidity (RH) until a constant mass was attained. 
The moisture sorption isotherm was measured by increasing percent RH at the step size of 
5% and covered the entire (0-100%) RH range. A maximum of 6 hours of equilibration 
time was given for each RH step, unless the rate of weight gain dropped to below 0.005% 
wt per 10 min. At the end of the sorption runs, samples were retrieved and subjected to the 
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polarized light microscopy and powder X-ray diffractometry to verify the absence of 
moisture-mediated crystallization.  
2.5 RESULTS AND DISCUSSIONS 
2.5.1 What is the Undissolved Solute When an ASD is in Equilibrium with Water? 
We start the discussion by asking the question: What exactly is the undissolved 
solute when an ASD is in equilibrium with water? This is a critical question because it is 
the activity of drug in the undissolved solute that governs the solubility. The answer for the 
question lies in the understanding of the phase behavior of the ternary system, which 
consists of three components (drug, polymer, and water) and up to three phases at constant 
temperature and pressure, as permitted by the phase rule.  
Most pharmaceutical ASDs share some common features: they are the binary 
system containing a poorly water soluble drug, and a polymer component which is 
hydrophilic and possesses high solubility with both water and the drug (such as PVP, 
PVPVA, or HPMC etc.). Because the water-equilibrated ASD exists as the supercooled 
liquid state due to significant water partitioning (see discussion in ensuing sections), the 
phase equilibria in the pharmaceutical drug-polymer-water system is analogous to the 
“polymer”-solvent-nonsolvent (P-S-N) system commonly encountered in the polymer 
industry (the quotation mark is used to distinguish from pharmaceutical polymers used in 
ASD) (32-34). Here, the pharmaceutical polymer is analogous to the solvent because the 
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polymer is miscible with both water and drug; the water is analogous to nonsolvent, and 
the drug to “polymer”. Just as the “polymer” is not soluble in nonsolvent, neither is the 
drug soluble in water. 
The simplest phase equilibria of the pharmaceutical ASD in water are demonstrated 
in the schematic ternary phase diagram shown in Figure 2.2. In the diagram, point A 
represents the state of a typical ASD solubility study, where a small quantity of ASD 
(assuming 50% drug loading here, corresponding to point D) is placed in a large amount 
of water. Like the P-S-N system, there is a miscibility gap that extends from the drug-water 
side into the ternary system. Because point A is located inside the miscibility gap, the ASD-
water system in equilibrium contains two phases, and their respective compositions are 
revealed through the tie line BC which extends through point A. The measured drug 
solubility in water can therefore be determined from point C, the phase where water is the 
prevalent component. Similarly, the final equilibrating ASD (or undissolved solute) 
corresponds to point B, the phase where the drug and polymer are the prevalent 
components. Figure 2.2 shows that the final equilibrating ASD in water has much higher 
drug loading (point F) than the original ASD (point D). The analysis on the simple version 
of the schematic ternary phase diagram indicates that the ASD solubility is a rather 
complicated issue. The apparent aqueous drug solubility of an ASD not only depends on 
the size and shape of the miscibility gap, which could be evaluated under the framework 
of the Flory-Huggins theory, it also depends on the initial ASD drug loading, as well as the 
amount of ASD added in water (because they control where the tie line is drawn).  
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To the question: What is the undissolved solute when an ASD is equilibrated with 
water? A possible answer by following Figure 2 is: as the first step, a 1-phase, 3-component 
system containing drug, polymer and water (such as point B in Figure 2.2), and the 
compositions of this solute may be different from the original ASD compositions. A 
subsequent crystallization step could occur if the chemical potential of the drug in this 
solute is higher than the free energy of the neat crystal. But even without crystallization, 
we may not expect the predicted solubility advantage, calculated on the basis of the initial 
drug loading and moisture sorption isotherm of the “dry” ASD, to be identical to the 
experimental data. However, if the compositions of the undissolved solute are known, then 
the drug solubility of ASD, relative to the neat form, can be calculated. The following 
sections center on the quantitative estimation of the effect of polymer and water on drug 
solubility, as they are inevitably present in the undissolved solute in the ASD-water system.  
2.5.2 Solubility Advantage of Amorphous Drug Can be Reduced Through ASD 
Formation 
The impact of ASD formation on IMC drug solubility is presented in Table 2.1 and 
Table 2.2. The tables list the experimental and predicted solubility ratio of IMC in the form 
of ASD, versus the neat crystalline form (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
) and versus the neat amorphous form (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡), 
respectively. The calculations were carried out by following equations 15 and 17, using the 
molecular properties of IMC and EPO given in Table 2.3. The experimental solubility 
ratios (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
 and 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡) were determined through the intrinsic dissolution rate obtained at 
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the early phase of the dissolution process, using the respective materials, i.e. IMC/EPO 
ASD, physical mixture of crystalline IMC and EPO, and physical mixture of amorphous 
IMC and EPO, all with the same drug loading (Figure 2.3). The intrinsic dissolution was 
used as an alternative to the equilibrium solubility measurement to minimize the potential 
confounding effect of water-mediated crystallization (see Materials and Methods section).  
The experimental data in Table 2.1 show that the solubility advantages of IMC in 
IMC/EPO ASD systems over the crystalline form are rather limited. The highest solubility 
ratio (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
) observed is 1.27, and for the ASD with 70% drug loading, the solubility of 
IMC is lower than that of its crystalline counterpart! As verification, our experimental 
solubility ratio of the neat amorphous IMC vs neat crystalline IMC at 25 oC, also through 
intrinsic dissolution measurements, is 3.4, close to the literature data (between 4.4-4.9).(11, 
12) These ASD solubility data demonstrate that: for an amorphous drug, the ASD 
formation could be a process of strong thermodynamic stabilization, leading to marked 
decrease in its chemical potential, which can be manifested by the lowering of its solubility. 
In order to capture this phenomenon, we purposely selected EPO as the polymeric 
component for the ASD, and conducted the dissolution experiments at pH 6.0, where EPO 
exhibits low solubility. Additionally, we determined the intrinsic dissolution rate using the 
data points collected in the first few minutes, so as to minimize any potential phase 
separation or phase transformation upon exposure of ASD to water.  
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The stabilization effect of ASD formation is equally evident from the experimental 
solubility ratio of IMC in the form of ASD vs. neat amorphous IMC (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡) (Table 2.2). In 
all ASD systems tested, the solubility of IMC in the form of ASD is lower than the neat 
amorphous form; value of 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡 as low as 21% is observed. These data suggest that, for a 
small molecule drug, its solubility advantage gained through amorphization can take a 
significant loss when the drug is mixed with another component to form a stable ASD 
system, even though the amorphous structure of the ASD is maintained.  
The solubility-reducing effect underlying the ASD formation can be understood 
through examining the theoretical calculations. As shown in Table 2.1 and 2.2, the ASD 
formation plays a significant role in lowering the predicted drug solubility. Quantitatively, 
the extent of solubility reduction through ASD formation is expressed by equation 10: 
∆ln𝑋𝐴
𝐴𝑆𝐷 =
∆𝜇𝑑𝑟𝑢𝑔
𝑅𝑇
= ln∅𝑑𝑟𝑢𝑔 + (1 −
1
𝑟
) ∅𝑝𝑜𝑙𝑦 + 𝜒∅𝑝𝑜𝑙𝑦
2
. Equation 10 indicates that the 
magnitude of chemical potential or solubility change of a drug in ASD depends primarily 
on two factors: 1) drug loading, and 2) drug-polymer interaction parameter . Using 
IMC/EPO ASD system as an example, the impact from these two factors is exhibited in 
Figure 2.4, where the solubility advantage of ASD over the crystal, 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
, and ASD-driven 
chemical potential change are plotted as the function of drug loading. To demonstrate the 
effect of drug-polymer interaction, Figure 2.4 also contains several curves calculated using 
the properties of the IMC/EPO ASD system but with hypothetical  values. The water 
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partitioning effect was not included in the calculation, so that Figure 2.4 focuses solely on 
the effect of ASD formation.  
Figure 2.4 shows that in the actual IMC/EPO ASD system ( = -0.58), the value of 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
 and the chemical potential of the drug decrease monotonically with decreasing drug 
loading. For this ASD system, the negative  value means the IMC-EPO mixing is an 
exothermic event. Thus, for as far as the IMC is concerned, its dilution with EPO is both 
entropically and enthalpically favored in a monotonic manner. In other words, for any ASD 
systems where the mixing is athermal or exothermal ( ≤ 0), the solubility and chemical 
potential of the drug will decrease with decreasing drug loading. This relationship is 
evident in Figure 2.4 for all the ASDs with zero or negative interaction parameter. It is only 
in the systems where  ≥ 0 (endothermic mixing) can the chemical potential of a drug rise 
with decreasing drug loading. Such ASD systems are nevertheless enthalpically disfavored 
and are usually not fully miscible in the long term. 
The interaction parameter  also has profound impact on the IMC solubility and 
chemical potential. By definition,  is the term to account for the non-athermal mixing in 
the Flory-Huggins formalism.(35) A large, negative  value translates to highly exothermic 
drug-polymer mixing and hence stronger attractive interactions. As shown in Figure 2.4, 
ASD systems possessing more negative  values exhibit more precipitous decrease in drug 
solubility and chemical potential with decreasing drug loading, indicating greater 
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stabilization effect. For these systems, the chemical potential or solubility of a drug can be 
depressed to below that of its crystalline counterpart! For example, for the “IMD/EPO 
ASD” with a hypothetical  value of -5 in Figure 2.4, the chemical potential and the 
solubility of the drug become lower than that of the crystalline form (represented as the 
horizontal line in Figure 2.4), when the drug loading drops to below 25%. The interaction 
parameter of this level has shown to be realistic in pharmaceutical ASDs both by 
computation and by experiments.(36,37). To summarize, the formation of an enthalpically 
favored, low drug loading ASD is a highly efficient means to reduce the chemical potential 
of an amorphous drug. If sufficient amount of polymer is present in the equilibrated 
undissolved solute, it will act as a strong thermodynamic stabilizer, which will be reflected 
by the significant decrease of the drug solubility. 
2.5.3 Solubility Advantage of Amorphous Drug Can be Further Reduced by 
Water Partitioning in ASD  
The deleterious effect of water partitioning on the solubility of neat amorphous 
materials has been described by Sacchetti and by Murdande et al.(12, 13, 24, 25) according 
to the Gibbs-Duhem equation. For ASD systems, the same principle applies, but because 
the undissolved solute in the ASD-water system is a 3-component phase, the Gibbs-Duhem 
equation must be presented as a ternary system (instead of binary system), comprising drug, 
polymer and water (see equation 14). The hydrophilic polymers employed in the 
pharmaceutical ASD typically exhibit greater hygroscopicity than the neat amorphous drug 
(such is the case for IMC/EPO system, see Figure 2.5), and are therefore capable of 
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absorbing more water. Essentially, the use of hydrophilic polymers facilitates water 
partitioning into the solid phase, and serves to further reduce the chemical potential of both 
the drug and polymer components.  
The impact of water partitioning on drug solubility in an ASD is significant. In 
Figure 2.6, the estimated solubility ratio 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
, with and without the correction on water 
partition, is shown for IMD/EPO ASD systems with different drug loadings. As expected, 
solubility reduction resulting from the water partitioning is not negligible across all ASD 
systems, including the neat amorphous IMC. It is more pronounced at low drug loading, 
owing to the higher level of water sorption for low drug loading ASDs (Figure 2.5). The 
smallest effect is on neat amorphous IMC, with 23% of decrease in 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
; the greatest effect 
is on ASD with lowest (30%) drug loading, with 67% of decrease in 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
. Combined with 
the previous section, this study shows that the solubility advantage of a drug in ASD can 
be very sensitively to drug loading. Lowering the drug loading leads to chemical potential 
decrease by means of two mechanisms: 1) greater level of polymer dilution and 2) more 
water partitioning. These mechanisms contribute synergistically to removing the solubility 
advantage of the drug originally gained from the process of amorphization.  
It is worth noting that we carried out the quantitative analysis by making an 
assumption that the drug-water interaction and polymer-water interaction are identical, so 
that ∆𝜇𝑑𝑟𝑢𝑔 = ∆𝜇𝑝𝑜𝑙𝑦  (see Theoretical section). We made this assumption because for the 
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ASD-water system, the Gibbs-Duhem equation contains three terms and cannot be resolved 
without a known relationship between ∆𝜇𝑑𝑟𝑢𝑔  and ∆𝜇𝑝𝑜𝑙𝑦 . While the relationship 
∆𝜇𝑑𝑟𝑢𝑔  and ∆𝜇𝑝𝑜𝑙𝑦  is not readily assessed in the miscible system, literature data are 
available for individual components. It was shown that for water partitioning into an 
amorphous drug or polymer, the solid phase usually undergoes a negative deviation from 
the ideal behavior (i.e. greater reduction in chemical potential than predicted by Raoult’s 
law),(24, 38) and that the hydrophilic polymers, such as PVP or microcrystalline cellulose, 
exhibit more negative deviation than indomethacin. If this observation also holds true for 
the 1-phase system, then the relationship becomes: ∆𝜇𝑝𝑜𝑙𝑦 = 𝑘∆𝜇𝑑𝑟𝑢𝑔  where 𝑘 > 1 . 
Equation 14 can therefore be re-written as 
∆𝜇𝑑𝑟𝑢𝑔
𝑅𝑇
= −(∫ (
𝑥𝑤𝑎𝑡𝑒𝑟
𝑥𝑑𝑟𝑢𝑔
)
1
𝑎𝑤𝑎𝑡𝑒𝑟
𝑑𝑎𝑤𝑎𝑡𝑒𝑟
1
0
) / (1 +
𝑘
𝑥𝑝𝑜𝑙𝑦
𝑥𝑑𝑟𝑢𝑔
), indicating that our data regarding drug solubility advantage loss due to water 
partition could be an over-estimate, predicting the worst-case scenario. 
2.5.4 The State of Undissolved Solute: Glass or Supercooled Liquid? 
For solubility assessment of ASDs, a pertinent question to consider is the state of 
the undissolved solute in equilibrium with water, as drug solubility is dictated by the 
activity of the drug in the undissolved solute. As discussed in the preceding section, 
significant water partitioning, with a minimum of a few percent by weight, will occur in 
pharmaceutical ASDs upon exposure to water. Because water is a strong plasticizer and 
possesses a much lower molecular weight than ASD components, the water sorption of this 
magnitude will inevitably depress the Tg to below the temperature of practical interests 
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(e.g. between 0 – 37 oC).(19, 39) Therefore, we believe that for a pharmaceutical ASD in 
equilibrium with water, the undissolved solute is presented as the supercooled liquid. 
Additionally, as proposed Murdande et al.,(12) because supercooled liquid is a quasi-
equilibrium state,(40) any prior thermal history gathered by the glassy ASD will be erased 
upon equilibration with water. For this reason, the solubility estimation in foregoing 
sections was carried out by treating the ASD as a supercooled liquid. 
We complete this question by providing a quantitative comparison of the 
supercooled liquid form and the glass form of IMC, regarding their energy state and 
solubility advantage over crystal. This assessment was carried out following equations 5 
and 8, using the heat capacity data of crystalline, glass, and liquid state of IMC (see 
Theoretical section for details). In Figure 2.7, the estimated solubility ratio between the 
neat amorphous IMC and crystalline IMC, 
𝑋𝐴
𝑋𝑋
, using either the supercooled liquid or glass 
as reference amorphous state, is provided over a range of temperatures below Tg 
(approximately 44 oC). As the temperature is reduced below Tg, the two solubility ratios 
depart, with the glass showing an increasingly higher solubility advantage than the 
supercooled liquid (Figure 2.7). This phenomenon is valid because the glass, being a 
thermodynamically arrested state, always exhibits higher entropy S than the supercooled 
liquid (as demonstrated in Figure 2.1). Because the slope of the G-T curve is –S, the rate 
of free energy increase with decreasing temperature in the glass must be higher than that 
of the supercooled liquid. The lower the temperature away from Tg, the greater this 
discrepancy. However, for IMC, since the temperature of our solubility measurements (25 
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oC) is very close to Tg, the difference between the solubility advantages calculated using 
either glass or supercooled liquid are negligible (
𝑋𝐴
𝑋𝑋
= 48.6  for glass vs. 47.1  for 
supercooled liquid). Yet, for materials possessing a much higher Tg, the difference is 
expected to be significant if the solubility or free energy is estimated at the ambient 
temperature.  
2.5.5 Discrepancy between Predicted and Experimental Solubilities 
Our model predicts that the solubility advantages of IMC in the IMC/EPO ASD 
systems are much less than the estimation based merely on the free energy elevation due 
to amorphization (Table 2.1 and 2.2). This conclusion is corroborated by our experimental 
data showing rather moderate solubility advantage, if at all, of the IMC/EPO ASDs over 
the IMC crystal. Still, the calculated solubility ratios using our model remain as an over-
estimate in comparison with the experimental data (predicted 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
 values of 6.2-25.8 vs. 
experimental values of 1.27-0.95). Most notably, our model indicates that the solubility 
advantage decreases with decreasing drug loading, whereas the experimental data show 
precisely the opposite.  
As stated in the preceding section, we do not expect the experimental solubility to 
be identical to the predicted value, because the final composition of the undissolved solute 
can be different from the original ASD (though we attempted to retard the water-mediated 
phase separation by using an ASD comprising a poorly water soluble polymeric 
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component). Another main contributor to this discrepancy is the evaluation of the 
interaction parameter . In this study,  was measured using the common melting point 
depression approach.(41) The method is known to suffer several limitations, one of which 
is the negligence of its temperature and composition dependence.(42) Due to the nature of 
the method, we assigned a single  value to all ASDs regardless of their composition, 
though  was reported to vary significantly with composition.(43) In our measurements, 
the melting point data were collected with up to 25% EPO in the mixture, and the resulting 
melting points are distant from the ambient temperature. The use of these data at the 
ambient temperature, and for compositions containing a maximum of 70% EPO, could lead 
to substantial deviation. Furthermore, Sun et al.(37) suggest that the typical DSC scanning 
rate for the melting point depression study (such as the rate used in our measurement: 1 
oC/min) could be too fast to attain the solubility equilibrium, so that the apparent melting 
temperature is higher than the value at which the solubility equilibrium would actually be 
arrived. By adding a lengthy annealing step at an elevated temperature to achieve solubility 
equilibrium, Sun et al. obtained  values which are up to one order of magnitude more 
negative than the original approach. This could mean that we significantly under-estimated 
the negativity of the  values for the IMC/EPO ASD systems, and hence over-estimated 
the solubility advantage of the ASDs.  
One evidence appearing to support this hypothesis is the Tg of the IMC/EPO ASDs 
relative to the theoretical values calculated using Gordon-Taylor equation, derived on the 
assumption of volume additivity and ideal mixing behavior.(44) As shown in Figure 2.8, 
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there is a strongly positive deviation from the theoretical Tg for the ASD with high drug 
loading (70%), and negative deviation for the ASD with low drug loading (30%). A 
positive deviation from the theoretical Tg is usually attributed to strong intermolecular 
interactions, and vice versa.(45, 46) While this notion may be an over-simplification and 
exceptions exist,(3) the substantial composition-dependence of Tg deviation of the 
IMC/EPO system agrees with the this hypothesis. Namely, the ASD with high drug loading 
possesses much stronger drug-polymer interaction than the ASD with low drug loading, 
and the actual  value at higher drug loading is more negative than at lower drug loading. 
Consequently, the greater polymer dilution brought about by lower drug loading could be 
offset by the weaker drug-polymer interactions, and the difference in solubility for the ASD 
with different drug loadings would be less pronounced than our original estimate assuming 
a constant  value.  
2.5.6 Pharmaceutical Significance 
Like any solubility study, the activity (or chemical potential) of the drug in the 
undissolved solute is the governing factor for drug solubility. A prerequisite to 
understanding the ASD solubility is to analyze the phase behavior of the drug-polymer-
water ternary system; in particular, the composition of the undissolved solute when the 
ASD is in equilibrium with water. This information should be valuable for pharmaceutical 
ASD development seeking superior solubility and dissolution behavior. To this end, we 
propose that, as a simplest case, the following phenomena could be expected when a 
pharmaceutical ASD is exposed to water: 
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1) A miscibility gap may exist in the drug-polymer-water system, which gives rise 
to phase separation upon exposure of ASD to water; 
2) The final undissolved solute may be a 1-phase, 3-component system containing 
drug, polymer, and water, and its composition could be different from that of the original 
ASD; 
3) For a stable ASD, both the polymer and water present in the undissolved solute 
serve to reduce the solubility advantage of the drug; 
4) The undissolved solute is in the supercooled liquid state; 
5) If only two phases are present in the ASD-water system, the ASD solubility will 
be dependent on the initial ASD drug loading and the amount of ASD and water used for 
equilibration, due to the extra degree of freedom permitted by the phase rule. Namely, the 
apparent solubility of ASD depends on how the experiments are carried out. 
If the equilibrium composition of the undissolved solute is known, then the 
solubility advantage of the drug in the ASD can be quantitatively determined. In light of 
this, the working equations are fully derived and discussed throughout the preceding 
sections. 
  
94 
Furthermore, we believe the pharmaceutical significance of this study goes beyond 
the ASD solubility evaluation. What is presented in this article is essentially the 
quantitative mapping of the chemical potential change of the drug as the result of 
amorphization, ASD preparation and water sorption. This approach, as a whole, also 
addresses questions relating to the thermodynamics of ASD, with solubility being just one 
of them.  
A fundamental question remaining in pharmaceutical ASD development is the 
mechanism by which the ASD stabilizes amorphous drugs and prevents their 
crystallization. The model presented in this article enables the actual quantitation of the 
chemical potential difference between the drug in ASD and the neat crystalline form, which 
is, by definition, the thermodynamic driving force. Through thermodynamic calculations 
and solubility experiments, we showed that this thermodynamic driving force can actually 
be determined, and under certain circumstances (such as low drug loading, highly 
exothermic drug-polymer mixing, and high moisture sorption), the driving force can 
become negative, meaning that the ASD stabilizes the drug to the extent that the chemical 
potential of the drug falls below its crystalline counterpart, essentially eliminating any 
possibility for crystallization. We also notice that the key to this practice is an accurate 
estimation of the drug-polymer interaction parameter. With such information available, we 
believe that the method presented in this article is useful for any pharmaceutical ASD 
screening process, as it informs scientists, quantitatively, the extent of thermodynamic 
stabilization for different polymer candidates and with different drug loading.  
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2.6 CONCLUSIONS 
Although amorphous solid dispersions (ASDs) have long entered the mainstream 
of pharmaceutical development arena as an approach to improve bioavailability, 
quantitative studies of its mechanism on solubility enhancement have been scarce. In this 
article, we provided a quantitative answer to the question of ASD solubility advantage, 
through the investigation of the drug-polymer-water system by means of heterogeneous 
phase equilibria analysis.  
We started by emphasizing that the ASD solubility is solely governed by the 
activity (or equivalently, chemical potential) of the drug in the undissolved solute in 
equilibrium with water, and the first question to answer in light of the ASD solubility is 
the phase behavior of the drug-polymer-water ternary system. We proposed that the state 
of pharmaceutical ASD in equilibrium with water resembles the polymer-solvent-
nonsolvent systems encountered in the polymer industry and that in a simplest case, a 
miscibility gap could be present. This miscibility gap will lead to phase separation, and the 
final undissolved solute in equilibrium with water is a 1-phase, 3-component material, 
containing drug, polymer, and water. The composition of this undissolved solute can be 
different from the composition of the original ASD.  
 We then presented the full thermodynamic model for the quantitative assessment 
of solubility advantage of such ASDs. Specifically, the method accounts for the solubility 
change as the result of 1) amorphization, 2) ASD formation, and 3) water partitioning. 
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Experimentally, we measured the solubility advantage of ASDs, by means of intrinsic 
dissolution measurements, using indomethacin/EPO ASD as the model system. Both the 
theoretical and experimental results showed that the solubility advantage of ASD can be 
significantly lower than the neat amorphous drug, due to the effect of polymer dilution and 
water sorption, both of which contributed to the lowering of the drug chemical potential.  
Particularly, for highly stable ASD systems characterized by low drug loading and strong 
drug-polymer interactions, the solubility advantage of ASD can be fully eliminated, leading 
to an apparent ASD solubility lower than that of the neat crystalline forms. We also showed 
that the key to the estimation of the ASD solubility is the ability to accurately assess the 
drug-polymer interaction parameters by accounting for its temperature and composition 
dependence. 
Finally, we noted that the study presented in this article is essentially on mapping 
out the chemical potential landscape of the drug in an ASD system containing one phase 
and three components. The chemical potential of the drug is the primary thermodynamic 
property that not only governs the drug solubility, but also affects the behaviors relating to 
physical stability, such as drug-polymer miscibility and crystallization. The method 
presented in this article can therefore be used in the effort to find the most optimal 
pharmaceutical ASD, i.e., a predictable drug-polymer phase with the lowest possible drug 
chemical potential to minimize the risk of crystallization and phase separation, and a 
predictable phase separation upon exposure to water to form an undissolved solute 
exhibiting higher drug chemical potential and favorable solubility advantage.  
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2.8 LIST OF FIGURES 
  
Figure 2.1 Schematic G-T and H/S-T diagrams showing the hypothetical process paths 
used to calculate the free energy difference between the amorphous and 
crystalline states of a neat drug. A: reference amorphous state is supercooled 
liquid; B: reference amorphous state is glass. 
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Figure 2.2 Schematic drug-polymer-water ternary phase diagram showing the phase 
behavior of ASD in equilibrium with water (ASD drug loading is 50%).  
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Figure 2.3 Overlay of intrinsic dissolution results of the IMC/EPO physical mixture 
(crystalline IMC), IMC/EPO physical mixture (amorphous IMC), and the 
IMC/EPO ASD. (A: 30% drug loading; B: 50% drug loading; C: 70% drug 
loading). The intrinsic dissolution rates were determined by linear 
regression of early time points which fit well into straight lines (shown in 
Figure). 
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Figure 2.4 Estimated solubility ratio 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
 and chemical potential change (
∆𝜇
𝑅𝑇
) of 
IMC as the function of drug loading for the IMC/EPO ASD systems, 
including curves calculated using hypothetical values of the interaction 
parameter .  
𝑋𝐴
𝐴𝑆𝐷
= 𝑋𝑋  
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Figure 2.5 Moisture sorption isotherms of amorphous IMC and IMC/EPO ASDs with 
different drug loading. 
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Figure 2.6 Estimated solubility ratio 
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
 for the amorphous IMC and the IMC/EPO 
ASD systems with different drug loading, with and without the correction 
for water partition.  
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Figure 2.7 Estimated solubility ratio between the amorphous and crystalline IMC, 
𝑋𝐴
𝑋𝑋
, 
as the function of temperature, using supercooled liquid or glass as the 
reference amorphous state.  
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Figure 2.8 Deviation from the theoretical Tg values calculated based on Gordon-Taylor 
equation, for IMC/EPO ASD systems of different drug loading. 
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2.9 LIST OF TABLES 
 
Table 2.1 Experimental and predicted solubility ratio for indomethacin: IMC/EPO 
ASD versus neat crystalline form: (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝑋
). T = 25 ℃. 
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Table 2.2 Experimental and predicted solubility ratio for indomethacin: IMC/EPO 
ASD versus neat amorphous form: (
𝑋𝐴
𝐴𝑆𝐷
𝑋𝐴
𝑛𝑒𝑎𝑡). T = 25 ℃. 
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Table 2.3 Molecular properties of indomethacin and EPO used to calculate the 
solubility ratios. 
 
  
  
116 
Chapter 3: A New Extrudable Form of Hypromellose: AFFINISOL™ 
HPMC HME2 
3.1 ABSTRACT 
Hypromellose is a hydrophilic polymer widely used in immediate and modified 
release oral pharmaceutical dosage forms. However, currently available grades of 
hypromellose are difficult, if not impossible, to process by hot-melt extrusion (HME) 
because of their high glass transition temperature, high melt viscosity, and low degradation 
temperature. To overcome these challenges, a modified grade of hypromellose, 
AFFINISOL™ HPMC HME, was recently introduced. It has a significantly lower glass 
transition temperature and melt-viscosity as compared to other available grades of 
hypromellose. The objective of this paper is to assess the extrudability and performance of 
AFFINISOL™ HPMC HME (100LV and 4M) as compared to other widely used polymers 
in HME, including HPMC 2910 100cP (the currently available hypromellose), Soluplus®, 
Kollidon® VA 64 and EUDRAGIT® E PO. Formulations containing polymer and 
carbamazepine (CBZ) were extruded on a co-rotating 16mm twin-screw extruder, and the 
effect of temperature, screw speed and feed rate was investigated. The performance of the 
solid dispersions was evaluated based on Flory-Huggins modeling, and characterized by 
differential scanning calorimetry (DSC), X-ray powder diffraction (XRD), Raman 
                                               
 
2 Huang S, O’Donnell KP, Keen JM, Rickard MA, McGinity JW, Williams RO. A New Extrudable Form 
of Hypromellose: AFFINISOL™ HPMC HME. AAPS PharmSciTech. 2016;17(1):106-19. doi: 
10.1208/s12249-015-0395-9. 
I am the primary author of this work. 
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spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and dissolution. All 
formulations extruded well except for HPMC 2910 100 cP, which resulted in over-
torqueing the extruder (machine overloading because motor cannot provide efficient 
energy to rotate the shaft). Among the HME extrudates, only the EUDRAGIT® E PO 
formulation was crystalline as confirmed by DSC, XRD and Raman, which agreed with 
predictions from Flory-Huggins modeling. Dissolution testing was conducted under both 
sink and non-sink conditions. Sink dissolution testing in neutral media revealed that 
amorphous CBZ in the HME extrudates completely dissolved within 15 minutes, which 
was much more rapid than the time for complete dissolution of bulk CBZ (60 minutes) and 
EUDRAGIT® E PO solid dispersion (more than 6 hours). Non-sink dissolution in acidic 
media testing revealed that only CBZ contained in the AFFINISOL™ HPMC HME and 
EUDRAGIT® E PO solid dispersions rapidly supersaturated after 15 minutes, reaching a 
2-fold drug concentration compared to the CBZ equilibrium solubility. In summary, 
AFFINISOL™ HPMC HME 100LV and AFFINISOL™ HPMC HME 4M are useful in 
the pharmaceutical HME process to increase wetting and dissolution properties of poorly 
water-soluble drugs like CBZ. 
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3.2 INTRODUCTION 
Applying high throughput screening in discovery and synthesis of small-molecule 
drugs has dramatically increased the number of poorly water-soluble compounds (1). The 
absorption of poorly water-soluble drugs into systemic circulation is highly dependent 
upon their aqueous solubility and therefore increasing the solubility/dissolution properties 
of poorly water-soluble drugs for oral delivery is a mandatory and challenging task in 
dosage form development. Solid dispersions are considered an attractive approach to 
increase solubility, dissolution and bioavailability of poorly soluble drugs (2). Solid 
dispersions have been prepared by various approaches such as HME, KinetiSol® 
technique, co-evaporation, hot spin mixing, roll-mixing or co-milling, thin film-freezing 
(i.e., ultra-rapid freezing), spray drying and supercritical fluid processing (3-7). 
HME was originally adapted from the plastics industry, ﬁrst used for 
pharmaceutical formulations in 1971 by El-Egakey et al., and reﬁned in later years by 
various research groups (8-11). HME technology has gained favor over traditional 
pharmaceutical formulation techniques in solubility enhancement because it is a solvent-
free and continuous operation process that does not require major downstream processing 
(9, 12). By selecting a suitable exit die and processing parameters, a variety of solid dosage 
forms including granules, pellets, tablets, suppositories, implants, stents, transdermal and 
transmucosal systems, and ophthalmic inserts can be produced using HME (9, 13). As for 
the quality of the extruded material (i.e., the extrudate), carrier (polymer) properties such 
as the glass transition temperature (i.e., Tg; the temperature at which the polymer starts to 
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soften), the solubility of the drug in the softened or molten polymer and the stability of the 
polymer are crucial to forming a homogeneous composition (11). 
Hypromellose is a hydrophilic polymer widely used in pharmaceutical dosage 
forms, including immediate release and modified release formulations. It is an amorphous 
polymer that typically exhibits a broad glass transition temperature from about 160 to 210 
C. The polymer has a comparatively low decomposition temperature, showing significant 
degradation at temperatures in the range of 200 to 250 C, depending upon the substitution 
(14). This high glass transition temperature and low degradation temperature together with 
the high melt viscosity make it challenging to process hypromellose by HME. Current 
techniques reported to improve the processability of hypromellose require the use of high 
levels of plasticizer and other processing aids (15), which for certain amorphous systems, 
including solid dispersions, may result in crystallization of the drug during storage and 
during imbibition of water as the dosage form travels through the gastrointestinal tract 
leading to a subsequent reduction in dissolution and absorption (e.g., decrease in 
bioavailability). Hypromellose has been shown to be an effective recrystallization inhibitor 
in stabilizing amorphous drugs which can enhance the bioavailability of poorly soluble 
compounds (16). Therefore, it is highly desirable to incorporate hypromellose into a HME 
formulation without the use of plasticizers. Although some recent studies suggest the 
possibility of extrusion of existing commercial grades of hypromellose at high 
temperatures (17, 18), it is very challenging to apply these conditions to most drug 
candidates due to thermal degradation of the drug itself. A modified hypromellose, 
  
120 
AFFINISOL™ HPMC HME was recently introduced by The Dow Chemical Company. It 
is produced using traditional HPMC manufacturing methods to result in a different 
substitution architecture, which makes AFFINISOL™ HPMC HME exhibit a significantly 
lower Tg (117-128 ℃) (19) and melt-viscosity than presently available grades of 
hypromellose making it more suitable to thermal processing. 
The purpose of this study was to compare the extrudability of two different grades 
of AFFINISOL™ HPMC HME 4M (552.8 kDa) and 100 LV (179.3 kDa) to currently 
available HPMC as well as alternative extrusion polymers. Additionally, the ability to 
generate and the performance of amorphous solid dispersions with the selected polymers 
was studied using carbamazepine as a poorly soluble model API. Flory-Huggins modeling 
was used to predict the initial experimental conditions and drug load. 
3.3 MATERIALS AND METHODS  
3.3.1 Materials 
Crystalline carbamazepine (CBZ) was purchased from Letco Medical (Decatur, 
AL). The Dow Chemical Company (Midland, MI) kindly donated AFFINISOL™ HPMC 
HME 4M and 100 LV (AFF4000 or AFF100) and HPMC 2910 100cP (HPMC100). BASF 
Corporation (Florham Park, NJ) kindly donated Soluplus® (Soluplus) and Kollidon® VA 
64 (VA64). Evonik (Piscataway, NJ) kindly donated EUDRAGIT® E PO (EPO). HPLC 
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grade acetonitrile and water were purchased from Fisher Scientific Co. (Houston, TX). All 
other chemicals used in this study were of American Chemical Society (ACS) grade. 
3.3.2 Methods 
3.3.2.1 Modeling Based on Flory–Huggins Theory  
Phase diagrams for CBZ and polymer systems were generated using Flory–Huggins 
Theory as previously described (20-26). Briefly speaking, the Gibbs free energy of mixing 
function that results from application of the Flory–Huggins model is dependent on the 
volume fraction of the drug, , a constant indicative of the relative size of the polymer in 
relation to the drug, m, and the interaction parameter, 
(1 )
ln ln(1 ) (1 )mix
G
RT m

     
 
    
  (1) 
DSC experiments was used to determine the melting enthalpy of the drug, ∆H, and 
either the melting temperature (22, 23), onset of melting (24) or ending of melting (25) 
have been applied by various authors to determine , which is a function of temperature 
(27). For CBZ and polymer systems, melting temperature was selected based on the 
reproducibility of this value in experimental trials. The temperature dependency of  at 
room temperature can be calculated with the application of solubility parameters (24). 
Calculation of the solubility parameters, along with the molar volume per Flory–Huggins 
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lattice size, were performed using Molecular Modeling Pro software (Chem SW Inc., 
Fairfield, CA) 
For our analysis,  is assumed to only be a function of temperature. Any 
dependency on composition is neglected, and this assumption is in line with that reported 
previously (22, 25). With the value at different temperatures being calculated by the 
linear equation predicted by the two points (at room temperature and Tm), a Gibbs free 
energy diagram at selected temperatures can be produced.  
Setting the second derivative of Equation 1 equal to 0, and determining  as a 
function of  allows for the determination of the boundary between unstable and metastable 
regions, or referred to as the spinodal curve. Furthermore, constructing the common 
tangents between the minima on the free energy diagram can form the boundary between 
the metastable and stable regions called bimodal curve. This corresponds to points in which 
the chemical potentials of the two phases are in equilibrium. The binodal curve which is 
solved numerically will intersect the spinodal curve at the critical point, the third derivative 
of Equation 1. 
3.3.2.2 Hot Melt Extrusion and Milling 
HME studies were conducted on a co-rotating Leistritz Nano-16 twin-screw 
extruder (American Leistritz Extruder Corp. USA, Somerville, NJ) equipped with screws 
containing two kneading elements (30 degree and 60 degree) were used in each screwand 
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a 3 mm strand die. A single screw feeder set on top of the barrel feed zone provided an 
accurate 5 grams/ minute feed rate of the powder blend. Polymer drug blend with 15% and 
30% CBZ loading were extruded by Leistritz extruder at different temperature ranging 
from 120 C to 180 C, screw speed at 100, 150 and 200 rpm. Extrudates were cooled to 
room temperature before milling. A Fitzmill L1A hammer mill (Fitzpatrick) operating at 
9000 RPM with knives side forward and a 0.020” screen installed in the chamber was used 
to mill the extrudates. The powder fraction retained between 60 mesh and 100 mesh screens 
was collected for further analysis. 
3.3.2.3 High Performance Liquid Chromatography (HPLC) 
CBZ was detected by a Dionex HPLC system (Thermo Fisher Scientific Inc., 
Waltham, MA) equipped with a Phenomenex® Luna 250 mm C18 (5 μm, 4.6×250 mm) 
column. The composition of HPLC mobile phase was 60:40 acetonitrile:water. Prior to use, 
the mobile phase was filtered through a 0.45 micron filter, and then degassed under vacuum 
with sonication. The mobile phase flow rate was 1 mL/min. The retention time of CBZ was 
approximately 4.2 min. The detection wavelength was 263 nm. 
3.3.2.4 X-ray Powder Diffraction (XRD) 
XRD studies were conducted on a Philips 1710 X-ray diffractometer with a copper 
target and a nickel filter (Philips Electronic Instruments, Inc., Mahwah, NJ). The voltage 
and current of the equipment were set to 40 KV and 40 mA, respectively. Prior to analysis, 
the sample was placed in the quartz slot of a zero background XRD sample holder, and 
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flattened with a glass slide. The 2-theta angle, step size, and dwell time were set to 10-50°, 
0.05°, and 2 s, respectively. In order to obtain XRD patterns, the raw data was processed 
using Jade 5.0 software (Materials Data, Inc., Livermore, CA). 
3.3.2.5 Modulated Differential Scanning Calorimetry (mDSC) 
To characterize the thermal behavior of the samples, modulated DSC equipped with 
a DSC refrigerated cooling system (DSC 2920, TA Instruments, New Castle, DE) was 
employed. Dry nitrogen gas at a flow rate of 40 mL/min throughout the testing was used 
to purge the DSC cell. Samples were accurately weighed in aluminum sample pan kits 
(PerkinElmer Inc., Waltham, MA) and crimped before analysis. Samples were heated from 
50°C to 220°C with a heating rate of 10°C/min using a 0.5°C/40 s modulation program. 
TA Universal Analysis 2000 software was used to process the raw data. 
3.3.2.6 Spectroscopy 
3.3.2.6.1 Raman Spectroscopy 
Raman spectra were collected with a Raman RXN1 microscope (Kaiser Optical 
Systems, Inc.) equipped with a 785 nm Invictus laser. The laser was focused on the sample 
with an Mk II probe and a 50x microscope objective (≈ 30 mW at sample), and the back-
scattered light was collected with the same optics. The total acquisition time of each 
spectrum was sixty seconds. The Raman shift axis was calibrated with the 801.8 cm-1 band 
of cyclohexane (28). The amorphous form of carbamazepine was prepared by heating the 
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material on a hot stage until it was completely melted and then quench cooling it in liquid 
nitrogen. 
3.3.2.6.2 Fourier-Transform Infrared Spectroscopy (FTIR) 
Attenuated total reflectance (ATR) infrared spectra were acquired with a Perkin 
Elmer Spectrum One FT-IR and Universal ATR Sampling Accessory at a resolution of 4 
cm-1. Sixteen scans (≈ 90 second acquisition time) were collected for each spectrum in the 
wavelength region between 300 and 4000 cm−1. The Universal ATR Sampling Accessory 
was equipped with a single bounce diamond/ZnSe crystal. 
3.3.2.7 Dissolution Testing  
3.3.2.7.1 Dissolution Testing at Sink Conditions 
A VanKel VK 7000 dissolution system (Varian, Inc., Palo Alto, CA) with the 
corresponding paddle was utilized to perform the testing according to USP 29 apparatus II. 
The paddle speed and temperature were set to 100 rpm and 37±0.5°C, respectively. Before 
testing, 1000 mL of DI water was pre-heated to 37 °C in each dissolution vessel. Milled 
extrudates containing 100 mg CBZ equivalent (n=6) were pre-wetted in a 20 mL 
scintillation vial using dissolution media for 10 seconds; the time at which the material was 
pre-wetted was considered the 0 minute time point. The wetted sample was then added 
immediately to the dissolution vessel. At time points of 15 min, 30 min, 45 min, 1 hr, 1 hr 
30 min, and 2 hr, a 1 mL sample was pulled and filtered through a 0.2 μm 13 mm PVDF 
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membrane filter. A 200 μL aliquot of filtered solution was diluted with 1.4 mL HPLC grade 
acetonitrile and the concentration of CBZ in the diluted sample was measured using HPLC. 
3.3.2.7.2 Dissolution Testing at Non-sink Conditions 
Dissolution testing was also conducted at non-sink conditions in acidic media using 
200 mL vessels and corresponding paddles. 100 mL of 0.1 N HCl solution was pre-heated 
to 37 °C in each dissolution vessel. Milled extrudate containing 100 mg CBZ equivalent 
(n=6) was pre-wetted in a 20 mL scintillation vial using dissolution media for 10 seconds; 
the time at which the material was pre-wetted was considered the 0 minute time point. The 
wetted sample was then added immediately to the dissolution vessel. At time points of 15 
min, 30 min, 45 min, 1 hr, 1 hr 30 min, 2 hr, 6 hr, a 1mL sample was taken and filtered 
through a 0.2 μm 13 mm PVDF membrane filter. Sample dilution and HPLC quantification 
were the same as the sink condition dissolution testing above. 
3.3.2.8 Statistical Analysis 
Data are presented as mean ± standard deviation. The data were analyzed through 
paired t-test and one way-ANOVA using the JMP® 11 software. For the paired t-test, p < 
0.05 was set as the significance threshold for the differences within groups. For one-way 
ANOVA, p < 0.05 was set as the significance threshold for differences between groups. 
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3.4 RESULTS 
3.4.1 Polymer – CBZ Miscibility Based on Flory–Huggins Theory 
The Flory–Huggins interaction parameter, , was calculated based on the linear 
equation predicted by the experimentally determined  at melting point of each polymer 
and drug mixture and solubility parameters estimated at 25 ℃. Substitution of value 
into Equation 1 yields the free energy of mixing versus drug composition plot which is 
shown in Figure 3.1A. As shown in Figure 3.1A, the free energy of mixing is convex at 
elevated temperatures (200 ℃), and homogeneous mixtures of CBZ and all polymers were 
stable for all compositions at this temperature and above. For all systems except AFF100 
and AFF4000,  decreased at elevated temperatures, which indicated mixing of CBZ and 
polymer became more favorable with increasing temperature. The results shown in Figure 
3.1B, which were generated by solving the free energy relationship (Equation 1) at speciﬁc 
temperatures, further highlight this relationship. To the contrary, for AFF100 and AFF4000 
systems, was negative at all temperatures between -200 ℃ to 200 ℃. Moreover,  
increased with increasing temperature for those two systems. Therefore, no unstable zone 
of CBZ was observed in Figure 3.1B unless at high drug load and temperature. 
3.4.2 Hot Melt Extrusion 
Hypromellose (2910 100cP) having the comparable viscosity in aqueous as 
AFF100 exhibited different properties when processed at elevated temperature by a twin-
screw melt extruder (Figure 3.2). Both AFF100 and HPMC100 were processed at 140C, 
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100 rpm, however at that condition it was not possible to extrude the HPMC100 
formulation due to machine over-torqueing. To decrease the viscosity of HPMC100, the 
processing temperature and screw speed were increased to 160C, 150 rpm. As seen in the 
figure, the AFF100 extrudate at 140C, 100 rpm (Figure 3.2A) was slightly less yellow and 
clear than AFF100 extruded at 160C, 150 rpm (Figure 3.2B). On the other hand, the higher 
temperature and shear force helped facilitate HPMC100 extrusion because the torque 
created during the extrusion process decreased enabling the machine to operate. However, 
after being exposed to a higher temperature for a long period of time (approximately 15 
minutes), together with more energy input caused by a higher rpm, the extrudate was 
burned as observed upon exiting (Figure 3.2C). The results demonstrated that at similar 
HME process conditions, currently available HPMC was difficult to extrude while the 
newly designed AFFINISOL™ HPMC HME was much more amendable to processing by 
HME. 
Moreover, Soluplus, VA64, EPO, and another grade of AFFINISOL™ HPMC 
HME with a higher viscosity (AFF4000) were used in HME as comparisons. As shown in 
Figure 3.3, except for the EPO formulation (white rod), all other extrudates were clear and 
transparent, indicating a good mixing between drug and polymers that concurred with the 
miscibility predicted by Flory–Huggins Theory. 
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3.4.3 X-ray Powder Diffraction (XRD) 
XRD diffractograms of the unprocessed powders (polymers and CBZ) are shown 
in Figure 3.4. Bulk CBZ powder showed characteristic crystalline peaks at 2θ = 15.2, 15.8 
and 27.4°, which agreed with the CBZ P-monoclinic form III pattern (29). No crystalline 
peaks were observed in the patterns of the extrudates except for the EPO extrudate which 
exhibited characteristic crystalline peaks at 2θ =12.8, 18.9, and 19.6°, corresponding to 
CBZ form I (29). Therefore, within these extrudates CBZ was confirmed to be in the 
amorphous or molecular state, or, the crystallinity was too low to be detected by XRD.  
3.4.4 Modulated Differential Scanning Calorimetry (mDSC) 
The thermograms of bulk CBZ and CBZ-polymer extrudates are shown in Figure 
3.5. Bulk CBZ, EPO, AFF100, and AFF4000 extrudates exhibited endothermic peaks that 
indicated the existence of crystalline CBZ. For bulk CBZ, three events were observed as 
described in previous reports (29, 30): 1) the endothermic peak observed at 175.4 ℃ was 
attributed to the melting of CBZ form III (P-monoclinic), 2) a very small exothermic peak 
was observed at 181.7 ℃ because form I CBZ crystal generates during heating process, 3) 
the third event observed at 195.7°C is attributed to the melting of form I (Triclinic). For 
EPO, AFF100 and AFF4000, however, the observed melting points did not match the 
endothermic peak of bulk CBZ. Soluplus and VA64 extrudates were amorphous due to the 
lack of any observed endothermic peak. 
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3.4.5 Raman and FTIR Spectroscopy 
Raman spectra of crystalline (form III) and amorphous CBZ are shown in Figure 
3.6. There are substantial changes in the frequencies, intensities and peak shapes of bands 
at 253, 374, 723, 768, 873, 987, 1222, 1250, 1412 and 1566 cm-1 from the crystalline to 
the amorphous form. The Raman spectra of CBZ extrudates in AFF100, AFF4000, EPO 
and VA64 were dominated by bands from CBZ (data not shown). An overlay of the 1600 
cm-1 region (Figure 3.7) illustrates the spectral changes among crystalline CBZ, amorphous 
CBZ and CBZ-polymer extrudates. The Raman spectra of CBZ-polymer extrudates were 
not consistent with either crystalline (form III) CBZ or amorphous CBZ, which indicated 
that all of the polymers had substantial interactions with CBZ. 
Infrared spectra of CBZ in EPO (Figure 3.8) were consistent with these 
observations. From the IR spectrum, the 30% CBZ formulation was partially crystalline 
(form I, bands at 3486 cm-1 and 1393 cm-1) (29), which was in agreement with the DSC 
and XRD results. However, the 15% CBZ formulation was amorphous. The carbonyl 
stretch of CBZ (31) occurs at 1674, 1681, 1686 and 1685 cm-1 in crystalline (form III) 
CBZ, amorphous CBZ, 15% CBZ in EPO and 30% CBZ in EPO, respectively. The ≈ 12 
cm-1 frequency increase from bulk CBZ to the CBZ-polymer extrudates indicated that there 
was less hydrogen bonding to the carbonyl group of CBZ in the EPO formulations. 
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3.4.6 Dissolution testing  
3.4.6.1 Dissolution Testing at Sink Conditions 
The dissolution profiles for bulk CBZ and CBZ-polymer extrudates are shown in 
Figure 3.9. The dissolution rate of bulk CBZ was slow, 90% release was achieved after 
about 60 minutes, due to poor wettability and agglomeration. The dissolution rates of the 
CBZ-polymer extrudates were faster than that of bulk CBZ, except for the crystalline drug-
EPO extrudate; all other drug-polymer extrudates achieved at least 90% release by 15 
minutes. For the CBZ-EPO extrudate, a much slower release rate (40% release at 2 hr) was 
observed. CBZ-polymer extrudates except for CBZ-EPO were well dispersed and 
gradually swelled and dissolved during the dissolution process. For CBZ-EPO extrudate, 
due to the low solubility of Eudragit® E PO at neutral pH, particles stayed at the bottom 
of the vessel and were not dissolved in the dissolution study. 
3.4.6.2 Dissolution Testing at Non-sink Conditions 
The results of dissolution testing at non-sink conditions are presented in Figure 
3.10. The CBZ-EPO extrudate exhibited the most rapid dissolution rate with approximately 
55% of CBZ released in solution at 15 min., and the concentration was maintained through 
360 minutes. Meanwhile, CBZ-AFF100, and CBZ-AFF4000 extrudates, as well as the 
CBZ -EPO physical mixture released 45% CBZ by 15 minutes and reached 50% after 45 
minutes; the super-saturation state did not change after that. However, CBZ-VA64 and 
CBZ-Soluplus extrudates dissolved remarkably more slowly than CBZ-AFF100, CBZ-
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AFF4000 and CBZ-EPO extrudates, and by the end of the study reached approximately the 
same drug release amount as bulk CBZ. Because of the limited volume of dissolution 
media, CBZ-AFFs (both AFF100 and AFF4000), CBZ-Soluplus and CBZ-VA64 
extrudates clumped at the beginning of the dissolution test, and were not fully dissolved at 
the final sampling time point. CBZ-EPO extrudate, however, was dispersed fast and 
homogeneously in the dissolution vessel due to the solubility of Eudragit® E PO at acidic 
conditions. Towards the end of the test, the dissolution media became a stable white 
suspension. 
To provide a more quantitative examination of these dissolution results, the area 
under the dissolution curve (AUDC) for the non-sink condition dissolution test in acidic 
environment was calculated by the linear trapezoidal method. These values are presented 
in Table 3.1. The AUDC values further indicated the significantly superiority of the CBZ-
AFFINISOL HPMC HME (both AFF100 and AFF4000) extrudates which exhibited 157, 
182, and 163% mean AUDC total values of bulk CBZ, CBZ-VA64, and CBZ-Soluplus 
extrudates, respectively. The AUDC of CBZ-EPO extrudate was 12% greater (not 
significantly) than CBZ-AFF (both AFF100 and AFF4000) extrudates. 
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3.5 DISCUSSIONS 
For HME applications in pharmaceutical industry, it is crucial to successfully 
develop amorphous dispersions without degrading drug and other ingredients in the 
formulation. Therefore, identifying drug loadings and processing temperatures become 
necessary to ensure chemical and physical stability of the final formulation. In our study, 
the phase diagram obtained through Flory-Huggins modeling shown in Figure 3.1B 
indicated that at 15% CBZ drug load, amorphous systems would be obtained at processing 
temperatures below 150 ℃ for all polymers. However, modeling result suggested that 30% 
CBZ concentration systems would be challenging to formulate, first because 30% CBZ 
systems require much higher energy input to achieve the amorphous state compared to 15% 
CBZ systems, and secondly, when extrudates are cooled, 30% CBZ systems will fall within 
the spinodal curve which refers to the unstable region (24). Based on the modeling results, 
15% and 30% drug loadings were chosen to compare the performance of different 
polymers. As for processing temperature, the upper boundary allowing the amorphous 
system to be generated without heat-induced drug degradation was determined by the 
thermal stability of CBZ. In forced-degradation study (exposure to heat for 6 minutes), 
CBZ was observed to be thermally stable at temperatures lower than 190 ℃ (Tm =192 ℃). 
When 30% (w/w) CBZ was mixed with 70% (w/w) polymers, CBZ degradation beyond 
0.5% was observed at temperatures greater than 170 ℃ (data not shown). Both CBZ by 
itself and CBZ polymer mixtures showed increasing rate of decomposition as temperature 
increased. Meanwhile, polymer decomposition temperatures have also been reported such 
as Soluplus at 250 ℃ (32), EPO at 200 ℃ (33), VA64 at 230 ℃ (32), HPMC at 200-250 ℃ 
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(34). According to these results, the processing temperature should be controlled below 
170 ℃ and other conditions like screw speed and screw design should be optimized based 
on the extrusion outcomes.  
To avoid drug degradation, HME was performed at 160 ℃, 150 rpm with 30% CBZ 
in AFF100 using the screw design in Figure 3.11 at 3 grams/min feed rate (F1). However, 
as shown in Table 3.2, at this condition, F1 only provided 85.46% drug recovery according 
to the HPLC result. From F1 to F3, increasing screw speeds were used. Inspection of CBZ 
recovery and extrudate appearance in Table 3.2, decrease in CBZ recovery rate and 
significant darkening of extrudate colors were observed due to more shear force being 
transferred to the materials (9, 35). For CBZ, according to forced-degradation studies 
(Figure 3.12), drug degradation happened at 170 ℃ and above with only heat applied to 
the sample. However, about 15% drug degradation was observed in F3 at 160 ℃, 200 rpm. 
It has been previously reported that significant heat will be generated inside the extruder 
chamber by shear and pressure at kneading elements that cannot be detected by the thermal 
sensors effectively, since sensors are normally built in the chamber wall which are not 
detecting material real temperature (on the screw) directly (36). As shown in Figure 3.11, 
two mixing elements (30 degree and 60 degree) were used in each screw, high shear and 
hot spots might occur at those areas. Moreover, unvented system was applied throughout 
the extruder, which helped keep heat inside. In other words, the actual temperature the 
samples were experiencing can be much higher than the set temperature for the extrusion 
process (36). Therefore, we believed that the degradation was attributed to localized hot 
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spots generated by shear and pressure. For further process optimization, 100 rpm was 
chosen instead of a higher speed to avoid drug degradation. From F4 to F7, the effect of 
barrel temperature was investigated. The opaque appearance of F4 processed at 120 °C as 
well as its XRD pattern shown in Figure 3.13 indicated that CBZ was not molecularly 
dispersed in the polymer during the extrusion process. Considering heat is one of the most 
important energy in-puts of the extrusion process to ensure complete mixing (36), it was 
determined that temperatures above 120 ℃ were necessary to generate an amorphous 
system. Moreover, for F4, the low temperature resulted in high melt viscosity of polymer, 
which provided higher energy transfer efficiency (10), thus more shear was transferred to 
CBZ causing degradation and low recovery. However, even with the increased melt 
viscosity at this low temperature (120 ℃), AFFINISOL™ HPMC HME did not result in 
operational failure. As for F8 and F9, different feed rates were tested. The results indicated 
that a faster feed rate can help increase CBZ recovery primarily because of a shorter 
residence time and thus less thermal and shear exposure. Ultimately, 100% CBZ recovery 
was achieved using 140 ℃, 100 rpm, at 5 g/min feed rate, and this condition was applied 
to all other formulations. 
The DSC thermogram (Figure 3.5) for 30% CBZ-polymer extrudates, showed a 
distinct endothermic peak in the CBZ-EPO formulation at 177.6 °C; this incomplete 
amorphicity was predicted by our Flory-Huggins model. The XRD (Figure 3.4) and FTIR 
results (Figure 3.8) indicated that after extrusion CBZ in EPO recrystallized into Form I 
(Triclinic) crystalline form, with the melting point of approximately 180°C (29). The 3 °C 
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difference in observed Tm and literature data was attributed to the molecular interaction 
between EPO and CBZ at elevated temperature (27), which was also predicted in our 
modeling result. The DSC results for VA64 and Soluplus formulations matched the 
information obtained from the XRD study, which showed that CBZ exists in amorphous 
form in those systems. Preparing of CBZ-VA64 and CBZ-Soluplus amorphous solid 
dispersions by HME has also been reported previously in literature (37). In contrast to our 
result, Djuris et al. reported immiscibility between Soluplus and carbamazepine at 30% 
drug load (38). However, that study was performed on a melt-fusion product instead of an 
HME product. For the Soluplus extrudate herein, CBZ dissolved to a higher degree in the 
polymer because of the shear provided by extruder, thus the final DSC thermogram did not 
show any endothermic peak. Small endothermic peaks at approximately 170 °C were also 
observed in AFF100 and AFF4000 formulations. As mentioned before, the depression of 
those two peaks compared with CBZ form III (P-monoclinic) (Tm approximately 175 °C) 
was also due to the strong interaction between AFF and CBZ. In Figure 3.4, however, the 
existence of crystalline CBZ in the AFF extrudates was not detected by XRD or Raman. 
Considering that Raman and FTIR have good sensitivity detecting crystalline material, we 
believe that the endothermic peaks detected in the DSC result are because that CBZ 
miscibility in both AFF100 and AFF4000 decreased at elevated temperature as predicted 
by the Flory-Huggins modeling results. 
Dissolution testing at sink conditions (Figure 3.9) showed significant enhancement 
of the drug dissolution rate in amorphous formulations. It has been widely reported (39, 
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40) that the strong interaction between drug and polymer in amorphous solid dispersions 
can increase dissolution rate. Raman spectroscopy was used in this research to characterize 
the interactions between CBZ and polymers. Subsets of the Raman bands that were 
reasonably strong and had little or no interference from the polymers were examined in 
greater detail. The positions of these bands in the 30% CBZ formulations and the frequency 
shifts from crystalline CBZ are shown in Table 3.3 and Figure 3.14. The frequency shifts 
are generally consistent with the amorphous form except for the 374 cm-1 (lattice vibration) 
and 1160 cm-1 (C-C ring stretch/C-N-C asymmetric stretch) bands. In these cases, the shifts 
are substantially greater than the amorphous form, which indicated that the polymers had 
substantial interactions with CBZ. These interactions may include contributions from both 
hydrogen bonding and dipole-dipole forces. But unlike amorphous formulations, CBZ-
EPO extrudate showed a decreased dissolution rate compared to bulk CBZ. This is first 
attributed to CBZ still existing in crystalline form in the CBZ-EPO extrudate; second, EPO 
is not soluble but swellable and permeable at neutral pH condition according to the USP 
monograph, therefore the matrix fromed by EPO can prevent crystalline CBZ from 
dissolving into the dissolution media; thirdly, during the dissolution process, CBZ in the 
CBZ-EPO extrudate (form I) changes to its less soluble di-hydrate form more rapidly than 
bulk CBZ (form III) (41). 
In non-sink dissolution testings (Figure 3.10), the significant dissolution rate 
improvement of CBZ-AFF extrudates was also observed and is because of the fact that 
cellulose-based polymers are excellent drug recrystallization inhibitors in amorphous 
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systems by lowering the thermodynamic tendency of drugs toward recrystallization (42, 
43). As for CBZ-Soluplus and CBZ-VA64 extrudates, CBZ dissolved rapidly because it 
existed in its high energy form. However, neither was able to reach supersaturation, despite 
being amorphous. From the Flory-Huggins modeling result of CBZ-VA64 and CBZ-
Soluplus systems shown in Figure 3.1, both extrudates were in the unstable state with low 
system mobility (within spinodal curve and below Tg of the CBZ-polymer system) when 
cooled down to room temperature after extrusion. In that state, phase separation is highly 
favorable (27). However, the reason why CBZ was amorphous may be because of the low 
mobility of these systems providing resistance to drug recrystallization (44). When 
calculating  at room temperature, instead of using an experimental method such as the 
melting point depression to estimate the interaction parameter  at elevated temperature 
(25), the solubility parameters were used. The limitation of using the solubility parameter 
method in this model is that it overlooks the interactions between polymer and CBZ (45). 
These interactions, however, were well represented at elevated temperatures using the 
experimental methods (23). Therefore, the F-H modeling results of CBZ-VA64 and CBZ-
Soluplus might not be accurate at room temperature. 
Once the CBZ-VA64 and CBZ-Soluplus extrudates mixed with the dissolution 
media, the incorporation of water into CBZ-VA64 and CBZ-Soluplus extrudates initiates 
drug crystallization due to the decrease of system Tg, which can provide necessary system 
mobility for CBZ to recrystallize (46). Moreover, water dominating H-bonds and dipole 
forces with water-soluble polymers like VA64 and Soluplus will also result in 
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thermodynamic driving forces for drug crystallization (47). It is known that the dissolution 
advantage of amorphous solids can be negated either by crystallization of the amorphous 
solid on contact with the dissolution medium or through rapid crystallization of the 
supersaturated solution (2). Therefore, CBZ-Soluplus and CBZ-VA64 extrudate lose the 
ability to reach supersaturation conditions as shown in Figure 3.10. It should be noted that 
the presence of CBZ with a Tg as low as 52 ℃ (48) may contribute to considerable Tg 
depression in the formulations. Therefore, system made by carrier with a higher Tg such as 
AFFINISOL™ HPMC HME (115 ℃) was more beneficial to improve physical stability of 
CBZ during storage and dissolution by preventing drug recrystallization or phase 
separation (49) compared to Soluplus® (70 ℃), Kollidon® VA 64 (101 ℃) (32). The 
difference in dissolution performance between CBZ-AFF, CBZ-Soluplus, and CBZ-VA64 
at non-sink condition can also be attributed to the gelification of HPMC-based polymer 
slowing down diffusion of water to the solid dispersion, which also decrease CBZ 
recrystallization rate (50). 
Surprisingly, the CBZ-EPO extrudate enabled CBZ to supersaturate in acidic 
dissolution media and maintain supersaturation over 6 hours (Figure 3.10). Based on the 
structure of CBZ and EPO, it is hypothesized that this result is due to cation-π interactions 
between CBZ and ionized EPO polymer. The most studied cation-π interactions involve 
binding between an aromatic π-system and an alkali metal or nitrogenous cation. Numerous 
studies have shown the existence of cation–π interactions in protein structures (51), 
protein–ligand (52), and protein-DNA complexes (53). It has been revealed that the 
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preferential localization of amine groups are close to aromatic rings (54). In particular, it 
is found that the positive charge of amines groups make favorable interactions with the π-
electron cloud of aromatic side chains. The optimal interaction geometry places the cation 
in Van der Waals contact with the aromatic ring, centered on top of the π face along the 6-
fold axis (55). This cation–π interaction, electrostatic in nature, is calculated to be more 
stabilizing than analogous salt-bridge interactions and comparable with hydrogen bonding 
(56, 57). Based on these literature studies, when ionized, EPO will generate the nitrogenous 
cation that can interact with the aromatic π-system in CBZ. Moreover, EPO does not ionize 
above pH 5.0 (58), therefore the cation-π interaction does not exist at neutral conditions. 
Thus slow release rate of CBZ from the EPO extrudate in neutral media (Figure 3.9) also 
supports this cation-π interaction hypothesis. On the other hand, it was also found that 
CBZ-EPO extrudate showed a higher dissolution rate of CBZ compared to the other 
extrudates. Besides the interaction between EPO and CBZ mentioned above, CBZ-EPO 
extrudate was better dispersed in acidic condition as observed in the experiment, which 
contributed to the higher dissolution rate as well. 
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3.6 CONCLUSIONS 
In this study, a co-rotating twin-screw extruder was used to evaluate the modified 
grades of hypromellose AFFINISOL™ HPMC HME 100LV and AFFINISOL™ HPMC 
HME 4M. The results revealed that these polymers are readily processed by HME without 
plasticizers and act as effective precipitation inhibitors of drug. Different extrusion 
conditions were tested on these new polymers, demonstrating that these modified HPMC 
polymers can serve as excellent carriers (polymers) for HME solid dispersions over a broad 
temperature range. Moreover, the newly developed HPMC made extruding viscous HPMC 
polymer possible (AFFINISOL™ HPMC HME 4M), and therefore has the potential of 
being used as a sustained release excipient in a HME process.  
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3.8 LIST OF FIGURES 
 
Figure 3.1 Free energy and phase diagrams. (A) Free energy diagram of the 
CBZ/polymers system as determined using Flory–Huggins Theory. (B) 
Thermal phase diagram of the CBZ/polymers representing the boundaries 
between thermodynamically unstable, metastable and stable regions as 
bounded by the spinodal and binodal curves along with the glass transition 
boundary. [Soluplus® (Soluplus), Kollidon® VA 64 (VA64), 
EUDRAGIT® E PO (EPO), HPMC 2910 100cP (HPMC100), and 
AFFINISOL™ HPMC HME 4000 (AFF4000) or 100 (AFF100)]  
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Figure 3.2 Extrudate of 30% CBZ and 70% (A) AFF100 at 140C, 100 rpm, (B) 
AFF100 and (C) HPMC100 at 160C, 150 rpm, using Leistritz Nano-16. 
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Figure 3.3 Extrudate of 30% CBZ and 70% (A) AFF100, (B) AFF4000, (C) EPO, (D) 
VA64, (E) Soluplus, at 140C, 100 rpm using Leistritz Nano-16. 
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Figure 3.4 XRD patterns of extrudate containing 30% CBZ and 70% polymer (listed 
above each XRD signal line See legend in Figure 3.1 for abbreviations of 
extrudates). 
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Figure 3.5 DSC thermograms of CBZ and extrudates containing 30% CBZ and 70% 
polymer (See legend in Figure 3.1 for abbreviations of extrudates). 
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Figure 3.6 Raman spectra of crystalline (top) and amorphous CBZ (bottom). 
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Figure 3.7 Raman spectra of the 1600 cm-1 region of crystalline CBZ (blue), 
amorphous CBZ (green) and 30% CBZ in AFF100 (purple), AFF4000 
(orange), EPO (pink), VA 64 (dark blue) and Soluplus (red). The spectra are 
scaled to the strongest band for comparison. (See legend in Figure 3.1 for 
abbreviations of extrudates). 
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Figure 3.8 ATR FTIR spectra of EPO (blue), 15% CBZ in EPO (green), 30% CBZ in 
EPO (purple), crystalline CBZ (orange) and amorphous CBZ (red). 
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Figure 3.9 Sink condition dissolution test of extrudates and bulk CBZ containing 100 
mg CBZ in 1000 mL DI water (n=3) (See legend in Figure 3.1 for 
abbreviations of extrudates). 
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Figure 3.10 Non-sink condition dissolution test of extrudates and bulk CBZ containing 
100 mg CBZ in 100 mL 0.1 HCl (n=3) (See legend in Figure 3.1 for 
abbreviations of extrudates). 
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Figure 3.11 Screw design for all formulations processed (Leistritz Nano-16). 
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Deg. 1 
RRT (1.862) 
Deg. 2 
RRT (1.973) 
Deg. 3 
RRT (3.221) 
Room Temperature 0 0 0 
170 1.2% <1% <1% 
180 2% <1% <1% 
190 2.2% <1% <1% 
200 2.9% <1% <1% 
210 3.2% <1% <1% 
Figure 3.12 Forced-degradation study of CBZ and AFF100 (peaks over 0.5% are marked 
in the figure). 
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Figure 3.13 XRD patterns of extruded material using different temperature. 
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Figure 3.14 Frequency shifts of selected Raman bands from crystalline CBZ (See legend 
in Figure 3.1 for abbreviations of extrudates). 
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3.9 LIST OF TABLES 
 
Table 3.1 Area under the dissolution curve (AUDC) values for non-sink dissolution 
testing in 0.1N HCl.  
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Formulation 
Temperature 
(℃) 
Screw Speed 
(rpm) 
Feed Rate 
(g/min) 
CBZ 
Recovery 
(%) 
Appearance 
1 160 150 3 85.46 
 
2 160 100 3 87.66 
 
3 160 200 3 82.53 
 
4 120 100 3 89.76 
 
5 130 100 3 92.23 
 
6 140 100 3 91.42 
 
7 180 100 3 82.88 
 
8 140 100 4 95.97 
 
9 140 100 5 99.81 
 
Table 3.2 Processing conditions optimization using AFF100-CBZ formulations and 
screw design shown in Figure. 4.11. 
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Table 3.3 Frequencies of selected Raman bands for the crystalline, amorphous and 
formulated forms of CBZ. For each formulation, the Raman spectrum of the 
neat polymer was subtracted from the Raman spectrum of the 30% 
CBZ/polymer formulation. 
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Chapter 4: Processing of a Thermally Labile Drug by Hot-Melt 
Extrusion 
4.1 ABSTRACT 
The formation of molecularly dispersed amorphous solid dispersions by the hot-
melt extrusion technique relies on the thermal and mechanical energy inputs provided by 
the extruder, which can cause chemical degradation of drugs and polymeric carriers. 
Additionally, drug degradation may be exacerbated as drugs convert from a more stable 
crystalline form to a higher energy amorphous form during the HME process. Therefore, 
it is imperative to minimize drug degradation caused by HME, especially for thermally 
labile drugs. In this work, gliclazide was used as a model thermally labile drug to evaluate 
the benefits of optimizing extruder screw designs, machine setup, and processing 
conditions. Preformulation studies were conducted using differential scanning calorimetry, 
thermogravimetric analysis, and liquid chromatography–mass spectroscopy to identify 
drug degradation pathways and to determine initial extrusion conditions. Formulations 
containing 10% drug and 90% AFFINISOL™ HPMC HME 100LV were then extruded 
using a twin screw extruder, and the extrudates were characterized using X-ray powder 
diffraction, modulated dynamic scanning calorimetry, and potency testing to evaluate 
physicochemical properties. For comparison, gliclazide amorphous solid dispersions were 
prepared using a spray drying technique for the degradation kinetics study, and the energies 
of activation for both amorphous gliclazide, crystalline gliclazide, and gliclazide solution 
were calculated using the Arrhenius equation to further guide the extrusion optimization 
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process. Results from the preformulation studies indicated that the 10% gliclazide blend 
was stable after holding at or below 140 ℃ for 4 min. At higher temperatures, the gliclazide 
blend started to degrade, and two hydrolysis degradation pathways of gliclazide were 
proposed. The activation energy study indicates a significantly higher degradation rate for 
the amorphous gliclazide compared to the crystalline form. After optimization of the hot-
melt extrusion process, including improved screw designs, machine setup, and processing 
conditions, we achieved gliclazide amorphous solid dispersion with ~95% drug recovery. 
This study clearly demonstrates the importance of the following factors on drug 
degradation: (a) changing screw design to facilitate shorter amorphous (melt) residence 
time, (b) lowering processing temperature to avoid excess thermal exposure, and (c) 
minimizing processing parameters to reduce unnecessary mechanical energy input. The 
ability to process thermally labile drugs and polymers using hot-melt extrusion will 
significantly expand the possible applications of this manufacturing process. 
4.2 INTRODUCTION 
The hot-melt extrusion (HME) technique has gained increasing popularity in the 
pharmaceutical industry due to its widespread applications as a drug delivery option, 
including device shaping (1), taste-masking (2), controlled release (3), and solubility 
enhancement (4). In particular, the manufacture of amorphous solid dispersions (ASDs) to 
improve the bioavailability of BCS Class II and Class IV drugs has been widely studied 
and has been commercially proven as an effective formulation strategy (5). However, 
during extrusion the conversion of the drug from the crystalline to amorphous form relies 
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on thermal and mechanical energy inputs from the extruder, and this energy input can 
degrade the active ingredient or excipients (6). Therefore, the application of HME with 
thermally labile materials is challenging. Thermal energy input during the extrusion 
process is normally supplied by heat conduction from the barrel and the friction of the 
material against the kneading elements and interior wall of the extruder barrel (7). 
Thermally induced chemical degradation has been widely reported to occur during HME 
process (8-10). Moreover, mechanical energy input is also supplied by the machine motor, 
and it is delivered through the interaction of the screw elements and the extruded materials 
(11). Part of the mechanical energy can be converted to thermal energy, especially in large-
scale extruders. However, when kneading elements are used, the relatively high-shear 
energy generated can still result in degradation of shear-sensitive materials (12).  
Due to the wide diversity of drugs and excipients, many may be susceptible to 
different degradation pathways during the extrusion process, including hydrolysis, 
oxidation, dehydration, isomerization, and photo-degradation (13). Among the different 
pathways, oxidation (14) and hydrolysis (15) are considered the most common degradation 
reactions. Chemical degradation can be triggered by some of the conditions involved in 
HME, such as elevated temperature (16), excipient incompatibility (17), the presence of 
oxygen (18), moisture (19), and pH level (20). Temperature, which is an important 
processing parameter in HME, is well known to significantly affect chemical degradation 
kinetics as predicted by the Arrhenius equation (21). Moreover, because of the high 
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molecular mobility of amorphous materials, amorphous drugs are more prone to chemical 
degradation compared to their crystalline counter-parts (22, 23). 
In general, extrusion involves melting and mixing of the materials. The melting 
process is highly influenced by the degree of filling, the material residence time, and the 
level of heat conduction from the barrel of co-rotating twin-screw extruders (24). The 
mixing performance depends significantly on the shear stress and stress duration of the 
mixing process. Therefore, it is important to find the optimum balance between providing 
enough energy for amorphous conversion and generating excess energy that triggers 
chemical degradation (25). Some formulation approaches such as decreasing the melting 
point, viscosity, and mixing temperature of the extruded materials (26, 27) have been used 
to achieve a milder extrusion conditions. Processing approaches, on the other hand, have 
also shown some success in minimizing degradation by optimizing barrel temperature, 
screw speed, machine throughput, and screw geometry (9, 28, 29). However, these studies 
do not provide a sufficiently detailed explanation of how and where drug degradation took 
place during the process, or a systematic strategy to solve the degradation problem during 
HME.  
The aim of this study was to investigate the cause of degradation of an ASD of 
gliclazide (GLZ) during the HME process and to investigate the degradation kinetics of 
different forms of GLZ. This information was then used to further optimize the extrusion 
process in order to minimize the chemical degradation of GLZ, which has not been 
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addressed previously in the thermal process of GLZ (30). In this paper, it was hypothesized 
that the screw design and processing condition optimization based on the degradation 
studies would reduce GLZ degradation during the HME manufacturing of an ASD. 
4.3 MATERIALS AND METHODS  
4.3.1 Materials 
Crystalline GLZ and AFFINISOL™ HPMC HME 100LV were donated by The 
Dow Chemical Company (Midland, MI). Soluplus® (Soluplus) and Kollidon® VA 64 
(PVP VA64) were donated by BASF Corporation (Florham Park, NJ). Indigo carmine was 
obtained from Acros Organics (Geel, Belgium). HPLC–grade acetonitrile and water were 
purchased from Fisher Scientific Co. (Houston, TX). All other chemicals used in this study 
were of American Chemical Society (ACS) grade. All percentages are based on w/w unless 
otherwise noted. 
4.3.2 Methods 
4.3.2.1 Hot Melt Extrusion and Milling 
HME processing was conducted on a co-rotating Leistritz Nano-16 twin-screw 
extruder (American Leistritz Extruder Corp., Somerville, NJ, USA) with a twin-screw 
volumetric feeder (Brabender Technology, Duisburg, Germany). Three screw designs were 
used to provide different levels of shear input. Blends with 10% GLZ loading were 
processed at temperatures ranging from 100–160 ℃ and with screw speeds set at 100 rpm, 
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200 rpm, and 300 rpm with or without a die. Extrudates were cooled to room temperature 
before milling. A Fitzpatrick L1A Fitzmill (Fitzpatrick, Inc., Elmhurst, IN, USA) operating 
at 9,000 rpm in the impact configuration with a 0.033-inch screen was used to mill HME 
materials. Powders retained between 37 μm (400 US mesh) and 44 μm (325 US mesh) 
were collected and stored in a desiccator over phosphorus pentoxide for further analysis. 
4.3.2.2 Residence Time Studies 
The residence time of GLZ formulations at different processing conditions was 
determined after the processing torque was stable. The time at which 0.2 g of indigo 
carmine was charged into the extruder feed port and into the sampling port was denoted as 
t = 0. The time at which colored extrudate emerged from the die was noted as the residence 
time. A calibrated timer was utilized to determine the time. 
4.3.2.3 High-Performance Liquid Chromatography (HPLC) 
GLZ content was analyzed with a Dionex Ultimate 3000 HPLC system (Thermo 
Fisher Scientific Inc., Waltham, MA) equipped with a Waters Spherisorb® ODS-2 250 
mm (5 μm, 4.6 mm × 250 mm) column. The HPLC system also included an Ultimate 3000 
autosampler to consistently inject 20 μL samples, an Ultimate RS variable wavelength 
detector extracting at a wavelength of 235 nm, and dual Ultimate 3000 pumps. The system 
was operated under isocratic flow at 1 mL/min using a mobile phase consisting of 60% 
ammonium acetate buffer (0.025 M, with pH adjusted to 3.1 using acetic acid) and 40% 
acetonitrile. The mobile phase was filtered through a 0.45-micron filter and degassed under 
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vacuum with sonication before use. The column was kept at 30 ℃. Chromeleon Version 
6.80 software (Thermo Fisher Scientific Inc., Waltham, MA) was used to process all 
chromatography data.  
Finely ground powder samples were accurately weighed to 20.0 ± 1.0 mg and 
transferred directly into a 20-mL scintillation vial. Measured powder samples were 
dissolved using 20 mL 1:1 acetonitrile:water diluent solution. Samples were then filtered 
using 13-mm 0.2-micron PTFE filters (Wheaton, Millville, NJ) and transferred into HPLC 
vials for analysis (Phenomenex, Torrance, CA) for analysis. 
4.3.2.4 X-Ray Powder Diffraction (XRD) 
XRD studies were performed with a Rigaku Miniflex 600 (Rigaku, Tokyo, Japan) 
X-Ray Diffractometer equipped with Cu Kα radiation at 40 kV, 15 mA. Data were 
collected in a scan mode with a step size of 0.02° and a step time of 2 s over a 2θ range of 
5–50°. Data analysis was performed with Bruker DIFFRACplus EVA diffraction software, 
version 15.0 (Billerica, MA, USA). 
4.3.2.5 Liquid Chromatography-Mass Spectroscopy (LC–MS) 
Analytes were analyzed using an Agilent 1290 Infinity binary liquid chromatograph 
and a 6538 UHD Accurate-Mass quadruple time of flight (QTOF) mass spectrometer 
(Santa Clara, CA). Analyte solutions were subjected to liquid separation on an Agilent 
Atlantis dC18 4.6 mm x 150 mm (3 μm particle size) column at a flow rate of 0.7 mL/min. 
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Mobile phases were composed of 0.1% formic acid (aqueous) and 0.1% formic acid in 
acetonitrile (organic). Starting conditions were held at 2% organic for 4 minutes and then 
ramped to 95% over 20 minutes, and the organic was held at 95% for 10 minutes. Analyte 
effluent was analyzed using electrospray ionization in the positive and negative ion modes. 
Mass spectra were subjected to an external calibration during the MS analysis to generate 
accurate mass assignments within +/−1 mDa. Agilent MassHunter Qualitative Analysis 
software (version B.03.01) was used to interpret the collected results. 
4.3.2.6 Modulated Differential Scanning Calorimetry (MDSC) 
MDSC analysis was performed with a TA Instruments Model Auto Q20 DSC (TA 
Instruments, New Castle, DE, USA). Samples were placed into Tzero® pans and crimped 
using a press. Raw materials were heated to 105 ℃ for 5 min to remove residual moisture 
and then equilibrated at −20 ℃, followed by heating to 250 ℃ at a ramp rate of 5 ℃/min 
with a modulation amplitude and period of 1 ℃ and 60 s, respectively. Processed samples 
were equilibrated at −20 ℃, followed by heating to 250 ℃ at a ramp rate of 5 ℃ /minute 
with a modulation amplitude and period of 1 ℃ and 60 s, respectively. During analyses, 
high-purity nitrogen flowed through the sample chamber at a rate of 50 mL/min. Data 
analysis was performed with TA Universal Analysis 2000 software. 
4.3.2.7 Thermogravimetric Analysis 
A Mettler Thermogravimetric Analyzer, Model TGA/DSC 1 (Mettler Toledo, 
Columbus, OH, USA) was utilized to evaluate the thermal stability of the drug. Samples 
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were weighed into individual 70-microliter alumina crucibles. Sample mass was monitored 
as the temperature ramped to 300 ℃ at 10 ℃/min under 65 mL/min nitrogen or air purging 
conditions. Weight loss (percentage) was analyzed using STARe software (Mettler Toledo, 
Columbus, OH, USA). Moreover, the thermogravimetric analyzer was also used to 
thermally treat the drug. Samples were also weighed in the 70-microliter alumina crucibles, 
and placed under 65 mL/min nitrogen or air purging conditions. Crucibles were heated to 
set temperature ranges from 100–200 ℃ with 10 ℃ intervals using the jump mode. 
Crucibles were then held for 4 min before being removed for HPLC drug potency analysis. 
Weight loss and HPLC analysis results were compared to determine the initial extrusion 
condition. 
4.3.2.8 Energy of Activation Study 
4.3.2.8.1 Spray Drying 
The amorphous solid dispersion of 10% GLZ in AFFINISOL™ HPMC HME 
100LV was prepared by spray drying to avoid thermal degradation. The drug and the 
polymer were dissolved in ethanol:dichloromethane (1:1) at a total solids load of 2% (w/v). 
This solution was then spray-dried using a Buchi B-290 (Buchi Corporation, Flawil, 
Switzerland) mini-spray dryer with an inlet temperature of approximately 67–69 ℃, 100% 
nitrogen gas aspirator rate (about 475 L/h), −10 ℃ condenser temperature, and a feed 
solution infusion rate of approximately 5 mL/min. The stable outlet temperature was about 
42 ℃. Following spray drying, the powder was secondarily dried in a vacuum oven (0.1 
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mPa) at ambient temperature for one week to remove the residual solvent. The size of the 
resulting spray-dried particles was approximately 40 μm. 
4.3.2.8.2 Forced-Degradation of Samples 
Samples of crystalline, ASD, and a 1 mg/mL DMSO solution of GLZ were weighed 
into 20-mL amber serum vials. Dried nitrogen gas was used to fill the vials before they 
were capped with bromobutyl stoppers and crimped with aluminum seals. The samples 
were then transferred to ovens pre-equilibrated at different temperatures ranging from 30–
120 ℃ depending on the materials contained in the vial. At designated sampling points, 
vials were taken out of the oven and stored in a freezer at −20 ℃ until they were tested. 
Samples were thawed and dissolved with 10 mL diluent (acetonitrile:water = 1:1) before 
HPLC measurement. The energy of activation values for the hydrolysis reactions of GLZ 
were obtained from a linear regression analysis of the degradation constants at different 
temperatures.  
4.4 RESULTS 
4.4.1 Preformulation Studies 
Thermogravimetric analysis results were used to study the thermal behavior of GLZ 
and its physical blends with polymers. As shown in Figure 4.1A, GLZ was stable up to 
approximately 165 ℃, which corresponds with the onset of GLZ melting measured by 
DSC as shown in Figure 4.2A. The weight loss of GLZ in both air and nitrogen conditions 
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was less than 10% between 165 ℃ and 240 ℃; however, when measured by HPLC, about 
10% of GLZ degradation was observed after holding at 170 ℃ for 4 min under air purging. 
For physical mixtures of GLZ and polymers, an initial 1% weight loss (water) was observed 
up to 100 ℃, as shown in Figure 4.1B. The onset temperature of GLZ degradation was 
depressed to about 140 ℃, which is also reflected in the depressed onset of GLZ melting 
measured by DSC (Figure 4.2B). The DSC result of the physical mixture of GLZ and 
polymer also confirmed the water loss by showing an apparent endothermic peak below 
100 ℃. 
Solid-state characterization of GLZ by XRD and MDSC were shown in 
Supplemental Figure S4.1. Besides the melting point shown in Figure 4.2A, a clear glass 
transition temperature at 39.95 ℃ was observed in the second heating cycle of the pure 
GLZ sample. In the XRD test, crystalline GLZ also showed characteristic diffraction peaks 
at 2ϑ = 10.42°, 14.90°, 17.00°, 18.12°, 20.72°, 21.96°, 25.22°, and 26.18°. Furthermore, 
1% crystalline GLZ was spiked into polymers, and the blend was mixed homogeneously 
before testing. Both XRD and MDSC exhibited the crystalline GLZ (data not shown), 
which indicates the capability of detecting small amounts of crystalline GLZ using both 
DSC and XRD methods. 
The origin of GLZ degradation and the resulting degradants were identified using 
LC–MS. Several samples were analyzed, including unheated and heated GLZ, extruded 
polymers without GLZ, and extruded polymers containing 10% GLZ. The unheated GLZ 
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sample was first subjected to reversed-phase LC–MS and subsequent ion activation 
through tandem mass spectrometry (MS/MS) to characterize GLZ and potential 
degradants. Both reversed-phase liquid chromatography and the positive ion mode total 
ion chromatogram (TIC) of the unheated GLZ drug generated elution of GLZ at 
approximately 18.5 min (see Supplemental Figure S4.2). Positive mode MS analysis of the 
18.5 min peak generated an ion signal at m/z 324.1378, which was consistent with the 
singly protonated form of GLZ (i.e., [C15H21N3O3S + H]+). No major degradants were 
identified in the LC–MS analysis of the unheated GLZ. Next, the extruded 10% GLZ and 
polymer blends were subjected to LC–MS analysis to determine any major degradants as 
a result of direct exposure to elevated temperatures. Upon LC–MS analysis of the 
extrudates, the LC/UV chromatogram generated a dominant peak at 13.3 min, while the 
signal from GLZ at 18.5 min was absent in the chromatogram regardless of polymer 
chemistry (Figure 4.3ABC). MS analysis of the 13.3 min peak generated ion responses at 
m/z 172.0427 and 189.0695, which is consistent with singly protonated and ammoniated 
cations of the empirical formula C7H9NO2S. The empirical formula, C7H9NO2S, is 
consistent with the sulfonamide structure in Figure 4.3A. Further MS analysis of the 
positive mode TIC identified other non-UV active GLZ degradants. For instance, the MS 
peak at 14.8 min with ion responses at m/z 279.2183 and 301.1995 (Figure 4.3DEF) is 
consistent with the singly protonated and sodiated cations with the empirical formula 
C15H27N4O. Structures for the additional degradants are illustrated in Figure 4.3D. 
Samples of GLZ heated at 200 ℃ for 4 min were also subjected to LC–MS analysis (data 
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not shown), and showed similar results as the extrudates of 10% GLZ in AFFINISOL™ 
HPMC HME 100LV, Soluplus, and PVP VA64. 
4.4.2 Processing and Characterization 
Five HME Runs, each comprising multiple batches at different conditions, were 
performed to improve the drug potency in the extruder, and the screw designs and machine 
setups are shown in Figure 4.4. Processing conditions, processing measurements, potency 
tests are summarized in Table 4.1.  
4.4.2.1 Run 1 
As shown in Figure 4.4, four sets of kneading elements were used to ensure 
sufficient mixing. During the run at 130 ℃, processing torque was 1,700–2,100 Gm, which 
was close to the limit of the machine. Also, die pressure was about 600 psi. Therefore, 
lower temperatures were not used in Run 1 in order to prevent machine over-torque failure. 
Total residence time (from port A to D) was about 12.6 min, and melt residence time (from 
port C to D) was 9.0 min, which indicated that the accumulation of material occurred 
toward the end of the extruder. The melt temperature of the material inside the extruder, 
measured at the die, was about 20 ℃ higher than the set processing temperature of the 
barrels. The drug potency in the extruded material measured by HPLC was 0%. 
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4.4.2.2 Run 2 
A less aggressive screw design, with one set of 30° forward-kneading elements 
located at the end of Zone 1, was used in Run 2. With the less aggressive screw design, 
processing torque decreased significantly to 1,000–1,500 Gm, based on the temperature 
used. The die pressures, however, were still high and, as expected, die pressure increased 
with the decrease of processing temperature. Both total residence time and melt residence 
time were shortened to about 10 min and 7.0 min, respectively. Melt temperature was about 
15 ℃ higher than the set processing temperature of the barrels. Unfortunately, with the 
milder screw design, the drug potency in the extruded material was still extremely low: 
only the batch 5 sample, processed at 100 ℃, showed 0.2% drug recovery. 
4.4.2.3 Run 3 
The screw design used in Run 2 was also used in Run 3; however, the die and die 
connector at the end of the extruder were removed (Figure 4.4). Without the block from 
the die and the die connector, the processing torque further decreased to 700–1,000 Gm, 
based on the temperature used. Moreover, total residence time and melt residence time 
were shortened to about 5 min and 2.5 min, respectively. The melt temperature of the 
extrudates measured by a calibrated IR thermometer, as shown in Table 4.1, was about the 
same as the set processing temperature of the barrels. To determine the status of the 
materials inside the extruder, samples were also taken from ports B, C, and D. XRD, DSC, 
and potency tests were performed to analyze the samples. GLZ remained in crystalline state 
at port B. However, for samples taken at port C, which was located after the kneading 
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element at the end of Zone 1, both DSC and XRD analysis revealed no crystalline signal. 
Drug recovery values of samples taken at port C were about 92.4–97.3%, and, for samples 
at port D, the values were about 5.7–25.8%. 
4.4.2.4 Run 4 
The screw design used in Run 4 is shown in Figure 4.4. Instead of being set at zone 
1, the kneading element was placed all the way towards the end of the barrel. The observed 
processing torque was comparable to Run 3 (700–850 Gm). As for the residence time, since 
the conversion of GLZ to its amorphous form occurred at the end of the extruder, only total 
residence time (about 3.0 min) was recorded. The melt temperature measured for the 
extrudates was about the same as the set processing temperature of the barrels (similar to 
Run 3). After the redesigning of the screw, ASDs with significantly higher drug recovery 
rates of 42.6% and 89.4% were achieved at 130 ℃ and 120 ℃, respectively. Processing at 
110 ℃ was not successful, as the extrudate emerged in powder form. 
4.4.2.5 Run 5 
To further optimize the specific mechanical energy input, nine more batches were 
processed with a varying feed rate (2.3–4.3 g/min) and screw speed (100–300 rpm), as 
shown Table 4.2, using the same screw design and setup used in Run 4. The drug recovery 
rates in the extrudates and the calculated specific energy inputs are also shown in Table 
4.2. It is clear that the drug recovery rate decreased with the increase in the specific energy 
input (Figure 4.5). Moreover, when the specific energy inputs were below 1 kW∙hr/kg (i.e., 
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batches 13, 14, and 21), it was insufficient to fully convert crystalline GLZ to its amorphous 
form. Therefore, batch 20, with 95.37% drug recovery, was the highest potency amorphous 
formulation achieved in this study. 
4.4.2.6 Energy of Activation Study 
Studies using energy of activation were performed to explain the observations in 
Run 3. Samples of crystalline, ASD, and 1 mg/mL DMSO solution of GLZ were analyzed 
at several temperatures ranging from 30–120 ℃. The degradation constants generated at 
different temperatures were used to plot the Arrhenius plots shown in Figure 4.6. The 
activation energies calculated from the linear regression of the plots for the hydrolysis 
reaction were shown in Table 4.3. Activation energy of crystalline GLZ was determined to 
be 68.53 kCal/mol, while the values calculated for GLZ ASD and DMSO solution were 
27.31 and 29.74 kCal/mol, respectively. Moreover, the extrapolated degradation constants 
and the corresponding half-lives at the extrusion processing temperatures were also 
summarized in Table 4.3.  
4.5 DISCUSSIONS 
Since all batches in this study were processed below the melting point of GLZ (166 
℃), the formation of ASDs relied on the solubilization of the drug in the polymer instead 
of the melting of the drug during extrusion (27). Therefore, the miscibility between GLZ 
and the selected polymer is crucial. The reader is reffered to the polymer screening method 
described in our previous paper (9). Briefly, as shown in Supplemental Figure S4.3, better 
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miscibility between AFFINISOL™ HPMC HME 100LV and GLZ was confirmed as 
compared to Soluplus and PVP VA64. Also, given that all observations regarding GLZ 
degradation were similarly observed for extrudates with these polymers, further 
optimization was done only with AFFINISOL™ HPMC HME 100LV. Successful 
processing using HME also requires excellent stability at elevated temperatures of the 
selected drug and polymer combinations. In this work, TGA and DSC data showed the 
challenges of processing GLZ using HME due to the limited processing window. The 
thermal degradation onset of GLZ sets the upper limit of the processing window. For pure 
GLZ, the degradation onset occurs at 165 ℃; however, when blended with AFFINISOL™ 
HPMC HME 100LV, the good miscibility between the two components as predicted by 
our model facilitates the solubilization of GLZ in the molten polymer, which depressed the 
melting point as well as the degradation onset of GLZ to 140 ℃. A recent publication has 
reported that due to the extruder torque limitation, AFFINISOL™ HPMC HME 100LV is 
difficult to process by itself at or below 130 ℃ (31). Although the incorporation of small 
molecule drugs can result in a plasticizing effect to lower the processing torque (32), the 
optimization window that remains is still very narrow in this study. 
The screw used in Run 1, which contains two sets of neutral kneading elements 
(90°) together with two sets of forward kneading elements (30°), has been reported to be 
able to provide enough mixing power to improve the dissolution behavior of an amorphous 
solid dispersion formulation (33). Surprisingly, no drug was recovered in the extrudate 
processed at 130 ℃, at which temperature GLZ should still be stable, according to the 
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preformulation studies. Two possible causes for this drug degradation problem are 
provided: (a) The extremely high torque and melt temperature observed in Run 1 indicates 
the potential of excess shear provided by the kneading elements (34), and (b) the neutral 
kneading elements used in Run 1 strongly held back the molten material, resulting in the 
long residence time (12.6 min) (35). Therefore, a milder screw design was used in Run 2. 
The decreased processing torque allowed for the application of lower barrel temperatures 
when extruding. The lowest processing temperature (100 ℃) helped achieve the 0.2% drug 
recovery rate for Batch 5. Similar to Run 1, both the die pressure and the melt temperature 
were still high. Given that polymers usually exhibit non-Newtonian shear-thinning 
viscoelastic properties (36), the high die pressure in this case can be attributed to the 
significant complex viscosity increase of the melt containing AFFINISOL™ HPMC HME 
100LV when it reaches the low-shear die area (31). Todd et al. established an equation that 
describes the relationship between polymer temperature rise and pressure generation, as 
shown in Equation 1 (37):  
/ pT P C E   , (1) 
where T  is the temperature rise, P  is the pressure rise,   is the melt 
density, pC  is the heat capacity of the melt, and E  is the pump efficiency. Under 
adiabatic conditions, with the assumptions of 1.0  , 0.5pC  , and 10%E  : 
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( ) ( ) / 29T K P psi  
 (2) 
Based on Equation 2 and the pressure recorded in Table 4.1, the temperature rise of 
the material should be around 17 ℃ in the die area, which is in agreement with the 
discrepancy between the measured melt temperatures and the set processing temperatures 
(about 15 ℃). Moreover, the high back pressure generated at the die area can also elongate 
the material residence time (37), thus causing more degradation. When the die and the die 
connector were removed in Run 3, the melt temperatures measured for all batches were 
close to the processing temperatures, and this supports the calculated results based on 
Equation (2). 
For hydrolysis reactions in solid state, moisture content has been shown to facilitate 
the reaction (38). Therefore, the impact of pre-drying the material on drug recovery was 
also investigated. There was about 1.10% moisture in the 10% GLZ and AFFINISOL™ 
HPMC HME 100LV physical blend, and the water content was found to be below 0.10% 
w/w by loss on drying test (105 ℃ for 5 min) after vacuum drying at room temperature for 
24 hours. As shown in Table 4.4, after drying the GLZ and AFFINISOL™ HPMC HME 
100LV physical blend, the torque of the extrusion process increased, causing a 50–70% 
specific mechanical energy input increase, according to Equation (4). Moreover, due to the 
extra mechanical energy input, drug recovery further decreased compared to the drug 
recovery rate of processing the non-dried blend (Run 3). In this case, the plasticizing effect 
of water (39) overcame the impact of the water as a reactant. It is believed that this occurs 
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because the hydrolysis reaction can still continue with the nucleophilic intermediate (as 
shown in Scheme 4.1) generated after the initiation reaction with water. 
Examining Run 3 more closely, it is interesting to note that there was no drug 
degradation between ports A and B, and even between port A and port C, less than 10% 
drug degradation was detected. Moreover, the residence time between port A and port C 
accounted for the first half of the total residence time. However, in the following half of 
the total residence time, between ports C and D, 70–85% of the drug degraded. Thus 
degradation kinetics studies were conducted to rationalize this observation. For crystalline 
GLZ in the solid state, hydrolysis degradation was not observed until the temperature was 
elevated to 80 ℃, because the energy and mobility of the molecules were so limited at 
lower temperatures that the reaction rates were too low to measure. On the other hand, the 
GLZ molecules in DMSO solution and ASD contained sufficient energy and mobility to 
overcome the reaction energy barrier. Therefore, as shown in Table 4.3, the activation 
energy of GLZ in amorphous and solution forms were significantly lower (27.31 and 29.74 
kCal/mol, respectively) than that of crystalline form (65.40 kCal/mol). Similar values of 
activation energy in the amide hydrolysis reaction have been reported in the literature (40, 
41). This result indicates that GLZ in amorphous and solution forms possesses much higher 
energy and molecular mobility, which is responsible for the faster degradation rate of GLZ 
after converting to the amorphous form in the second half of the extruder (42). 
Furthermore, as shown in Table 4.3, the hydrolysis reaction half-life of ASD at the 
processing temperatures in Run 3 was in the order of minutes, suggesting an extremely fast 
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degradation. It is important to point out that for the activation study, we only used the first 
15 to 25% of degradation data, where the reaction takes place in one-phase state 
(amorphous or crystalline) and is not affected by any phase transitions. Moreover, we have 
(a) expressed the hydrolysis reaction in terms of the first-order rate constant in all cases 
based on the data fit, same as the method previously reported (22), (b) and assumed the 
hydrolysis reaction of Scheme 4.1B is the main degradation pathway. 
An emerging fusion-based manufacturing technique called KinetiSol® Dispersing 
has been used successfully to prepare ASDs. KinetiSol® Dispersing utilizes a combination 
of frictional and shear energies to rapidly produce ASDs (43). By rapidly applying high 
mixing energy in a short time (less than 30 seconds), materials only briefly achieve elevated 
temperatures. Because of this, ASDs that contain thermally labile drugs have been 
successfully processed using KinetiSol® Dispersing (27, 44). The strategy we used in Run 
4 to address the GLZ degradation was based in part on KinetiSol® Dispersing. As 
demonstrated in Run 3, the kneading element played an important role in the amorphous 
conversion process. And after being moved to the end of the extruder in Run 4, the 
residence time of the amorphous form of GLZ is notably shortened, resulting in a 
significant improvement in drug recovery of 89.4% (Batch 11). A similar concept has also 
been used to avoid water loss and decomposition of nicotine bitartrate by side-feeding the 
drug downstream (45).  
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To further improve drug recovery, the specific mechanical energy input was 
optimized. The specific mechanical energy refers to the amount of power that is contributed 
by the extruder motor per kilogram of material being processed. A two-step equation has 
been established for the calculation of specific mechanical energy, as shown below (8, 46): 
( ) ( ) % 0.97( )
Applied Powe
max
r
rpm running
KW applied KW motor rating Torque gearbox efficiency
rpm
   
 (3) 
 
Specific Mechanical Ener
( )
)
g
(
y
KW applied
Specific Energy applied
Feed Rate

 (4) 
As mentioned before, we extruded GLZ well below its melting point (166 ℃), at 
which point the solubilization regime is responsible for the achievement of a single-phase 
amorphous system (47). Compared to the miscibility regime, a higher amount of shear will 
be required per unit of mass to adjust the kinetic aspects of the melt materials to maximize 
the mass transfer rates in the solubilization regime (48). The shear input is especially 
important for screw design used in Run 4, due to the extremely short solubilization time. 
However, as shown previously in this paper, excess amounts of shear energy input would 
cause degradation (Run 1). Therefore, it is critical to provide the proper amount of specific 
mechanical energy to completely solubilize the drug while avoiding excess mechanical 
energy that triggers GLZ degradation. In Run 5, different feed rates and screw rpm settings 
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were applied, resulting in specific mechanical energy inputs that ranged from 0.209–1.397 
kW∙hr/kg, which is in agreement with previous reported values (49, 50). Moreover, 
crystalline GLZ was detected in batches with specific mechanical energy less than 1 
kW∙hr/kg, which is extremely high in comparison to the specific mechanical energy input 
using sugar alcohol (range from 0.003–0.128 kW∙hr/kg) in pharmaceutical melt extrusion 
(51) and starch (range from 0.107–0.320 kW∙hr/kg) for cooking extrusion (52). We believe 
that the high specific mechanical energy input required for the complete conversion of GLZ 
from crystalline to amorphous form for the following reasons: (a) The specific mechanical 
energy input increases with the difference in ∆TMP-process, which means that the further the 
processing temperature deviates from the API melting point, the more mechanical energy 
input is required to produce homogeneous ASD (and in this case, ∆TMP-process is more than 
36 ℃). And, (b) the conversion occurred at the end of the extruder, which did not leave 
much time for the kinetics of the solubilization process to complete; therefore, more energy 
is required at the kneading elements to facilitate the mixing. Batch 20 was chosen, since 
the single phase ASD was achieved with the minimal specific mechanical energy input, 
resulting in a 95.37% drug recovery. The optimization method used in Run 5 can result in 
a potential homogeneity problem (53), since the minimized mechanical energy input 
required was determined by XRD and DSC results. Although the amorphous form of Batch 
20 extrudate was confirmed by the lack of a characteristic peak in XRD and the single Tg 
detected in DSC, the in vivo performance of the ASD may still be affected due to the 
limitation of the characterization techniques on ASDs (54).  
  
194 
The LC–MS analysis of thermal forced-degradation studied samples revealed two 
major degradants with molecular weight of 171 (a major peak in UV) and 278 (a major 
peak in TIC). As a typical sulfonylurea hydrolysis (55), water or the intermediate 
nucleophilic agents can attack the carbonyl carbon, hydrolyze GLZ to a sulfonamide and 
an amine with liberation of CO upon cleavage of the amide linkage as shown in Scheme 
4.1. Forced-degradation of GLZ at different conditions were studied previously (56, 57) 
and confirmed the similar hydrolysis reactions on sulfonylureas (55). Interestingly, the 
intact GLZ and the sulfonamide degradant (Deg. A) exhibited identical responses when 
comparing the UV absorption at 227 nm (Figure 4.7). Moreover, both hydrolysis pathways 
proposed in Scheme 4.1 lead to Deg. A, which means that GLZ molecules will end up with 
the same amount of Deg. A molecules after hydrolysis. Therefore, when analyzing the 
100% degraded sample (Run 1) using a previously reported UV method (measuring drug 
concentration using UV absorption at 227 nm) (58), a false 100% drug recovery was 
detected. This observation necessitates the use of liquid chromatography with absorption 
measurements. Without liquid separation, distinguishing intact drug and degradation 
products via UV/VIS spectrophotometry cannot be achieved.  
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4.6 CONCLUSIONS 
The application of HME in manufacturing ASDs that contain thermally labile drugs 
has been limited due to the degradation caused by elevated temperatures, instability nature 
of amorphous form of drugs, and excess mechanical energy inputs applied during the HME 
process. In this study, GLZ was used as a model thermally labile drug. After adapting the 
proper machine setup to reduce the processing pressure, applying the optimal screw design 
to minimize melt residence time, and selecting the optimized specific mechanical energy 
input to fulfill the amorphous conversion without providing excess shear force, GLZ ASD 
with an improved drug recovery rate was successfully manufactured using HME. This 
study demonstrates that, with proper process optimizations, HME can be used to produce 
ASDs with a wider range of drugs and polymers. 
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4.8 LIST OF FIGURES 
 
Scheme 4.1  Thermal degradation of GLZ by the hydrolysis of amide group generating 
two major degradants. 
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Figure 4.1 Thermogravimetric forced-degradation analysis of: (A) pure GLZ under 
nitrogen and air purging, and potency result analyzed by HPLC after 4 min 
heat exposure in air; (B) pure HPMC polymers, a physical mixture of 
GLZ:METHOCEL™ E5 (1:9), GLZ:AFFINISOL™ HPMC HME 100LV 
(1:9), and potency result analyzed of GLZ:AFFINISOL™ HPMC HME 
100LV physical mixture by HPLC after 4 min heat exposure in air. 
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Figure 4.2 DSC analysis of (A) pure GLZ, and (B) physical mixture of 10% GLZ and 
AFFINISOL™ HPMC HME 100LV GLZ and AFFINISOL™ HPMC HME 
100LV (1:9). 
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Figure 4.3 LC/UV chromatograms (210–600 nm) from the accurate mass LC–MS/MS 
analysis of extruded (A) AFFINISOL™ HPMC HME 100LV/GLZ, (B) 
Solupolus/GLZ, and (C) PVP VA64/GLZ samples. Positive ion mode total 
ion chromatograms (TIC) from the accurate mass LC–MS/MS analysis of 
extruded (D) AFFINISOL™ HPMC HME 100LV/GLZ, (E) 
Solupolus/GLZ, and (F) PVP VA64/GLZ samples. The symbol * represents 
ion signal from the polymer.  
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Figure 4.4 The extruder setup and screw design for the five extrusion runs. 
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Figure 4.5 GLZ potency in the extrudates and the specific mechanical energy input of 
the nine batches in Run 5.  
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Figure 4.6 Figure Arrhenius plots of the hydrolysis reaction of (a) GLZ DMSO 
solution, (b) GLZ and AFFINISOL™ HPMC HME 100LV (1:9) spray dried 
ASD, and (c) crystalline GLZ.  
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Figure 4.7 UV absorption (190–260 nm) of GLZ and its major hydrolysis degradant A 
(Deg. A). 
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4.9 SUPPLEMENTAL FIGURES 
 
Supplemental Figure S4.1 (A) Second heating cycle of MDSC and (B) XRD analysis of 
pure GLZ. 
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Supplemental Figure S4.2 LC/UV chromatograms (210–600 nm) and positive ion mode 
total ion chromatograms (TIC) from the accurate mass LC–
MS/MS analysis of pure GLZ. 
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Supplemental Figure S4.3 Thermal phase diagram of GLZ and (A) AFFINISOL™ 
HPMC HME 100LV (B) PVP VA64 (C) Soluplus system 
representing the boundaries between thermodynamically 
unstable, metastable, and stable regions as bounded by the 
spinodal and binodal curves along with the glass transition 
boundary. 
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4.10 LIST OF TABLES 
 
Table 4.1 HME processing conditions and physical-chemical characterizations of the 
machine setup and screw design optimization batches. 
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Table 4.2 HME processing conditions and physical-chemical characterizations of the 
specific mechanical energy input optimization batches. 
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a) Data acquired by measurement 
b) Data acquired by extrapolation 
Table 4.3 Hydrolysis degradation rate of crystalline GLZ, GLZ ASD, and GLZ 
DMSO solution at extrusion processing temperatures. 
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Melt temperature measured by an IR thermometer 
Sample in amorphous form 
Table 4.4 HME processing conditions and physicochemical characterizations of Run 3 
with and without drying the feed materials.   
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APPENDIX A: Solvent-assist Melt Extrusion 
A.1 INTRODUCTION 
Poorly water soluble therapeutic compounds typically have low absorption and 
poor bioavailability when they are present in their crystalline forms. To enhance their 
dissolution rates and solubility, researchers have sought to prepare formulations, in which 
drug molecules are present at higher energy states than in crystalline forms. One type of 
dosage form used to accomplish this higher energy form is a solid dispersion. Solid 
dispersions can be characterized as a molecular dispersion of the therapeutic compound in 
an inert carrier in a solid state. 
Spray drying and melt extrusion are two common techniques to prepare amorphous 
solid dispersions in order to improve the biopharmaceutical performance of various classes 
of therapeutically-active, poorly water soluble agents. 
In the spray drying process, a solution containing a therapeutically-active poorly 
water soluble agent and a polymer are dissolved in organic solvent or solvent mixture along 
with other additives. A spray dryer is then used to process the solution into a powder form. 
During the typical spray drying process, the solution is atomized into fine droplets and 
sprayed into the drying chamber of a spray dryer. This necessitates that the atomized liquids 
must be of such low viscosity to enable atomization into fine droplets. Therefore, the total 
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solid contents of the feed solution are typically in the range of 5 to 20%, w/w. Hot gases 
such as air and nitrogen are commonly used as the drying medium to quickly evaporate the 
solvent from the fine droplets inside the drying chamber. The dry powder is then carried 
by the drying gas stream into a collection vessel. Following the primary drying in a spray 
dryer, the resulted dry powder collected most times undergo secondary drying using a tray 
drying oven or double-cone dryer to reduce the residual solvent to levels acceptable to 
health authorities before the spray-dried powder is further processed into various dosage 
forms. In this process, the solvent is flashed off the droplets so quickly that crystallization 
of drug is inhibited and drug molecules are “locked” in an amorphous state. After blending 
with excipients, the either direct compression or dry granulation process is used to process 
spray dried amorphous solid dispersion into various dosage forms such as tablets and 
capsules. 
The advantage of the spray drying process is the minimal heat exposure. The 
temperature of the drying gas is typically in the range of 70 °C to 140 °C. However, the 
actual temperature of the processed formulations is exposed to is much lower than the 
temperature of the drying gas because of the evaporative cooling effect. The processed 
formulations are typically exposed to 50°C to 80°C for less than 2 minutes. As a result, the 
spray drying process avoids degradation problems which are typically associated with 
conventional melt extrusion process. The other advantage of the spray drying is that 
solutions homogeneous at molecular levels are initially prepared prior to the spray drying. 
Both the feed solution composition and processing conditions must be designed to inhibit 
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potential phase separation during the drying process. However, the spray drying process 
has several disadvantages over conventional melt extrusion process. Organic solvents must 
be used as the medium to dissolve poorly water soluble drugs to prepare the solutions for 
spray drying. There are environmental and health concerns associated with the usage of 
organic solvents. Depending on the solvent composition and drying kinetics, phase 
separation between drug and polymer could take place drying the spray drying. Secondary 
drying is needed to reduce the residual solvent to levels acceptable by health authorities in 
most cases. Solvent evaporation is very energy consuming and the production rate is quite 
low given that total solid contents of the feed solution are typically in the range of 5 to 
20%, w/w.  
Conventional melt extrusion, as an alternative process to prepare amorphous solid 
dispersions, is a solvent free process. In a typical melt extrusion process, a dry blend 
containing a therapeutically-active agent, thermoplastic polymer, and other additives, such 
as antioxidants, is processed using a twin screw melt extruder. During melt extrusion, the 
active agent, in certain cases, is gradually dissolved into the formulation matrix as the result 
of the shearing and mixing by the rotating screw and the heat conducted from the barrel, 
generally in the range of 100 °C to 140 °C, and pressure inside the extruder barrel. In 
certain cases, drug is at first melted inside the extruder and the molten drug is then further 
mixed with polymer melt to prepare amorphous solid dispersion. In certain cases, both the 
“solubilization” and “melting and mixing” mechanisms discussed above are involved. The 
residency time inside the extruder ranges typically from 15 seconds to 5 minutes. After 
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being cooled using either compressed air or a chilled-roller, the extrudate is milled into fine 
granules for further downstream processing into various dosage forms. Due to the high 
viscosity of the polymeric matrix, drug molecules are “locked” in an amorphous state 
following the conventional melt extrusion.  
As a solvent free and continuous process, melt extrusion is generally considered to 
be a more efficient manufacturing process than spray drying. The most challenging aspect 
reported for melt extrusion is the high level of thermal and mechanical energy are required 
to transform a physical blend of drug and polymer into amorphous solid dispersions 
homogenous at molecular level. Drug and polymer often degrade during conventional melt 
extrusion process. As a result, the applicability of the melt extrusion process is limited to 
active agents and polymers that can withstand these conditions. 
Thus, there is a need for a manufacturing process that avoids the degradation 
problems associated with melt extrusion, facilitates the dispersion of drug molecules in 
polymer during melt extrusion and the eliminates the problems associated with spray 
drying resulting from the use of large amounts of solvent. 
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A.2 METHODS 
Solvent-assist HME (SA-HME) overcomes the limits of conventional HME and 
SD processes. P-aminosalicylic acid (p-ASA) is a poorly water-soluble and thermal-labile 
drug used in this study to evaluate the SA-HME technology. Its degradation pathway was 
confirmed by LC-MS, and a thermal forced degradation study was performed to determine 
the processing conditions. A composition was prepared by geometrically blending 10% wt 
p-aminosalicylic acid with 90% wt Kollidon VA64 (pre-dried at 70 ℃ for 20 hours) using 
mortar & pestle. The blend was processed by a twin-screw extruder (Nano 16, Leistriz, 
Nuremberg, Germany). The extruder used to process the blend was set up with a feeding 
zone, four heating zones and a die. Feeding zone was cooled with a water jacket to maintain 
the temperature below 35 ºC. The four heating zones were maintained at various elevated 
temperatures list in Table A1. Solvent was injected at the second heating zone as shown in 
Figure A1. Three screw configurations with high, medium and low shear input were used 
in the extrusion runs as shown in Figure A2, and the screw speed was maintained at 200 
rpm in all runs. The extrudates were evaluated for their chemical stabilities, solvent 
residuals and crystalline properties. The chemical stabilities of the extrudates were 
analyzed by HPLC (Ultimate 3000, Dionex Corp., Sunnyvale, CA). The solvent residuals 
were measured by moister analyzer (MF-50, A&D Company, Tokyo, Japan). The 
crystalline properties were examined by X-ray diffraction (Rigaku MiniFlex 600, Rigaku 
Americas, Woodlands, TX). 
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Table A1 showed an overview of the processing conditions varied in the extrusion 
studies of the p-aminosalicylic acid/Kollidon VA64 blend. Run 1-3, run 9-10, and run 14-
15 were control runs without solvent injections. In run 4-8, run 11-13, run 16-20 acetone 
at 30%-60% wt ratio of the solid feed rate was introduced by a Shimadzu (Kyoto, Japan) 
HPLC pump during the extrusion runs through an injection nozzle in zone 2. 
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A.3 RESULTS 
By analyzing the forced degradation of p-ASA using LC-MC, the major thermally 
induced decomposition pathway was identified, as shown in Figure A3. More degradation 
has also been reported with the increasing temperature, due to which, we managed to keep 
the processing temperature as low as possible without over-torqueing the extruder during 
the processing of p-aminosalicylic acid. 
As shown in Table A2 run 1 to 9, with the high shear screw configuration, the 
machine reached the torque limit at 120 ℃ (run 3) without solvent injection, resulting in 
21.10% drug recovery rate in the extrudate. The incorporation of acetone in the extrusion 
runs allowed further decreasing the processing temperature to 100 ℃ with the same screw 
configuration, bringing the drug recovery rate up to 45.48% (run 8). In run 9 to 18, milder 
screw configurations were applied in the extrusion runs to minimize drug degradation. In 
runs without solvent (run 9, 10, 14 and 15), drug degradations were slightly reduced 
compared to high shear screw configuration. Run 15 at 120 ℃ with the low shear screw 
configuration achieved the highest drug recovery rate (33.75%) without solvent assist. On 
the contrary, the presence of acetone in run 11 to 13 and run 16 to 18 significantly improved 
the drug recovery rate in the extrudates, especially when low shear screw configuration 
and low temperature conditions were used (run 17), 98.84% drug recovery rate was 
achieved with the solvent assist extrusion. Furthermore, a higher amount of acetone (2.0 
mL/min) injected in the extrusion run further improved the drug recovery rate to 102% (run 
20). XRD results indicated drug existed in amorphous form in all extrudates. In summary, 
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solvent assist extrusion prevented a thermolabile drug p-aminosalicylic acid degradation 
during extrusion process to manufacture amorphous solid dispersion. 
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A.4 CONCLUSIONS 
The study demonstrated that SA-HME was capable of decreasing the extrusion 
torque thus minimizing the processing temperature. With the milder energy input applied 
to the drug and polymer, significantly less degradation was observed. Therefore, SA-HME 
made thermal processing of thermal-labile compounds by HME possible. 
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A.5 FIGURES 
 
Figure A1 Solvent-assist hot-melt extrusion barrel setup. 
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Figure A2 Screw designs for extrusion runs. 
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Figure A3 P-aminosalicylic Acid Degradation Pathway. 
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Figure A4 Solvent injection effectively decreased processing torque (@ 130 °C). 
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Figure A5 Solvent injection and mild screw design contributed to higher drug recovery 
(@ 130 °C). 
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Figure A6 P-aminosalicylic acid recovery rate under different processing conditions. 
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A.6 TABLES 
 
*Torque limit was considered as 2000 Gm during extrusion to protect the machine 
Table A1. Extrusion processing conditions 
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Table A2. Percent p-aminosalicylic acid remaining, crystallinity, and Solvent Residual 
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APPENDIX B: Traditional Chinese Medicine Project 
B.1 INTRODUCTION 
Breviscapine is a traditional herbal compound extracted from the Chinese herb 
Erigeron breviscapus. The main active ingredient is Scutellarin, which account for more 
than 90% content of the extract. Breviscapine has several commercialized products (tablets 
or injections) on the market in China. The injectable formulation of Breviscapine is 
clinically used in China to treat ischemic cerebrovascular diseases such as cerebral 
infarction, apoplexy, coronary heart disease and angina pectoris. However, similar to most 
flavonoids, a clinical application is limited due to its poor physicochemical properties (low 
aqueous solubility and poor chemical stability) resulting in a limited bioavailability, despite 
demonstrated pharmacological effects. Furthermore, the blood-brain-barrier is regulating 
the molecules access to the brain through many mechanisms such as efflux transport 
systems as the P-Glycoprotein. Several attempts have been made to develop new delivery 
systems for this molecule. For example: Polymeric nanoparticles, liposomes, and solid 
dispersions formulations have been tested with some success. Yet, no attempt was made to 
formulate amorphous solid dispersions of Breviscapine using the hot melt extrusion 
technic. 
Puerarin is an isoflavone C-Glucoside isolated from a Chinese herbal medicine: 
Radix Puerariae Lobatae, which is the dried root of Pueraria lobata. According to the 
Chinese Pharmacopea, it has been reported to have several biological activities such as the 
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dilation of coronary arteries. It has also been reported as an antioxidant, a hepato-
protective, an anticancer and could be used to treat diabetes or cardiovascular diseases. It 
is currently mostly used to treat cardiovascular diseases such as angina pectoris or 
myocardial infarction. However, its clinical applications are limited due to its low water 
solubility and dissolution rate. Moreover, this molecule is very hydrophobic and has a poor 
liposolubility limiting its absorption in-vivo. 
Most of the time, because it was classified as a class IV in Biopharmaceutics 
Classification System (BCS), Puerarin has to be used by injection and a solubilizer has to 
be added to increase its solubility. Yet, the addition of cosolvents (that can be sensitizing 
agents), can lead to side effects such as pruritus, chest tightness or shortness of breath. In 
addition, the elimination half-life of Puerarin has been shown to be short and frequent 
injection may be required, leading to a higher risk of side effects. All this factors can 
explain the interest of researchers for the development of an oral administration form for 
this drug. Thus, various technics are being studied for this drug such as the preparation of 
nanocrystals, phospholipids complex, nanoparticles, etc. 
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B.2 RESULTS AND DISCUSSIONS 
I. Characterization of the drug substances: 
Before going further in this project, we had to characterize these drugs in order to 
know more about their characteristics (melting point and glass transition temperature (Tg), 
thermal degradation profile, crystallinity, etc.) 
1. Determination of the drugs’ melting point and glass transition temperature: 
In order to determine these crucial temperature, we used modulate DSC. Two 
methods were used: A simple ramping (reach a higher temperature of our chosen at a 
specific rate) to determine the Tm, and a “Heat-Cool- Heat” method to determine the Tg 
of the drug. 
a) Ramping method: 
Based on our research, we found some hypothetical value for the Tm, which 
were respectively 187°C for Puerarin and 260°C for Breviscapine.  
Equilibrate at -20°C; Isothermal for 5 min; Modulate +1°C every 60 second; 
Ramp 5°C/min from -20°C to 40°C above the Tm value. 
b) Heat Cool Heat method: 
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Cycle 1: Equilibrate at 20°C, Modulate +2°C every 60 sec, Ramp 20°C/min 
to 20°C above Tm. 
Cycle 2: Ramp 40°C/min to -40°CIsothermal for 5 min. 
Cycle 3: Modulate +/- 1°C every 60s, -Ramp 5°C/min to 40°C above Tm. 
The results showed a Tm around 350°C for Breviscapine (Figure B1, left) and 
around 210°C for Puerarin (Figure B1, right). Furthermore, the Heat Cool Heat results 
seemed to indicate a change in the crystalline form for Breviscapine around 200°C (melting 
followed by crystallization). Both drugs also showed a big “drop” of the Heat Flow and 
Non Reverse Heat flow Curve around 100°C, this is probably a simple solvent/water 
evaporation. However, additional tested will be perform to confirm this hypothesis. 
The Heat Cool Heat method was used to determine the Glass transition temperature 
since the drug was heat above its melting point and then cooled allowing the drug to reach 
the Tg. The values were respectively 102°C for Breviscapine and 144°C for Puerarin 
(Figure B2). As expected by the high Tm values the Tg values are relatively high as well. 
The pure drugs were analysed using Polarized Light Microscopy (PLM) to confirm 
the values obtained with DSC and determine the thermal profile of each drug. 
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In order to do that, the melting of the drugs was studied throught Hot-Stage PLM. 
The method was made to reach the melting point of the drug throught a simple ramping. 
Breviscapine was heat to 350°C (above its Tm value) as follows: Ramp 10°C/min to 100°C 
and then ramp 5°C/min to 350°C. Similarly, Puerarin was heat above the Tm value found 
with DSC: Ramp 10°C/min to 100°C and then ramp 5°C/min to 250°C. Pictures were taken 
automatically by the software in order to monitor any modifications very carefully. The 
images taken confirmed the values and events found using DSC. Indeed, Breviscapine 
showed an interesting behavior with the appearance of needle shapes around 220°C (Figure 
B3) that could confirm the “recrystallization” event seen on the DSC results. A clear 
melting was hard to see since Breviscapine has a wide melting point (as seen on the DSC 
results) that starts around 340 °C and ends at 351 °C. This relatively broad melting could 
explain that it is harder and longer to observe on PLM. (Figure B4). Regarding Puerarin, 
the events observed perfectly fitted those observed throught DSC: The crystals started to 
melt around 220°C (more clearly around 230 °C) and the melting was complete at 240 °C 
(drug was then liquid). (Figure B5 and Figure B6). It should be noted that, for both drugs, 
nothing noticeable happens around 100 °C, this seems to confirm that the drop around this 
temperature is probably not a melting but a solvent evaporation. 
But, in order to confirm this, both samples of pure drug were heated with a LOD to 
150°C for 3 min, the weight loss was calculated for both drugs, showing respectively a loss 
of 5,95% for Puerarin and 10,15% for Breviscapine. The samples were then directly 
analyzed with XRD to check the cristallinity of the samples when compared to pure 
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unheated drugs. The objective was to prove that the drugs are still crystalline at these 
temperatures and that it is not the drug melting. For both drugs, the peaks were perfectly 
identical to the pure unheated drug’s crystalline peaks. This confirms that the drop visible 
in DSC around 100°C is probably moisture evaporation and not a melting point. 
2. Characterization of the crystallinity: 
XRD analysis was conducted to identify the 2-theta angle of the diffraction peaks. 
Those 2-theta angles will be monitored in the hot-melt extrusion formulations to identify 
any residual crystals or crystallization of the drug substance.  
3. Characterization of the degradation profile using TGA 
The thermal degradation temperature of each drug substance was identified using 
TGA with both nitrogen (N2) and O2 gas. The results were used to confirm the previous 
results obtained with DSC and Hot stage PLM and to help determine the processing 
temperature of the hot-melt extrusion process. 
Breviscapine was analyzed from 45°C to 400°C with a constant heating rate of 
10°C/min and under a gas flow of N2 or air (both at a 65ml/min rate).The data (Figure B7) 
are comparable to those obtain with DSC: We can see solvent evaporation from 100°C to 
200°C, then weight loss (drop) around 210°C due to the recrystallization and finally 
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another drop at the Tm value (340°C). The drug is probably degrading. Puerarin was 
analyzed from 45°C to 325°C with a constant heating-rate of 10°Cmin and under a gas 
flow of N2 or air (both at a 65mL/min rate). The curve obtained for Puerarin (Figure B8), 
shows the weight loss (%) of the drug in function of the temperature. From 0 to 100°C 
about 5% of the sample weight is lost; this can be explained by the loss of solvent/water. 
This result is similar to the result previously obtain with the LOD showing a loss of 5,95% 
after heating the sample for 3 min at 150°C. The weight loss is then stabilizing from 100°C 
to the Tm value (210°C). This is in accordance with the result obtained with DSC. Above 
the Tm temperature, the drug starts degrading (probably by hydrolysis) and the weight loss 
starts increasing again. It must be noted that the curves obtained with the N2 environment 
and the air are similar until higher temperatures where they start to separate: The weight 
loss of the sample at the end of the analysis is less important in the air environment (25% 
loss) than in nitrogen environment (35% loss). This could be due to oxidation of the sample 
at high temperature; the reaction of the drug with oxygen atoms contained in the air leading 
to the addition of oxygen atoms on the drug could compensate the weight loss. 
As detected, the melting points temperatures of the two drugs are high which could 
be an issue to obtain amorphous solid dispersions using hot melt extrusion. In order to 
successfully convert crystalline into amorphous form, the drug must be heated above its 
melting point and above the polymer’s Tg to induce plasticity during the extrusion process. 
When the drug’s Tm is high, it can induce the drug and/or polymer’s degradation. 
Fortunately, by choosing the right polymer for each drug in good proportion, it is possible 
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to lower the melting temperature of the drug and consequently prevent any degradation 
during the process. 
II. Miscibility with polymers: 
1. Preparation of the physical mixtures: 
The 2 drugs were blended with 6 different polymers: EPO®, HPMC-AS, PVPK12, 
Affinisol®, Soluplus® and PVPVA64. First, the drug loading tested was 30%. Hot stage 
PLM was used to determine the miscibility of the drug with each polymer and their effect 
on the drug Tm (diminution of the melting temperature). 
The method used for the heating was as following: 
Ramp 20°C above the polymer’s Tg to induce its melting, hold this temperature for 
10 minutes, ramp 10°C to 185°C, hold for 10 minutes. 
Pictures were taken during the entire experiment in order to detect any changes in 
the drug’s aspect.  
As it can be seen in Table B1 and Table B2, PVPK12 was by far the polymer 
showing the best miscibility with Breviscapine while Soluplus was one of the best 
polymers for Puerarin. Based on these results, physical mixtures were made this time using 
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different drug loading, and analyse using DSC to study the effect of the different drug 
loading and the polymer’s effect on the thermal profile of each drug. The method used for 
DSC was the same ramping than previously. 
As we can see on Figure B9, Breviscapine’s Tm (usually around 350°C) disappears 
with high polymer content, but is still visible with the lowest polymer content (10%). The 
disappearance of the drug Tm on the DSC results is a sign of good miscibility between 
drug and polymer. The recrystallization phenomenon happening around 200°C decreases 
with a high polymer content however without completely disappearing. These results 
suggest the 15% drug loading to be used for the extrusion runs. Regarding Puerarin, the 
results were satisfying as well (Figure B10). As seen previously, the pure drug only had 
one melting peak around 210 °C but with high polymer content another peak appears later 
(this is probably due to degradation). The miscibility is satisfying for the higher content in 
polymer since the melting peak of the drug is no longer visible on the curve. (Figure 
B4)This polymer can thus be used for a low drug loading (lower than 50%). 
III. Hot melt extrusion: 
The hot melt extrusion technic was then used to obtain amorphous solid dispersions 
of these drugs in polymers. 200g of each physical mixture was prepared by mixing the 
polymer and the API with a mortar and pestle. First, equal quantity of drug and polymer 
powders were mixed (in a 50:50 ratio) to ensure a homogeneous mixing. More polymer 
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was then added to reach a final ratio of 15% of drug with 85% of polymer. The extruder 
used was a Leistriz Nano 16 with a Brebender twin screw feeder. 
For Breviscapine: 
The feeder was calibrated to 300rpm to obtain a feeding rate of 3,33g/min. The time 
necessary for extrudates to come out of the extruder was 7minutes and 2 seconds. Screw 
design were shown in Figure B11. The screw can be divided in 4 zones from the left to the 
right (die). Zone 1 (in blue), is the feeding zone, zone 2 is the venting zone, zone 3 is where 
the mixing takes place (particularly with screws 13 and 14) and finally zone 4 is a mixing 
and ejection zone.  
Based on the PLM and DSC results regarding the melting temperatures of the drug 
with polymer, 3 different temperatures were used to run Breviscapine (Table B3): First, 
150 °C, the aspect of the extrudates was satisfying so it was decided to try to decrease the 
run temperature in the extruder to 130°C for each zone. But at this temperature, the torque 
needed is excessive (exceeding 2200 Gm). 
Following these results, we tried the intermediate temperature (140 °C) which was 
also satisfying. It must be noted that we use lower temperature than the real Tm because, 
in the extruder, beside the thermal energy input that is provided there also is the impact of 
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the mechanical energy of the screws that will help dissolve the drug. Aspect of the 
extrudates (150°C and 140°C) can be seen on Figure B12 and Figure B13. 
For Puerarin, the feeder was calibrated in order to reach a feed rate close to 3g/min: 
At 220rpm the feed rate was 3,7g/min. This was the setting used during the entire process. 
However it must be noted that this feed rate decreased to 2,5g/min at the end of the run due 
to the decreasing of the amount of powder remaining in the feeder (decreased the pressure 
at the entrance of the feeding zone). The screw design was similar to the one used for the 
Breviscapine sample. As presented in Table B4, the temperatures were set to 150°C and 
170°C. The extrudates obtained (Figure B14) are clear which is a good sign of 
amorphization. 
IV. Characterization of the extrudates: 
First, the extrudates were grinded into very fine powder in order to be analyzed 
through different technics and prove that the samples obtained through extrusion were 
indeed amorphous. 
1. Polarized Light Microscopy: 
The images obtained with PLM (Figure B15 and Figure B16) seem to confirm the 
amorphization of both drugs after extrusion. The images obtained with the microscope 
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(figure 51) clearly indicated that the Breviscapine is now in its amorphous state especially 
if we compare to the previous aspect of pure Breviscapine (Figure B16). Similarly, the 
images obtained through PLM demonstate the amorphization of Puerarin (Before 
processing Figure B17, after processing Figure B18). Indeed, the extrudates did not show 
any birefringence properties and had a “glassy” aspect. (Figure B18). 
2. XRD analysis 
The XRD spectra of Breviscapine show typical results: Very characteristics 
crystalline peaks for the pure drug, once mixed with polymer most of these peaks disappear 
and the curve is a mix between an amorphous “halo” and a few crystalline peaks. And 
finally, the extrudates are proven to be amorphous since no crystalline peaks are visible. 
(Figure B19). Results are similar with XRD analysis of Puerarin and confirm 
amorphization of the drug after HME. (Figure B20). 
3. DSC analysis 
The DSC analysis of the extrudates confirmed these previous results showing the 
lack of a Tm on the Non-reverse heat flow curve (Figure B21 and Figure B22). This is a 
sign that the drug is now in its amorphous state and no longer crystalline. 
4. FTIR analysis: 
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For Breviscapine: 
The FTIR analysis of Breviscapine shows a good interaction of the polymer with 
the drug. Indeed, if we compare the spectra between them, we can see that the spectrum of 
the physical mixture attenuates the drug’s and polymer’s peaks and is a mix between the 
two spectra. (Figure B23). FTIR analysis was then run on the extrudates (Figure B24), and 
shows amorphization of the drug indeed, the drug’s peaks disappeared and the spectra of 
the extrudates are flatter, showing mostly the polymer’s peaks around 3500 and 3000 cm-
1. 
For Puerarin: 
Similar to Breviscapine, the FTIR results show a good interaction between the drug 
and the polymer (Figure B25). The second figure (Figure B26) also confirms 
amorphization of Puerarin with disappearance on the main drug’s peaks while still some 
polymer’s peaks on the extrudates spectra. 
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B.3 CONCLUSIONS 
With this work we have shown that it is possible to produce amorphous solid 
dispersions of high melting temperature’s drugs using HME. This can be facilitated by 
choosing the right polymer with the right ratio. But this work is still unfinished, the in vitro 
dissolution studies and in vivo tests be further conducted in China. 
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B.4 FIGURES 
 
Figure B1 Tm values of Breviscapine (left) and Puerarin (right). 
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Figure B2 Tg values of Breviscapine (left) and Puerarin (right). 
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Figure B3 Breviscapine at T0 and 230 °C. Needles are clearly visible at 230 °C. 
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Figure B4 Breviscapine at 350°C. 
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Figure B5 Puerarin at T0 and 230 °C. 
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Figure B6 Puerarin at 240 °C. 
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Figure B7 TGA analysis of Breviscapine in air and N2. 
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Figure B8 TGA analysis of Puerarin in air and N2. 
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Figure B9 DSC results of different drug loading of Breviscapine with PVP K12. 
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Figure B10 DSC results of different drug loading of Puerarin with Soluplus. 
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Figure B11 Screw design used for the extrusion. 
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Figure B12 Breviscapine extrudates after a 150 °C run. 
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Figure B13 Breviscapine extrudates after the 140 °C run. 
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Figure B14 Aspect of the Puerarin extrudates (150 °C and 170 °C). 
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Figure B15 Breviscapine samples extruded at 140 °C (top images) and samples extruded 
at 150 °C (bottom). 
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Figure B16 Breviscapine before extrusion (left) and physical mixture of 15% 
Breviscapine with 85% PVP K12 before extrusion (right). 
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Figure B17 Pure Puerarin (left) and physical mixture of Puerarin with Soluplus (15% 
and 85%) on the right. 
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Figure B18 From left to right: Puerarin extrudates at 150 °C and 170 °C. 
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Figure B19 XRD spectra of pure Breviscapine, physical mixture and extrudates. 
  
15% Breviscapine + Soluplus PM 
 
Extrudate at 140°C 
Extrudate at 150°C 
Pure Breviscapine 
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Figure B20 XRD spectra for Pure Puerarin, physical mixture and extrudates. 
  
15% Puerarin + Soluplus PM 
 
Extrudate at 150°C 
Extrudate at 170°C 
Pure Puerarin 
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Figure B21 DSC spectra of the Breviscapine extrudates 140 °C and 150 °C. 
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Figure B22 DSC analysis of Puerarin extrudates at 150 °C and 170°C. 
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Figure B23 Spectra of Breviscapine (blue), PVPK12 (purple) and physical mixture 
(red). 
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Figure B24 Spectra of physical mixture (blue) and the extrudates at 140 °C (purple) and 
150 °C (red). 
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Figure B25 Spectra of Puerarin (green), Soluplus (blue) and physical mixture (red). 
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Figure B26 Spectra of the physical mixture (red) and the extrudates at 150 °C (purple) 
and 170 °C (green). 
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B.5 TABLES 
 
Table B1 Polymers miscibility study with Breviscapine. 
  
Polymer Before heating 
After holding 
10 min 60 °C 
above drug Tg 
Before holding 
at 185 °C 
After holding 
10 min at 
185 °C 
PVP K12 
 
   
Affinisol 
 
 
  
EPO 
 
 
  
Soluplus 
  
 
 
VA 64 
 
 
 
 
HPMC AS 
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Table B2 Polymer miscibility study with Puerarin. 
  
Polymer Before heating 
After holding 10 
min 60 °C above 
polymer Tg 
Before holding 
10 min at 185 °C 
After holding 10 
min at 185 °C 
PVP K12 
    
Affinisol 
    
EPO 
    
Soluplus 
    
VA64 
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Table B3 Extrusion conditions for Breviscapine. 
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Table B4 Extrusion conditions for Puerarin. 
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APPENDIX C: Investigating the Cation-π Interaction in a Drug-
polymer Complex 
C.1 INTRODUCTION 
Numerous studies have shown the strong interactions between polymer and drug 
are important not only to maintain physical stabilities of amorphous solid dispersion (ASD) 
during and storage, and to achieve enhanced and sustained transient solubility of ASDs in 
aqueous medium. Other interactions have been studied. Cation–π interaction, which plays 
an important role in protein–ligand, protein-DNA interactions as well as maintaining 
protein structures, however, has not been studied in solid dispersions. This study was 
designed to investigate the effect of cation-π interaction on dissolution performance of 
solid  
C.2 METHODS 
Solid dispersions of 30% and 15% Carbamazepine (CBZ) and 70% EUDRAGIT® 
EPO were prepared using a NANO-16 twin screw extruder (Leistritz Advanced 
Technologies Corp.). Crystallinity in the HME extrudates was evaluated using differential 
scanning calorimetry (DSC) and powder X-ray diffraction (XRD). Dissolution testing was 
conducted under both sink and non-sink conditions using USP Apparatus II. FTIR and 
Raman spectroscopy were used to characterize drug-polymer interactions before and after 
polymer ionization. Discovery Studio (Accelrys Inc.) was used docking compound with 
polymers to predict molecular interactions.  
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C.3 RESULTS 
XRD and DSC results indicated the existence of crystalline form of CBZ in the 
extrudates. Sink dissolution testing in neutral media revealed that the unprocessed 
carbamazepine was completely dissolved in 60 minutes, but the CBZ-EPO extrudate 
released only 40% at 2 hrs. Non-sink dissolution in acidic media testing revealed that 30% 
CBZ-EPO and 15% CBZ-EPO extrudate rapid released 55% and 80% of CBZ in solution 
at 15 minutes, respectively, reaching a 1.5 and 2.5-fold increase in drug concentration 
compared to equilibrium solubility. The concentration was maintained through 360 
minutes. However, bulk CBZ reached its equilibrium concentration (30% CBZ released) 
at 2 hrs. The computational docking results suggested the existence Cation-π interaction 
between CBZ and EUDRAGIT® EPO, and the interaction was confirmed by FTIR and 
Raman spectroscopy. 
C.4 CONCLUSIONS 
Cation-π interaction has been observed between CBZ and EUDRAGIT® EPO, 
resulting in an increased dissolution rate and apparent solubility of the drug. Based on the 
results, this interaction between alkali metal or nitrogenous cation groups and the aromatic 
π system can be further studied and used to broaden drug candidate pool in the formulation 
screening process. 
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